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ABSTRACT
By administering systemic therapy before definitive local surgery in patients with large
operable breast cancers (T2, T3, NO, Nl, MO) an in vivo human tumour model system
has been devised which allows direct objective assessment of response to systemic
therapy in the individual patient. Response was assessed following 12 weeks of
systemic therapy by linear regression analysis of changes in tumour volume measured
at weekly intervals. Definitive locoregional surgery (mastectomy n = 82, wide local
excision n = 6) was performed on completion of systemic therapy (3-6 months).
Response to both endocrine (n = 61) and cytotoxic therapies (n = 47) have been
studied. Twenty-seven patients received both forms of treatment.
A biopsy of the tumour (fine-needle aspirate and open wedge biopsy) was performed
prior to initiating systemic therapy. Using the human tumour model system it has been
possible to evaluate the predictive value for response of several pretreatment tumour
indices. These have included tumour ER concentration assayed by either dextran-
coated charcoal method or immunocytochemical staining (ERICA), the activity of
enzymes involved in local steroidogenesis (i.e. tumour aromatase activity and
peritumour fat 17B hydroxysteroid dehydrogenase activity), tumour grade and tumour
ploidy. By obtaining a biopsy of tumour after systemic therapy it has also been
possible to determine the effects of systemic therapy on these potential indices of
response.
Response was observed in 24 (39%) of the 61 patients who received endocrine therapy
and 34 (72%) of the 47 patients who received cytotoxic therapy. Of the predictive
indices examined within this study only ER concentration and possibly tumour
aromatase activity have been shown to be of any value in relation to response to
endocrine therapy and aromatase inhibitors respectively. The other parameters studied
have been uniformly disappointing in their prophetic value.
When systemic therapy is given as the preferred first line therapy, response to therapy
can be assessed on an individual basis and hence allow determination of appropriate
systemic therapy. By using this principle a selective protocol for adjuvant systemic
therapy has been devised. Endocrine therapy should be reserved for patients with
tumours of ER concentration of > 20 fmol/mg cytosol protein. Patients with ER-
poor/negative tumours or those which fail to respond to endocrine therapy should
receive cytotoxic therapy. Using this protocol the overall survival rate at 4 years was
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77% (+/-5%) with 83 (+/-4%) remaining free from local relapse. This treatment




It has now been established from statistical analyses of large controlled randomised
trials that the long term survival of patients with operable breast cancer can be
improved by systemic endocrine or cytotoxic therapy (Early Breast Cancer Trialists'
Collaborative Group 1988; 1992a; 1992b). To date it has been more usual to give
adjuvant systemic therapy after definitive surgery. Once the primary tumour has been
removed however there is no direct index of the efficacy of systemic therapy and as yet
these trials have not defined which therapy is most suitable for an individual patient.
For this reason it was decided to reverse the conventional treatment sequence for
patients with large operable breast cancers, a group of patient with a poor prognosis,
and give systemic therapy before definitive locoregional surgery with the following
objectives;
1. to devise an in vivo human tumour model system to allow direct objective
assessment of response to systemic therapy in the individual patient.
2. to test the feasibility and efficacy of this novel approach in allowing selection of
appropriate systemic therapy.
3. to use the in vivo model system to evaluate potential predictive indices of tumour
response.





BREAST CANCER AS A SYSTEMIC DISEASE
For the last 35 years breast carcinoma has been one of the leading causes of cancer
death among women of the western world (Cancer statistics, 1988). In 1986 breast
cancer accounted for the deaths of 15,250 women in the United Kingdom alone, with 1
in 12 women developing breast cancer. Despite improvements in the diagnosis and
treatment of breast cancer epidemiological data show that mortality has not reduced
(Cancer statistics, 1988). It would therefore be complacent to continue our current
therapeutic practice without critical review.
The Natural History of Untreated Breast Cancer
So few patients with breast cancer remain without some form of therapy that adequate
information on the natural history of breast cancer is difficult to obtain and has relied on
retrospective analyses (Greenwood 1926, Daland 1927, Nathanson & Welch 1936,
Phillips 1959, Bloom Richardson & Harries 1962). The 3 year survival figures within
these studies have varied considerably from 19 - 44%. More agreement was noted after
the third year with a 5 year survival of approximately 20% and 5% of patients
remaining alive at 10 years. The median survival of untreated patients from onset of
symptoms was approximately 2 years and has varied little over the preceding one and a
half centuries (Bloom 1967).
Breast Cancer as a Systemic Disease
Halsted's (Halsted 1898) initial use of radical mastectomy as the preferred treatment
for breast cancer emphasised the management of the local tumour. Halstead initially
applied radical mastectomy to all patients with breast cancer, but in 1943 Haagensen
defined disease characteristics which if treated by radical mastectomy alone were
associated with high local recurrence and poor survival rates (Haagensen 1943). Such
'grave signs' included solid fixation of the tumour to the chest wall, oedema or
ulceration of the skin and massive involvement or fixation of the axillary lymph nodes
and were associated with 5 year survival rates of less than 40% with 40% of patients
developing local recurrence despite radical mastectomy. Even lower overall survival
(0-5% at 5 years) and higher local relapse rates (50-60% at 5 years) were observed
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with more advanced local disease, including the presence of two or more 'grave signs',
satellite skin nodules, inflammatory carcinoma, involvement of supraclavicular or
parasternal lymph nodes or oedema of the arm. The presence of any one of these signs
is now considered evidence of inoperability.
For patients whose tumours do not exhibit any of Haagenson's 'grave signs', surgery
remains the conventional form of primary management. Mastectomy with axillary
clearance (Turner et al. 1981; Maddox et al. 1983), and more recently breast-
conserving surgery (Fisher et al. 1985; 1989; Veronessi, Zucali & Del Vecchio 1985;
Veronessi 1987), in association with radiotherapy, has been found to give control of
the primary tumour and the associated axillary lymph node metastasis in the majority of
cases when the primary tumour is less than 2 or 4 cm respectively (Veronessi et al.
1981; Veronessi, Zucali & Del Vecchio 1985; Veronessi 1987;, Fisher et al.
1985,1989).
The precise effect of definitive local surgery on survival however has been difficult to
interpret since no case-control studies exist. Direct comparison with historical control
series is difficult since these contain a high proportion of patients with larger tumour
or more advanced disease. This has led to conflicting opinions with evidence for both
improved short and long term survival rate in favour of surgical management (Bloom,
Richardson & Harries 1962) and no overall survival advantage (McKinnon 1954; Park
& Lees 1951). Duncan and Kerr (1976) have suggested that the survival benefit
associated with adequate locoregional surgery was limited to those patients whose
tumours measured 3 cm or less in diameter at initial presentation.
The latest national survival figures for England and Wales have demonstrated that
approximately 60% of women diagnosed with breast cancer in 1981 were alive 5 years
later (Cancer Statistics 1988). Other series report 5 year survival rates for technically
operable breast cancer, treated by local means alone, of between 51 and 74% (Delarue,
Anderson & Starr 1969; Meyer, Smith & Potter 1978), with 43% of patients surviving
to 10 years (Meyer, Smith & Potter 1978).
Long term survival data for patients with so called "operable" breast cancer has
indicated however that despite adequate locoregional therapy women still show an
excess mortality from breast cancer 15 years, (Mueller & Jeffries 1975; Bond 1968;
Myers 1973; Ariel 1979; Haagenson & Bodian 1984) 20 years (Adair et al. 1974;
Mueller, Ames & Anderson 1978) and even 30 years (Brinkley & Haybittle 1975,1984;
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Hibberd, Horwood & Wells 1983) post-initial treatment. One study of patients aged 40
years or less at diagnosis has demonstrated that for this selected group of patients the
excess mortality from breast cancer persisted for up to 40 years (Rutqvist & Wallgren
1985). Although statistical 'cure' (annual death rate from all causes is similar to that of
a normal population group of similar sex and age distribution, Eason & Russel 1968)
for patients with "operable" breast cancer has yet to be demonstrated, personal 'cure'
(freedom from clinically detectable disease during the remainder of a patient's life-span)
does occur. The proportion effecting personal cure has been reported as around 20-
30% (Meuller & Jeffriesl975; Muller, Ames & Anderson 1978; Brinkley & Haybittle
1984; Rutqvist & Wallgren 1985). These data imply that in the majority of patients
presenting with palpable breast cancer, tumour cells have already disseminated into the
systemic circulation.
Breast cancer constitutes a very heterogeneous collection of disease entities with
survival patterns which vary greatly between individuals. Since no direct method exists
by which the exact timing of metastasis can be studied within individual patients, the
precise factors which determine tumour cells dissemination and successful
establishment of metastasis, are not yet fully understood. It is generally accepted that
the development of a metastasis is the culmination of a whole series of complex events.
The enormous disparity between the relatively large number of cells released from the
primary lesions (Butler & Gullino 1975; Liotta, Kleinermann & Saidel 1974) and the
relatively small number of overt metastases resulting from this release indicates that
metastasis is a very inefficient process. The disparity could be accounted for by the fact
that only a small subpopulation of aggressive cancer cell clones are capable of surviving
'ordeal by metastasis' or it may be that the trauma inherent in the various steps of
metastasis, including cell separation, dissemination and arrest in lymphatic or vascular
channels, adherence and tissue infiltration and eventual establishment with
vascularisation may result in a random survival of cancer cells (Weiss 1977; 1979).
Factors Which Relate to Probability and Timing of Metastatic
Dissemination
Tumour Size and Metastatic Potential
A direct relationship can be demonstrated between the size of the tumour at initial
presentation and prognosis (Fisher, Slack & Biass 1969; Duncan & Kerr 1976; Ariel
1979; Adair et al. 1974; Foster & Costanza 1984; Daly, Clark & McLoure 1974;
Fracchia et al. 1985; Pascval et al. 1983, Harveit, Thoresen & Maehle 1984;
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Ketterhagen, Quackenbush & Haushalter 1984; Coulson et al., 1984; Peterson et al.
1982; Carter et al. 1978; Blarney et al. 1979; Rosen et al. 1981; Wallgren, Silfversward
& Eklund 1976; Atkinson, Brown & Montague 1986; Carter, Allen & Henson 1989).
A progressively worsening prognosis and incidence of local relapse has been shown as
tumour size at initial presentation increases from 1 cm to 4 cm in diameter. Thereafter
no further decline in prognosis was observed (Duncan & Kerr 1976). The expected
survival for tumours greater than 4 cm at initial presentation and treated by mastectomy
is shown in Table 1. The equivalent incidence of local recurrence following radical
mastectomy for tumour of >4cm is between 24-31% at 5 years (Danforth & Lippman
1988).
The probability of distant metastasis therefore appears to be a function of tumour
volume. A detailed study of the relationship between the size of the primary tumour at
initial treatment and the incidence of distant metastasis was performed on 2648 breast
cancer patients treated at the Institut Gustave Roussy between 1954 and 1972
(Koscielny , Tubiana & Le, 1984). A remarkable linear relationship was demonstrated
between tumour volume (log) at the time of detection and metastatic probability to either
regional lymph nodes or distant sites (Table 2) and by the time a tumour reached a
diameter of 3.5cm, 50% had established systemic metastases. A similar relationship
between metastatic potential and tumour volume has been shown by Atkinson
(Atkinson, Brown & Montague 1986).
By retrograde extrapolation of the growth rate of metastasis it has been suggested by
other workers, that metastatic spread occurs even earlier in the life cycle of breast
tumours (Igot & Le Gal 1968). Bauer and Le Gal (Bauer & Le Gal 1973), estimated
that axillary metastases were established in 346 out of 348 primary tumours when the
primary tumour was less than 1cm in diameter. Such calculations have however been
criticised since they presume that tumour growth is exponential in type and the growth
rate of a primary tumour and its metastasis are equal. The doubling time of a
metastasis has been demonstrated to be shorter than its primary tumour (Charbit,
Malaise & Tubiana 1971; Steel 1977). Tumours consisting of only 10 cells have




Review of overall survival of patients with operable breast cancers of diameter 4 cm or
greater treated by mastectomy with or without radiotherapy.
Patient Rx Survival
group 3yrs 5yrs
Duncan and Kerr 1976 >4cm Mx/XRT 75% 65%
Seidman & Mushinski >4cm Mx - 55%
1987
(1940-1943, n=1458)
Seidman & Mushinski >5cm Mx - 50%
1987
(1940-1956, n=1978)
Fentiman et al. 1984 >5cm Mx - 60%
(n=42)
Ariel 1979 >4cm Mx 44-63%
(n=266)
Veronesi et al. 1981 >5cm Mx N- 60-91%
N+ 23-50%
Carter, Allen & Henson >5cm Mx 75% 60%
1989
Rx = treatment given; Mx = mastectomy; XRT = radiotherapy; N- = axillary nodes free
from metastases; N+ axillary nodes contained metastases by histological examination.
Axillary Lymph Node Involvement, Histological Grade and Metastatic
Potential
Histological examination of axillary node status is the single most reliable factor in
predicting the timing of recurrence and death (Carter, Allen & Henson 1989). The
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absolute number of nodes involved, the level and size of lymph node involvement are
all associated with prognosis (Fisher et al. 1969; Daly, Clark & McLoure 1974;
Fracchia et al. 1985; Pascual et al. 1983, Harveit, Thoresen & Maehle 1984;
Ketterhagen, Quackenbush & Haushalter 1984; Coulson et al., 1984; Peterson et al.
1982; Carter et al. 1978; Rosen et al. 1981; Wallgren, Silfversward & Eklund 1976;
Atkinson, Brown & Montague 1986; Carter, Allen & Henson 1989). Prognosis
however is not related to either the fraction of lymph nodes involved or the total number
of lymph nodes identified.
The presence of axillary lymph node metastasis is a marker of, but not synonymous
with systemic dissemination. It correctly predicts for recurrence in only 75% of all
patients during the first 10 years post-mastectomy. The probability of systemic
metastasis has been shown to strongly correlate with number of involved axillary
lymph nodes (Koscielny, Tubiana & Le 1984; Tubiana & Koscielny 1986; Atkinson
Brown & Montague 1986) and histological grade of the primary tumour (Koscielny ,
Tubiana & Le 1984; Tubiana & Koscielny 1986). Tumours with a large number of
involved axillary lymph nodes have a high probability of systemic metastases. Well
differentiated tumours (histological grade 1) demonstrate a particularly low potential for
dissemination while no significant difference could be demonstrated between
moderately or poorly differentiated tumours (grade 2 and 3; Tubiana & Koscielny
1986). These effects were related to but could be demonstrated independent of tumour
size (Table 2 and 3). These data confirm the prognostic significance of axillary node




Volume (V50) for which 50% of the tumour have metastasised in relation to
histological grade and number of axillary lymph nodes involved (Tubiana & Koscielny
1986).
Group Number of V50 Corresponding Variation
patients (ml) Diameter (cm) Interval(ml
Overall 2648 23.6 3.56 19.3-28.8
Histological Grade
known 1596 41.0 4.27 30.5-54.8
1 298 584 10.4 191 - 1765
2 766 29.5 3.83 19.5-44.7
3 532 23.0 3.53 14.6-35.0
Number of involved axillary lymph nodes
known 1722 32.8 3.97 24.5-43.8
0 560 290 11.0 217-2180
1 to 3 657 30.3 3.87 19.0-48.4
>3 505 7.2 2.4 4.0-13.1
Table 3.
Theoretical diameter for which 50% of the tumours have initiated distant metastases,
according to histological grade and the number of invaded axillary lymph nodes at
equivalent diameters (Tubiana & Koscielny 1986).
Number of Invaded Axillary Lymph Nodes
0 1 to 3 4 to 10 >10
Histological
Grade 1 9 cm 4.8 cm 3.1cm 2.5 cm
Histological
Grade 2 or 3 3.7 cm 2.6 cm 2 cm 1.8 cm
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Other Prognostic Variables
Data has suggested that the metastatic potential of a tumour evolves as the tumour
grows, and that nodal status simply reflects the ability of a tumour to spread. The
evolution of metastatic potential is not the same for all tumours and a newer generation
of prognostic markers have been based on measurement of tumour aggressiveness, of
which growth rate is an integral part. The introduction of the concept of tumour
doubling time enabled a quantitative estimation of tumour growth rate. A higher
incidence of positive axillary lymph nodes has been recorded in patients with tumours
showing rapid as compared to slow growth rates (Geshon-Cohen, Berger &
Klickstein, 1963; Heuser, Spratt & Polk, 1979). Tumour doubling time has also been
correlated to long term survival after surgical treatment (Kusama et al., 1972), relapse-
free interval and duration of survival after relapse (Malaise et ah, 1974). However the
direct measurement of doubling time necessitates sequential clinical and mammographic
examinations over several months and this type of assessment in an
untreated patient is not ethically acceptable for routine use. More indirect methods have
therefore been employed by which to measure tumour kinetics.
An inverse relationship has been documented between the indices of proliferation and
the degree of tumour differentiation or tumour grade (Steel 1977; Meyer & Connor
1977). The clinical relevance of histological grade as a prognostic index was initially
reported by Bloom (Bloom 1950a 1950b) and since then there have been numerous
studies which confirm that patients with well differentiated tumours have a considerable
better survival when compared to those with poorly differentiated tumours (Elston et
al., 1982; Fisher, Gregorio & Fisher 1975; Haybittle et al., 1982; Freedman et al.
1979). The use of histological grading has however been criticised because of
inconsistency and lack of reproducibility in assessment (Cutler et al. 1966; Gresham
1976; Gilchrist et al. 1985). More objective automated systems for the evaluation of
proliferative activity have been developed. The use of radiolabelled tritiated iodine
labelled precursors of DNA synthesis have allowed the measurement of the fraction of
cells synthesising DNA (Tubiana & Malaise 1976; Chavaudra, Richard & Malaise
1979). The thymidine labelling index, as determined by this method is directly
correlated to prognosis such that patient with a high labelling index have a very high
incidence of relapse and death (Tubiana & Koscielny 1987; Meyer et al. 1983;
Silvestrini, Diadone & Gasparini 1985; Silvestrini et al., 1989). It would appear that
this cannot be explained simply by differences in the growth rates of metastases but
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appears to be due at least partly to differences in the metastasising potential of the
neoplastic cells (Tubiana & Koscielny 1988).
Although effective thymidine labelling techniques requires autoradiography, are time
consuming and inconvenient. Furthermore the proportion of cells present within the
S-phase can be directly computed from quantitative analysis of a flow cytometric DNA
histogram and although a practical problem exists for aneuploid tumours. The % S-
phase calculated from flow cytometric histograms has tended to be slightly higher than
the corresponding thymidine labelling index, and this excess has been attributed largely
to debris in the histogram (Meyer et al., 1987). Although a high % S phase has been
associated with poor prognostic features, that is a poor histological grade (Hery et al.,
1987; Olszewski et al., 1981; Kallioniemi et al., 1987), the absence of ER or PR
(Kallioniemi et al., 1987; Dressier et al., 1988) and positive lymph node status
(Dressier et al., 1988; Kallioniemi et al., 1987; Silvestrini et al., 1985) it has been
shown to be of independent prognostic significance for both overall survival and
disease-free survival in patients with (Kintenburg et al., 1986; Kallioniemi et al., 1987)
or without axillary node metastases (Hery et al., 1987; Silvestrini et al., 1985; 1986;
1989; Clark et al., 1989). Some authors have suggested that the prognostic impact of %
S phase in relation to disease recurrence decreases with time (Stal et al., 1989).
Recently, more specific methods for measuring tumour cell kinetics have been
described using antigens incorporated or present within cycling cells and detected by
simple immunocytochemical techniques. Such antibodies include bromodeoxyuridine
(Gratzner 1982; Haag et al. 1987; Khochbin et al. 1988; Lacombe et al. 1988; Wilson
et al. 1988) and Ki 67 (Gerdes et al. 1984,1986; Lelle et al. 1987; Barnaud et al. 1987;
Charpin et al. 1988; Walker & Camplejohn 1988; Sasaki et al. 1988). In general the
bromodeoxyuridine labelling index relates to that of the Ki-67 labelling index (mean
ratio 0.58, Sasaki et al. 1988). The clinical relevance of the kinetic parameters remains
to be demonstrated.
Measurement of cellular DNA content by flow cytometry is a simple and rapid
technique which provides information about tumour ploidy and proliferative activity.
The mean labelling index of aneuploid tumour is significantly higher than that of diploid
tumour (Dean et al., 1984; Coulson et al., 1984; Dressier et al., 1986) and breast
tumours with diploid DNA content tend to be of low histologic grade and oestrogen
rich, whereas those with a high ploidy are more anaplastic and poorer in ER proteins
(McDivitt et al., 1986; Olszewski et al., 1981; McGuire et al., 1986, Daver et al.,
1983). The value of tumour DNA content as an independent prognostic variable is a
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little more controversial. DNA aneuploidy has been shown to be significantly
associated with a shorter recurrence free survival by some (Comelisse et al., 1987;
Fallenius 1986; Hedley, Rugg & Gelber 1987; Hedley et al., 1984; Kallioniemi et al.,
1987) but not all studies (Stal et al., 1989; Hedley, Rugg & Gelber 1987; Klintenberg
et al., 1986), while in yet others the predictive effect was confined only to node-
positive postmenopausal women (Comelisse et al., 1987; Fallenius 1986). Kallioniemi
and colleagues have demonstrated an independent association with overall survival
(Kallioniemi et al., 1987). Tetraploid tumours would appear to show a better
prognosis than other hyperdiploid tumours (Kintenberg et al., 1986; Fallenius 1986;
Kallioniemi et al., 1987; Baildam et al., 1987b; Stal et al., 1989).
Hormone Receptors
The maintenance of the ER and the presence of progestogen receptors (PR) are more
common associated with well differentiated tumours (Fisher, Sass & Fisher 1987;
Kamby et al. 1988; Singh et al. 1988). The expression of ER has been inversely
correlated with high proliferation rates, whether measured by ploidy, flow cytometry or
thymidine labelling index (Stal et al., 1989; Kute et al., 1985; Tubiana et al., 1989).
Some studies have however disputed the correlation of ER with ploidy (Fossa et al.,
1984; Taylor et al., 1983) and as yet no correlation between Ki-67 staining and ER
expression has been demonstrated (Bouzubar et al., 1989).
The value of steroid receptors as prognostic indicators remains controversial. Several
authors have concluded that patients with ER-positive tumours have a longer overall
and disease-free survival (Spyratos et al. 1989; Sutton et al. 1987; Hawkins et al. 1987;
Chevalier et al. 1988; Shek & Godolphin 1989; Raemakers et al. 1985; Knight et al.
1977; Pari et al. 1984; Godolphin, Elwood & Spinelli 1981; Mason et al. 1983). Only
six studies however have assess the effects of hormone receptors on prognosis by
multivariant analysis (Spyratos et al. 1989; Sutton et al. 1987; Stewart et al. 1983;
McGuire et al. 1986; Caldarola et al. 1986; Todd et al. 1987). Other studies with a
longer follow-up suggest that the beneficial effect of positive ER status on survival
(Spyratos et al. 1989; Todd et al. 1987) had no independent value or gradually
diminished with time (Howat et al. 1983). In node negative patients, measurement of
steroid receptors has also mostly failed to identify those patients who relapsed
(Williams et al. 1987; Maki & Hoehn 1989). In addition relatively few studies
compare both ER and PR, and at present controversy exists as to which hormonal
receptor actually conveys the favourable prognosis (Sutton et al. 1987; Mason et al.
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1983; Howat et al. 1983; Stewart et al. 1983; McGuire et al. 1986; Caldarola et al.
1986).
Oncogenes
More recent investigations have called attention to the possible prognostic relevance of
oncogenes. In breast cancer, a variety of specific alterations in DNA or gene
expression (messenger RNA or protein) have been demonstrated in breast cancer
(MacKay et al., 1990) some of which have already been associated with either early
disease recurrence and death e.g. c-myc (Varley et al., 1987) and erb B-2 (Slamon et
al., 1984; 1987; Wright et al., 1989) or very aggressive growth i.e. Int2 on llql3p
(Zhou, Casey & Cline, 1988). High levels of Harvey-ras, a gene which encodes for
proteins of approximately 21,000 daltons (p21) are thought to be involved in signal
transduction andhave been found in the majority of breast tumours (Horan-Hand et al.
1984). Although activation of Harvey-ras may be rare in breast cancer (Rochlitz, Scott
& Dodson 1989), it is possible to demonstrate a concentration-dependent effect of p21
on tumourogenicity (Redmond et al. 1988) and elevated levels of Harvey-ras mRNA in
malignant compared to normal breast tissue (Spandidos & Agnatis 1987; Slamon et al.,
1989). In the experimental setting transfection of v-Harvey-ras into MCF-7 cells
changes their hormone sensitivity such that they become oestrogen independent (Kasid,
Knabbe & Lippman, 1987) suggesting that Harvey-ras may be involved in hormone
independence rather than initiation of breast cancer (Agnatis et al., 1986; Lundy et al.,
1986). At present there is little evidence that p21 expression significantly affects the
metastasing potential of breast cancer cells. A significant association has however been
demonstrated between increasing levels of p21 (or its related mRNA) and the presence
of lymph node metastasis (Watson et al. 1990; Clair, Miller & Cho- Chung 1987,
Querzoli et al. 1988).
Reduced expression of a gene named nm23 and its messenger RNA have been
observed in highly metastatic cells in experimental animal systems (Steeg et al. 1988;
Liotta, Steeg & Steller-Stevenson 1991). In human breast cancer the loss of nm23
messenger RNA has been strongly associated with metastatic involvement of regional
lymph nodes (Bevilacqua et al. 1989) and poor survival (Hennessy et al. 1991). The
exact effect of the protein encoded for by the nm23 gene is still uncertain but the amino
acid sequence is similar to nucleoside diphosphate kinase (Rosengard et al. 1989;
Munoz-Darado, Inouge & Inouge 1990a, 1990b).
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Enhanced expression of growth factors and growth factor receptors is also a possible
prognostic indicator for human tumours. Epidermal Growth factor (EGF) is a 53-
aminoacid polypeptide (Carpenter & Cohen 1979) originally characterised from rodent
salivary glands (Cohen 1962) and now thought to be more widely expressed in human
tissues. Epidermal growth factor (EGF) is a potent mitogen for many tissues
(Carpenter 1981; Carpenter & Cohen 1976) including mammary carcinoma cells in
vitro (Osborne et al. 1980; Imai et al. 1982, Davidson et al. 1987). Cellular events are
induced by EGF via its cell membrane receptor (EGFR, Carpenter et al. 1983). These
receptors have a molecular weight of approximately 170 kD, are glycoprotein in nature
(Cohen et al. 1982) and are possibly a product of c-erb B proto-oncogene (Downward
et al. 1984; Lin et al. 1984). TGF-& is a growth factor produced by human breast
cancer cells under the control of oestrogen (Bates et al. 1988). It contains a protein
sequence homologous with that of EGF and although not recognised by all anti-EGF
antibodies, competes with EGF for binding to its receptor to produce its effect
(Todaro et al. 1980; Carpenter et al. 1983). Suppression of growth of MCF-7 cell lines
can be produced by antibodies directed against TGF-a or EGF-receptors (Bates et al.
1988). The EGF-receptor may therefore have a pivotal role in control of tumour cell
growth at an autocrine paracrine or level.
In human breast cancer tissue a 35-50% excess EGFR expression has been detected in
primary tumours and several cultured cells by means of biochemical binding
(Fitzpatrick et al. 1984a, 1984b; Sainsbury et al. 1985; Fabio et al. 1986; Perez et al.
1984, Macias et al. 1986). A significantly higher proprotion of cycling cells has been
found in EGFR-positive compared to negative tumours and an inverse relationship
between EGFR and ER (Toi et al. 1991; Sainsbury et al. 1985; Fitzpatrick et al. 1984;
Nicholson et al. 1988, 1989) and PR (Delarue et al. 1988) can be demonstrated.
Expression has also been correlated with other markers of poor prognosis such as a
high Bloom and Richardson grade (Sainsbury et al. 1985b). In clinical studies EGFR
expression has been associated with a poor prognosis (Sainsbury et al. 1987; Toi et al.
1991; Spyratos et al. 1990) and it has been suggested that the overexpression of EGFR
may be important in determining a biologically high malignant potential but this remains
to be defined.
In summary, breast cancer differs from most other epithelial tumours in that it can run a
very variable clinical course which may extend over thirty years. Although there has
been an increasing understanding of the factors which can be used to predict prognosis
following the diagnosis of breast cancer, the exact factors which determine metastatic
24
potential are complex and as yet not fully understood. It is likely however that breast
cancer cells disseminate early in the life history of the tumour and in the majority of




SYSTEMIC THERAPY FOR BREAST CANCER
The aim of all primary cancer therapy is "cure". This requires the total eradication of all
cancer cells. If a tumour can be detected before it disseminates, then appropriate
surgical removal with or without additional radiotherapy may suffice. In the majority
of patients presenting with palpable breast cancer however, the tumour has already
spread outwith the breast and locoregional lymph nodes. In such patient "cure" can
only be achieved by the additional use of effective tumouricidal systemic therapy. Many
systemic approaches to the management of breast cancer have been developed since the
introduction of endocrine therapy nearly a century ago and there is now substantial
clinical data demonstrating antitumour activity of both endocrine and cytotoxic
therapies. Initially systemic therapy was reserved for those patients with recurrent or
locally advanced disease. Evidence from both "in vitro" and "in vivo" studies have
suggested that the ability of chemotherapeutic drugs to produce cytoeradication is
inversely related to tumour burden (Goldin et al. 1956). This has formed the theoretical
basis for adjuvant chemotherapy, where the systemic therapy is given before the clinical
signs of metastasis become apparent. The precise effect of adjuvant systemic therapy
on overall survival has not been easily reached. Many trials, when taken in isolation,
contained only small number of patients (Stewart 1989) and so a major overview of
adjuvant systemic therapy was recently undertaken (Early Breast Cancer Trialists'
Collaborative Group 1988). This involved central collation of data from the major
randomised trials worldwide and was based on summation of the deaths observed in
the treatment group minus those in the control group (observed minus expected deaths)
within those individual studies which have addressed related questions. Significance
testing can then be performed on the variance of this summation. By using this method
the favourable trend in each study reinforces the trends of others to provide a total
which is less subject to random error than that of individual trials. This technique has
facilitated the study of major subgroups of patients and their treatment schedules, with
confirmation of conclusions tentatively deduced from individual trials. Many questions
however still remain to be answered.
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THE ROLE OF OESTROGENS AND ANTIOESTROGENS IN BREAST
CANCER
The essential role of ovarian function in normal glandular development of the breast
was originally described by Sir Percival Pott in 1775 (Pott 1775). Although
Schinzinger, a German surgeon, was first to postulate that oophorectomy might lead to
regression of breast cancer (Schinzinger 1889), it was Beatson who confirmed the
relationship in clinical practice (Beatsonl896). In 1923 the ovarian hormone oestrogen
(Allan & Doisy 1923), was identified and it was not long before the stimulatory effect
of oestrogen on the growth of mammary cancer in mice was demonstrated (Murray
1928; Lacassagne 1932). The proliferative effect was later verified for human breast
cancer by Pearson who demonstrated an increase in urinary calcium excretion following
the administration of oestrogens to patients with bone metastases (Pearson et al. 1955).
Epidemiological studies have shown that oophorectomy, especially early in life,
reduces the risk of breast cancer suggesting a primary promotional effect of ovarian
oestrogen in the development of breast cancer (Feinleib 1968). Although the
mechanisms by which oestrogens favour breast cancer development are largely
unknown the direct stimulatory effect of oestradiol on at least a proportion of breast
cancers has now been well established. On average one third of tumours are known to
regress when subjected to hormonal manipulation. The following section reviews the
relevance of local oestrogen production in breast cancer and therapeutic forms of
oestrogen deprivation.
Tissue Oestradiol and its Synthesis
Glandular and Extraglandular Production
In premenopausal women the principal source of plasma oestradiol is the ovary. Lesser
amounts of oestradiol arises from extraglandular aromatisation of androstenedione and
to a lesser extent testosterone (Siiteri & MacDonald 1973). In the ovary the enzyme
aromatase, catalyses the conversion of androstenedione to oestrone and testosterone to
oestradiol. The amount of oestradiol produced depends on two factors, the amount of
substrate present and the magnitude of enzyme activity. Luteinising hormone (LH)
provides the primary control for the amount of substrate present, whereas follicle
stimulating hormone (FSH) regulates the activity of the aromatase enzyme (Channing &
Segal 1981).
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After the menopause, the production of both androstenedione and oestradiol by the
ovary is substantially reduced and the oestrogens are primarily derived from
extraglandular aromatisation of adrenal precursors (Siiteri & MacDonald 1973; Judd et
al. 1974). Androgens such as androstenedione, dehydroepiandrosterone and its
sulphate are then the major precursor and are secreted by the adrenal gland. Their
production varies with stress and positively correlates with the degree of obesity
(Kirschner 1979; Meldrum et al. 1981). Peripheral tissues such as fat (Perel, Wilkin &
Killinger 1980), skin (Schweikert, Milewich & Wilson 1976), liver and muscle
(Longcope 1972) the breast and its tumours (Miller & Forrest 1976; Geier et al. 1975;
Perel, Wilkin & Killinger 1980), all have the potential to synthesis and metabolise
oestrogens. Peripheral conversion of circulating androstenedione to oestrone increases
not only with obesity but also age (Grodin, Siiteri & MacDonald 1973; MacDonald et
al. 1978). Oestrone is then converted to oestradiol by the enzyme 17-B-hydroxysteroid
dehydrogenase. The activity of this enzyme does not appear to be regulated by the
degree of obesity or by age (Santen et al. 1986).
Approximately 40% of plasma oestrone and oestradiol are converted to oestrone
sulphate, a compound with a slow metabolic turnover and consequently relatively high
plasma levels (Longcope 1972). Approximately 15% of the oestrone sulphate is then
recycled back to oestrone. This storage pool pathway may provide an important source
of precursor substrate for local oestradiol production in breast cancer. Most of the
circulating oestrogens are protein bound, however it is the non-protein bound or
'free'hormone which is biologically active. It has been suggested that high levels of
free oestradiol may be associated with increased risk of breast cancer but this remains
controversial (Fishman et al. 1978; Dao 1979; Van Landeghem et al. 1981; Moore et al.
1982; Reed et al. 1983; Bruning, Bonfrer & Hart 1985). Biological effects are more
likely however to be a function of the levels of endogenous steroids within the target
tissues.
Oestrogen Concentration in Breast Tissues
Marked differences in the concentrations and/or patterns of major oestrogens between
the plasma and breast tissues have been observed, particularly in postmenopausal
women (Van Landeghem et al. 1985; Vermeulen 1976). In postmenopausal women,
endogenous levels of oestrogen were significantly higher in breast tissue when
compared to plasma, mean tissue : plasma ratios of about 3 for oestrone and 20 for
oestradiol having been demonstrated (Vermeulen 1976). In addition oestradiol levels
in normal or malignant breast tissue were found not to change significantly with
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advancing age, in contrast to the large decrease in plasma concentration which occurs
after the menopause (Millington et al. 1974; Van Landeghem et al. 1985; Vermeulen
1976). Malignant breast tissue was found to contained higher concentrations of
oestradiol when compared to benign breast tissue, irrespective of the ER status of the
tumour (Fishman et al. 1977). The mean oestradiol level did tend to be higher in ER-
positive compared to ER-negative tumours, but a significant quantitative correlation
between ER status and oestradiol levels has not been demonstrated (Fishman et al.
1977; Edery et al. 1981; Van Landeghem et al. 1985; Thijsen & Blankenstein 1989).
In contrast no relationship between oestrone levels and ER status of breast tumours has
been demonstrated (Fishman et al. 1977). The levels of endogenous oestrogen in
breast fat also exceed plasma concentrations, although the difference was observed
mainly for oestrone (Feher et al. 1982).
The differential in oestrogen concentrations between plasma and breast tissue may
either be a function of selective uptake from the circulation against a concentration
gradient or active synthesis and metabolism of oestrogens within the breast. A positive
arterio-venous gradient, suggesting active uptake from the plasma to mammary aciner
tissue has been demonstrated for several androgens including androstenedione and
testosterone (Deslypere 1984; Van Landeghem et al. 1981; Vermeulen & Deslypere
1989). Some (Duvivier et al. 1981) but not all workers (Vermeulen & Deslypere 1989)
have demonstrated a positive arteriovenous gradient for oestrodiol.
Local Oestrogen Synthesis
The degree to which active synthesis occurs in individual tumours is highly variable
and the percentage of oestrogen accounted for by local biosynthesis may vary between
0 to 78% of the total oestrogen content (James et al. 1989). Oestrone can be produced
either from aromatisation of androstenedione, or hydrolysis of the oestrone sulphate.
Th resulting oestrone is then converted to the more active oestrogen, oestradiol, by the
enzyme 17B-hydroxysteroid dehydrogenase (James & Reed 1980). No consistent
relationship however has been demonstrated between in vitro activity of any of the
above enzymes and the levels of endogenous oestrogens within the breast (Bonney et
al. 1983; Vermeulen 1986; Hawkins, Thijssen & Miller 1987) or tumour tissue (Miller
& O'Neill 1989).
Aromatase. This enzyme catalyses the conversion of C19 androgens to CI8
oestrogens with the concomitant aromatisation of the steroid A ring. Aromatase activity
can be detected in normal glandular tissue (Miller 1986; Vermeulen et al. 1986), breast
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fat (Perel, Wilkin & Killinger 1980; O'Neill, Elton & Miller 1988) and at least 60-70%
of breast tumours (Miller 1986). The activity within cancer tissue has been found to be
equivalent to, or higher than that in the surrounding breast tissue (Abul-Hajj, Iverson &
Kiang 1979; Perel, Wilkin & Killinger 1980; Vermeulen & Deslypere 1989). The
level of aromatisation in the breast fat of patients with breast cancer is significantly
higher when compared to that of patients with benign disease (O'Neill & Miller 1987)
and within an individual breast appears to be higher in the quadrant of breast in which
the cancer was located (O'Neill, Elton & Miller 1988). Although the latter observation
may be a spurious finding related to contamination with tumour cells which are known
to have higher aromatase activity (Abul-Hajj, Iverson & Kiang 1979; Perel, Wilkin &
Killinger 1980). Studies on the expression of the aromatase enzyme in human adipose
stromal cells have indicated that its activity may be regulated by a number of factors
including cAMP, phorbol esters, and the growth factors, EGF, TGF-a, TGF-b and
TNF (Simpson et al. 1989). Several of these factors are produced by breast cancer
cells in response to oestrogens (Lippman et al. 1976; Knabbe et al. 1987). The
possibility of paracrine and autocrine feedback system exists within the breast. Growth
of a tumour may be regulated by oestrogen produced locally in the adipose cells of the
surrounding tissues, which in turn is regulated by growth factors produced by the
tumour as a result of oestrogenic action. Unlike oestradiol production in the ovary,
gonadotrophins do not appear to be the principal regulation system for aromatase
activity in adipose tissue.
Sulphatase/sulphokinase axis. These two enzymes are concerned with the
interconversion of unconjugated and sulphated oestrogens. The enzymes are relatively
ubiquitous and can be found in both benign and malignant tumours, as well as most
types of breast tissues (Hawkins, Thomson & Killen 1985; Dao & Libby 1972; Adams
et al. 1979). In disrupted cell preparations it can be shown that sulphatase activity
exceed that of sulphokinase. In whole cell preparations under physiological conditions
sulphokinase activity may be more important giving a positive gradient towards free
oestrogens (Santner, Feil & Santen 1984; Vermeulen & Deslypere 1989).
17B-hydroxysteroid dehydrogenase. The interconversion of oestrone and
oestradiol is under control of this enzyme and activity is higher in carcinomatous than
normal glandular tissue (Bonney et al. 1983; Vermeulen et al. 1986). Unlike aromatase
activity no association has been demonstrated between the level of 17B hydroxysteroid
dehydrogenase activity in breast fat and the presence or location of the tumour within
the breast (Miller & O'Neill 1989). High 17B hydroxysteroid dehydrogenase activity
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in breast fat has however been associated with indices of advanced tumour stage, and in
particular the presence of axillary node metastasis (Miller & O'Neill 1989) and larger
tumour size (Beranek et al. 1985).
The position of equilibrium between oestrone and oestradiol is unclear. In vitro studies
support oxidation to oestrone (Bonney et al. 1983, Vermeulen et al. 1986), whereas in
vivo perfusion studies have favoured reduction to oestradiol (McNeill et al. 1986a).
Both oestrone and oestradiol directly stimulate reductive activity but have no effect on
the oxidative reaction (James et al. 1989) while homogenates from breast cancers cells
(McNeill et al. 1986; James et al. 1989) also influence the activity of the enzyme in the
direction of the reduction. This suggests a degree of autocrine or paracrine control in
the in vivo situation which favours oestradiol production.
Therapeutic Inhibition of Oestrogen Synthesis
Surgical (Beatson 1896; Pearson et al. 1954) and later radiotherapeutic induction of
ovarian ablation (De Cormelles 1922) was the first form of hormone manipulation
available for systemic control of breast cancer. With the recognition of the important
role of the adrenal glands in maintaining breast cancer growth, total bilateral
adrenalectomy (Huggins & Scott 1945) was introduced but was never a viable
proposition until the discovery and widespread availability of synthetic glucocorticoids.
Hypophysectomy was introduced in 1952 by Luft (Luft, Olivecrona & Sjorgen 1952)
and the procedure later refined to a transnasal implantation of radioactive material by
Forrest (Forrest & Peebles-Brown 1955). These ablative procedures however are not
without significant morbidity, and even mortality in a population of patients who may
already be systemically unwell from their tumour and the response rate is only around
30%. They have now mainly been succeeded by new and potent pharmacological
agents.
Ovarian ablation
Following the initial enthusiasm for oophorectomy in the management of patients with
advanced breast cancer, it fell into temporary disfavour only to be resurrected by
Pearson in the 1950's (Pearson et al. 1955). Reasons for its demise included
introduction of photon irradiation to ablate ovarian function (De Cormelles 1922) and
development of pharmacological methods of influencing the endocrine environment
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such as testosterone (Loeser 1938; Ulrich 1939), the synthetic oestrogen
diethylstilbestrol (Haddow, Watkinson & Paterson 1944), progestogens (Taylor &
Mrris 1951) and corticosteroids (Pearson et al. 1954). In addition these
pharmacological methods were effective in control of advanced breast malignancy in
post-menopausal women. Although now mainly replaced by the LHRH analogues,
oophorectomy still has an occasional and effective role in the management of advanced
breast cancer.
In the adjuvant situation, both surgery (Ravdin et al. 1970; Lewison 1978; Bryant &
Weir 1981) and radiotherapy (Paterson & Russel 1959; Cole 1975; Meakin et al. 1983;
Meakin 1986; Nissen-Meyer 1968) have been used to secure premature menopause
with good effect. With the exception of the Ravdin study (Ravdin et al. 1970) these
trials have all shown a statistically significant improvement in both relapse-free and
overall survival in favour of ovarian ablation for premenopausal patients with evidence
of axillary lymph node metastasis. The order of magnitude of improved survival at 10
years in crude survival rates was around 11% . The addition of 7.5mg of prednisolone
per day to ovarian radiation in the Meakin study was found to further improve survival
(17% at 10 years) over that achieved by ovarian irradiation alone (Meakin et al. 1983).
The beneficial effect of ovarian ablation on survival was not evident until after 3 years
in the Meakin study (Meakin et al. 1983) and 5 years in the Bryant study (Bryant &
Weir 1981) and it may be that the limited follow-up period in the Ravdig study
accounts for its failure to demonstrate a positive effect.
The Nissen Meyer group (Nissen-Meyer 1968) have been unique in demonstrating a
positive effect in postmenopausal women.
A meta-analysis of the results of adjuvant oophorectomy has recently been published
(Early Breast Cancer Trialist's Collaborative Group 1992a). Data was available for 10
of the 12 trials of ablation began before 1985 (with a total of 3000 women randomised)
Within this analysis age has been used as a surrogate for menopause, and the results
analysed separately for women aged over 50 (most of whom were presumably
postmenopausal) and under 50 (most of whom were presumably premenopausal)
when randomised. For recurrence-free survival among all women aged under 50, the
predominant effect was seen within the first 10 years. A small but insignificant
difference was still apparent after 10 years. By year 15, the overall difference in
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recurrence-free survival was 10.6 %, SD 2.7, log rank 2p = 0.00007, proportional
reduction in annual risk 26% SD6).
For survival, the effect of treatment on the average annual death rate was similar up to
and beyond year 10. By year 15 the absolute difference in overall survival for the
treatment arm was 10.2% SD 2.7 (logrank test 2p = 0.0004, proportional reduction in
annual risk 25% SD7).
The size of the absolute benefit was dependent on axillary node status. Among node
positive women aged < 50, the improvement in recurrence-free survival and overall
survival at 15 years are highly significant at 10.5% SD 3.4 and 13% SD 3.6
respectively. For node-negative women, the number of positive events were smaller
and when each trial was analysed separately no benefit was demonstrated. When all the
trials were analysed by meta-analysis however a small but significant effect can be seen
with treatment for both recurrence-free survival and overall survival.
Among the 1326 women aged over 50 no significant effect either on recurrence-free
survival or overall survival was demonstrated. The addition of cytotoxic chemotherapy
to ovarian ablation appeared to reduce the beneficial effect from ovarian ablation. This
interaction however was not statistically significant, and even in the presence of
cytotoxic chemotherapy, ovarian ablation still reduced both recurrence and mortality to
an extent which just reached significance.
No significant effect of ovarian ablation was demonstrated on causes of death other
than breast cancer.
Tamoxifen
With the advent of tamoxifen, a competitive inhibitor for oestrogen at its target receptor
(Harper and Walpole 1967), a simpler and less invasive method became available to
reduce the biological effectiveness of oestrogen in vivo. The first indication of the
value of tamoxifen came from its use in the palliation of advanced breast cancer. After
Cole, Jones and Todd published their results in 1971, many studies were quickly
undertaken to determine the likely overall response rate and confirm the low toxicity. A
recent comprehensive review of these studies (Litherland & Jackson 1988) has shown
that one-third of 5353 patients with advanced breast cancer obtained a complete or
partial response and that the likelihood of response increased with age. In over 30
studies objective evidence of response was demonstrable after six to eight weeks and
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lasted on average twenty-four months. About 12% of patients with ER-negative
tumours can be expected to benefit from tamoxifen therapy in the advanced disease
situation, the response rate increases to near 50% when ER levels are above 5 fmol/mg
protein.
At least 57 randomised trials testing the efficacy of adjuvant tamoxifen have now been
undertaken (Stewart 1989). The collaborated results from 28 of the most major trials,
involving 16,513 women, were initially reported in 1988 (Early Breast Cancer
Trialists' Collaborative Group 1988) and have recently been updated to include 42
randomised trials involving 30,000 women (Early Breast Cancer Trialists'
Collaborative Group 1992a). Overall the administration of adjuvant tamoxifen is
associated with a highly significant reduction in recurrence-free and overall survival.
The main benefit to recurrence-free survival would appear to take place during the first
5 years, such that at the end of the fifth year an 8.3% difference in overall relapse-free
survival can be demonstrated (proportional reduction in annual risk 25% SD 2). This
gain is not significantly increased or decreased during the next 5 years. After year 10
there are as yet few data. When overall survival was considered however, the mortality
difference between the tamoxifen and control groups grew steadily throughout years 1
to 10, such that at year 5, the absolute difference in survival is 3.6%. In the next 5
years a highly significant additional mortality reduction can be demonstrated such that
by 10 years the overall difference in survival is 6.2% (SD 0.9). The proportional
reduction in annual risk was similar during the first 5 and subsequent 5 years at 17%
(SD 2).
The most extensively tested tamoxifen regimens, involved doses of at least 20mg per
day given for a minimum of 2 years. There is no evidence that a dose of more than
20mg per day provided additional benefit but within the overview a highly significant
benefit could be demonstrated with respect to relapse and survival with more
prolonged courses of tamoxifen (Early Breast Cancer Trialists' Collaborative Group
1992). Within individual randomised trials currently addressing the effect of duration
of tamoxifen therapy survival results are at present immature. At present results are
only available from one randomised trial. This has demonstrated a significant benefit
from the addition of a thud year of tamoxifen therapy over no further therapy beyond
two years, in patients over the age of 50 with involved axillary nodes (Fisher et al.
1987).
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Although the absolute benefits at 10 years are larger for women who are axillary node-
positive than those who are axillary node negative (recurrence-free survival absolute
improvement in node-positive 8.8%SD 1.1, versus 5.1% SD1,4 for node-negative
women, overall survival 8.2% SD 1.1 for node-positive women versus 3.5% SD 1.4
for node-negative women) the proportional reductions in annual risk was independent
of axillary node status (Early Breast Cancer Trialists' Collaborative Group 1992a).
This has also been demonstrated in individual trials (Scottish Cancer Trials Office
1987, Ribiero & Swindell 1988, Nolvadex Adjuvant Trial Organisation 1988, Bianco
et al. 1988, CRC Adjuvant Breast Trial Working Party 1988).
Tamoxifen in general is well tolerated with few major side effect (Litherland & Jackson
1988; Fisher et al. 1989). An increased incidence of endometrial cancers in patients
receiving long term tamoxifen has however been demonstrated and was more
pronounced in those treated for over 2 years (Fournander et al. 1989). This has not
been supported in other studies (Scottish Cancer Trial Office - personal
communication; Fisher et al. 1989; Early Breast Cancer Trialists' Collaborative Group
1992a) and may be a function of the high dose (40mg per day) of tamoxifen given
within that particular trial (Fournander et al. 1989). Within the recent overview,
tamoxifen was associated with a significant reduction in non- breast-cancer deaths
(12% SD 6, Early Breast Cancer Trialists' Collaborative Group 1992a). The reduction
in deaths was highest amongst vascular causes at 25% SD 13 (p = 0.06). In addition
a highly significant reduction in contralateral breast cancers was demonstrated with
tamoxifen (odds reduction 39% SD 9), with a nonsignificant trend towards a greater
effect for long-term treatment (Early Breast Cancer Trialists' Collaborative Group
1992a). The morbidity as well as the benefits of longterm tamoxifen therapy obviously
require to be under continuous review.
The clinical efficacy of adjuvant tamoxifen in relation to irradiation induced menopause
has been tested in 1005 premenopausal patients with operable breast cancer (Ribeiro &
Swindell 1988). At 10 years the analysis shows no significant difference in overall or
disease free survival between either treatment group. For premenopausal node negative
patients however there was a trend in favour of the tamoxifen treated patients with a
93% ten year survival versus 82% for the irradiation menopause group (p=0.09). In
this study however irradiation menopause, a permanent method of oestrogen
deprivation was compared to only one year of tamoxifen therapy. Since there is
evidence to suggest that more prolonged use of tamoxifen may be more effective (Early
Breast Cancer Trialist's Collaborative Group 1988, 1992a; Fisher et al. 1987), the
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results may therefore be unfairly biased in favour of the group receiving an irradiation
menopause.
Aromatase Inhibitors
Aminoglutethimide was the first clinically useful drug available which utilised the
strategy of inhibition of oestrogen production. Initially developed as an anticonvulsant,
it was shown to produce adrenal insufficiency and later introduced as a method of
providing "medical adrenalectomy" in breast cancer patients (Cash et al. 1967).
Although at high doses of aminoglutethimide, inhibition of the the adrenal desmolase
enzyme system could be demonstrated, the drug was still efficacious at lower doses
which produced little effect on adrenal steroids. It was thus suggested that
aminoglutethimide might inhibit the production of oestrone from androstenedione
(Samojlik, Santen & Wells 1977) and in 1978 Santen and his coworkers confirmed that
aminoglutethimide caused a 95-98% inhibition of aromatase activity in post-menopausal
patients with breast cancer (Santen et al. 1978). This led to the introduction of the term
'aromatase inhibition' as a mechanism of endocrine treatment for breast cancer. The
question of optimum dosage for aminoglutethimide remains open. Results from the
daily use of 250mg of aminoglutethimide alone seems to be inferior to those using the
conventional lOOOmg/day plus hydrocortisone (Stuart-Harris et al. 1985; Murray & Pitt
1985). The addition of hydrocortisone to low dose aminoglutethimide may give rise to
further suppression of oestrogen synthesis, by reduction in the availability of
androstenedione as a substrate in a setting of incomplete aromatase inhibition (Dowsett
et al. 1985; Harris et al. 1986). At higher dosages of aminoglutethimide, the addition
of glucocorticoids does not seem to improve response (Ceci et al. 1989). Furthermore
a randomised trial comparing aminoglutethimide 500mg/day to 1000 mg/day revealed
no significant difference in response rate (Boneterre et al. 1985). In summary the
optimal aminoglutethimide regime is not yet clearly established, until further data from
randomised trials are available a dose of 250-500mg aminoglutethimide daily with 40
mg hydrocortisone appears to be sufficient. Treatment trials using this agent in
postmenopausal patients with breast cancer revealed an efficacy equal to that achieved
by surgical adrenalectomy (Newsome et al. 1977; Santen & Henderson 1982; Brodie
& Santen 1986) and tamoxifen (Harvey et al. 1982; Lipton et al. 1982; Smith et al.
1981) but at the expense of substantial side effects including skin rash, ataxia,
drowsiness and lethargy; in addition when used at high doses glucocorticoid
supplementation was required. For these reasons further inhibitors have been
developed in an attempt to enhance aromatase inhibitory potency while improving
specificity and reducing side-effects.
36
4- Hydroxyandrostenedione
4-hydroxyandrostenedione (40HA) is a structural analogue of androstenedione and is
a specific, selective suicide or non-reversible inhibitor for the aromatase enzyme. In
vitro studies have shown it to have a sixty-fold greater activity when compared to
aminoglutethimide as an inhibitor of placental aromatase (Brodie, Schwarzel & Brodie,
1976; Brodie et al. 1977). Unfortunately 40HA is rapidly inactivated by hepatic
glucuronidation, and this has limited its efficacy when administered by the oral route
(Goss et al. 1986; Dowsett et al 1989). The drug is therefore usually given
parenterally, by deep intra-musclar injection into the buttock. Efficacy of a daily oral
dose of 500mg per day has been reported in postmenopausal patients with advanced
breast cancer (Cunningham et al. 1987; Coombes et al. 1987).
Endocrinological Effects
The predominant endocrinological effect of 40HA administration is a reduction in
plasma oestradiol concentration (Goss et al. 1986; Dowsett et al. 1987). A paradoxical
failure to lower plasma oestrone, as measured by radioimmunoassay, was recorded
(Goss et al. 1986) but when measured by gas chromatography-mass
spectrophotometry, oestrone levels were found to be suppressed by a mean value of
60% (Dowsett et al. 1989). The failure of initial results to show a fall in oestrone is
thought to be related to interference of 40HA and its metabolites in the
radioimmunoassay technique.
Following a single intramuscular injection of 40HA (500mg), serum oestradiol levels
have been found to fall to a nadir, by 4-7 days, of approximately one third pretreatment
concentrations, the effect being maintained for longer than 14 days in the majority of
patients . A similar degree of oestradiol suppression was seen following a single
injection of 125mg 40HA but recovery of serum oestradiol levels occurs more rapidly,
rising at the end of the second week to 54 +/- 6.4% of the pretreatment values
(Coombes, Stein & Dowsett 1989). The optimum clinical dose is not fully established
but the response rates in 55 patients were equivalent irrespective of whether the patients
had received 250mg (i.m.) at 14 day intervals, 500mg (i.m.) at weekly intervals, or
500mg orally daily (Coombes, Stein & Dowsett 1989).
Effects on Local Metabolism
Little information is available concerning the direct effect of aromatase inhibitors on
local oestrogen biosynthesis within the breast tissue. James and colleagues (1989)
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have reported the effect of 4-hydroxyandrostenedione in the tumours of 6
postmenopausal women and suggested that peripheral production was substantially
inhibited, with a marked reduction in aromatase activity in 4 of the 5 patients. The
levels of DNA polymerase &, an indicator of mitotic activity also showed a marked
reduction, suggesting a reduction in the growth rate of the tumour (James et al. 1989).
Conversion of androstenedione to oestrone was below the limits of detection in 6
postmenopausal patients following 40HA therapy.
Clinical studies
In postmenopausal patients with advanced disease one third will demonstrate regression
to 40HA and this relates to the ER status of the tumour, in that of the 43 patients with
ER-negative tumours, only 3 demonstrated clinical regression (Coombes, Stein &
Dowsett 1989). The incidence of side effects (29%) experienced by patients treated by
40HA is low when compared to aminoglutethimide (40-80%, Smith et al. 1981,
Coombes et al. 1986). Side effects relate mainly to the local administration site with the
development of sterile abscesses and painful lumps (8%). Systemic reactions are
usually mild and transient and included flushing, perioral oedema, lethargy,
drowsiness, myalgia and one skin rash. Two cases of anaphylactoid reaction have been
noted (Coombes, Stein & Dowsett 1989). In experimental systems it is also known to
have weak androgenic effects (Brodie & Santen 1986) but this has not been a marked
problem in vivo.
Recently, a non-steroidal compound, CGS 16949A has been identified as a potent
specific inhibitor of aromatase activity without intrinsic androgenic or oestrogenic
properties (Steele et al. 1987; Schieweck, Bhatnager & Matter 1988). This drug is
effective when administered orally (Santen 1989). Its value in the clinical situation is
currently under test (Santen 1989; Coombes, Stein & Dowsett 1989).
Gonadotrophin-Releasing Hormone Superagonist Analogues
Analogues of the gonadotrophin-releasing hormone (GnRH) have been developed
which, even when given intermittently, appear to mimic the effects of a constant
infusion of GnRH and produce a paradoxical inhibition of gonadotrophins (Santen ,
Manni & Harvey 1986). Under normal physiological conditions GnRH is secreted in
pulses at approximately two hourly intervals. The prolonged half-life of clearance after
subcutaneous injection (Clayton et al. 1985) and more importantly, the longer duration
of binding of the superagonist analogues to the GnRH receptor, produce a state of
constant GnRH receptor occupancy. This desensitises the pituitary to further GnRH
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stimulation and following an initial transient rise causes paradoxical inhibition of LH
and FSH secretion. This in effect produces a reversible medical oophorectomy
(Maynard & Nicholson 1979; Nicholson et al. 1984). Several analogues are now
available for clinical practice including Zoladex (ICI 118630; D-ser(But)6, AzglylO,
LH-RH; goserelin), Buserelin (D-Ser (Bu1)^, LH-RH proethylamide^), Leuprolide (D-
Leu^, LH-RH proethylamide^) and Decapeptyl (D-Trp^, LH-RH). These appear to
vary little in their efficacy (Klijn & De Jong 1987; Nicholson et al. 1984,1987; Harvey
1988; Hoffken et al. 1986).
Endocrinological Effects
The pattern of gonadotrophins released during treatment with the Gn-RH agonists
appear largely independent of whether treatment is initiated during follicular or luteal
phase of the menstrual cycle (Nicholson & Walker 1989). Following initial exposure
to the drug a short burst of elevated gonadotrophin levels are observed which is
translated into a transient rise of serum oestradiol and progesterone concentration. On
continued treatment plasma gonadotrophin levels fall to low levels within 3 days for
follicle-stimulating hormone and within 3 weeks for lutenising hormone (Klijn 1984;
Klijn & De Jong 1982,1987; Klijn et al. 1984; Harvey , Lipton & Max 1984; Manni et
al. 1986; Nicholson et al 1984, 1987; Walker et al. 1986). Serum oestradiol and
progesterone concentrations fall to the castrate or postmenopausal range within 3-4
weeks (Nicholson et al. 1987). The rate of decline in serum sex steroids is not as
rapid as that following surgical oophorectomy, where postmenopausal levels are
reached within 7 days (Vermeulen 1976, Beksac et al. 1983). Plasma gonadotrophin
levels have been kept low for several years on maintenance treatment with no ovulatory
peaks being observed (Klijn & Foekens 1986). A depot preparations of the LHRH
agonist Zoladex is now available and provides sustained release of the drug over a 4
week period (ICI Zoladex).
A reduction in the plasma levels of oestrone, androstenedione, and testosterone to
postmenopausal levels also occurs with Gn-RH agonist therapy (Nicholson et al. 1987;
Harvey 1988). Long term administration of Zoladex in contrast to Buserilin or
Leuprolide also causes a reduction in the circulating levels of prolactin (Nicholson &
Walker 1989).
Clinical Studies
To date clinical trials of GnRH analogues in relation to breast cancer have been mainly
restricted to patients with advanced disease. An overall response rate of around 40%
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has been reported in premenopausal women (Nicholson & Walker 1989; Klijn & De
Jong 1987; Nicholson et al. 1987; Harvey et al. 1984; Hoffken et al. 1986).
Regression has been restricted mainly to women with ER-positive tumours in whom
the response rate is around 53% (Harvey 1988, Nicholson & Walker 1989). The
observed response is equivalent in extent and duration to that observed following
oophorectomy (Nicholson et al. 1987b). The side-effects to GnRH agonist therapy are
minimal and associated mainly with a hypo-oestrogenic state. They include cessation
of menstruation (usually by two months), hot flushes and occasional nausea (Williams
et al. 1986, Harvey, Lipton & Max 1987; Klijn & De Jong 1987).
Tumour remissions have also been recorded in 10 % of a total of 118 postmenopausal
patients with ER-negative tumours (Nicholson & Walker 1989). The mechanism of
induction of regression in these women, is unclear. Possible explanations include a
reduction of the androgen output of the ovary which is still under gonadotropin
control in the postmenopausal women (Dowsett et al. 1988), or a direct inherent
antitumour action of the GnRH analogues themselves (Miller et al 1987). GnRH
binding sites have been identified in human breast tumours (Eidne, Flanagan, Miller
1985), while a direct inhibitory action of Buserelin has been demonstrated on some
(Miller et al. 1985, 1987; Blankenstein, Henkelman & Klijn 1985) but not all
(Wilding, Chen & Gelmann 1987) clones of MCF-7 cell lines.
Clinical studies are currently underway comparing GnRH analogues to either surgical
and X-ray induced menopause in pre- and perimenopausal women (ICI study 2301,
Harvey 1988). In addition the efficacy of GnRH analogues is being examined in
combination with other endocrine therapies, in particular tamoxifen (Walker et al.
1989).
Other Endocrine Therapy
Other endocrine treatments have received relatively little attention in the adjuvant
setting. A prospective comparative trial of androgens did not show any benefit from
this treatment (Karydas et al. 1987), but early results from a trial of aminoglutethimide




It is now twenty-eight years since Greespan and colleagues first suggested the
combination of multiple drugs to manage advanced breast cancer (Greenspan et al.
1963). Since that observation, innumerable studies have appeared in the literature
demonstrating that a variety of drug combinations can all be expected to result in fairly
high initial response rates in patients with metastatic breast cancer (Carbone et al. 1977;
Bonadonna & Valagussa 1983). While there is considerable variability in overall
response rates between one study and another several conclusions can be drawn.
First, virtually no combination chemotherapy studies have reported response rates in
excess of approximately 65-70% in the management of metastatic disease. The median
duration of response is usually less than one year (Carbone & Tormey 1977; Jones,
Durie & Salmon 1975) and few studies demonstrate a clinical complete response rate of
over 25%. While it is true that complete responders have an increased response
duration as compared to partial responders , there are very few patients who remain in
durable complete remission for prolonged periods of time (Legha et al. 1979; Decker et
al. 1979). These overall results appear to be independent of specific agents chosen.
The first trials of adjuvant cytotoxic therapy studied the value of perioperative
chemotherapy and were based on the theory that malignant cells were disseminated
during surgery and their subsequent implantation could be inhibited by chemotherapy
given around the time of challenge. Two randomised trials of perioperative
chemotherapy in operable breast cancer were started in the 1960s (Fisher et al. 1975;
Nissen-Meyer et al. 1978). The National Surgical Adjuvant Breast and Bowel Project
demonstrated that a postoperative course of thiotepa significantly increased survival in
premenopausal patients with four or more metastatic nodes (Fisher et al. 1986). In the
Scandinavian Adjuvant Chemotherapy Study Group a short perioperative of
cyclophosphamide 5mg/kg for 6 days, given after closure of the surgical wound
(Nissen-Meyer et al. 1978) was found to produce a survival advantage after 5 years
which became significant after 12 years for both relapse-free and crude survival. The
effect was found to be independent of nodal or menopausal status (Nissen-Meyer et al
1986). More recently performed studies have further confirmed the advantage of a
short perioperative course of chemotherapy. In the Ludwig study a single perioperative
cycle of cyclophosphamide, methotrexate, flurouracil and leucoverin was shown to
produce a significant improvement in disease-free survival at 4 years; the advantage
was observed for both pre and post menopausal women with the magnitude of effect
being largest among patients with no or low oestrogen- receptor content in the primary
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tumour (Ludwig Breast Cancer Study Group 1989). The CRC Adjuvant Trial also
reports a survival advantage for patients receiving a 6 day course of immediate
postoperative cyclophosphamide versus no systemic therapy (CRC Adjuvant Breast
Trial Working Party 1988).
With the recognition from long term survival data that breast cancer is already a
systemic disease by the time of initial clinical presentation, it was thought that
prolonged postoperative chemotherapy may be more effective in preventing recurrent
disease. The cardinal trials which pioneered this principle were from the National
Surgical Adjuvant Breast Project in the United States (Fisher et al. 1986) and the
Instituro Nazionale Tumori in Milan (Bonadonna et al. 1985; Bonadonna & Valagussa
1987). Numerous trials are now available and the collaborative results from 40 trials
involving a total of 13442 women have been reviewed (Early Breast Cancer Trialists'
Collaborative Group 1988) and now updated (Early Breast Cancer Trialists'
Collaborative Group 1992b). Thirty-one of these trials compared adjuvant
chemotherapy with no chemotherapy, the remainder involved a combination of
cytotoxic drugs with other systemic agents, particularly tamoxifen. Clear benefits can
be seen in recurrence-free survival and overall survival for patients receiving adjuvant
polychemotherapy when compared to those who did not receive chemotherapy. The
main effect on recurrence-free survival is seen during the first 5 years, after which no
additional gains can be demonstrated. The absolute difference at 5 years is 9.2% SD
1.2. while the average proportional reduction in annual risk is 28% SD3. The
beneficial effect on survival however continues at a steady rate (reduction in annual
hazard of 16% SD 3) up to 10 years, such that the absolute mortality difference at 5
years (3.2% SD 3.3) has doubled by 10 years (6.3% SD 1.4 2p , 0.00001). An
additional benefit can be demonstrated past 10 years but as yet there exists too little
extra information beyond year 10 for this additional benefit to be statistically reliable.
Improving The Efficacy of Chemotherapy
In the absence of new and more effective chemotherapeutic agents for breast cancer,
efforts are currently being made to explore the pharmacodynamics and scheduling of
the presently available chemotherapeutic agents.
Dose and Duration of Treatment
Undoubtedly dose intensity is important and when this is as high as possible
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commensurate with acceptable side effects, better therapeutic results can be expected
(Hrynuik, Levine & Levin 1986). Firm prospective data confirming this has recently
become available in metastatic disease (Carmo-Periera et al. 1987, Engelsman et al.
1987) but the optimal dose for adjuvant adjuvant therapy still remains undefined.
Prolonged (6 to 24 months) cytotoxic therapy have been found to offer no further
benefit over less prolonged (3-6 months) regimes (Early Breast Cancer Trialists'
Collaborative Group 1988; 1992b). A nonsignificant difference of 10(+/-8)% was in
fact found in favour of the less prolonged therapy (Early Breast Cancer Trialists'
Collaborative Group 1988).
Efficacy of Combination Chemotherapy
Second generation chemotherapy trials have evolved to compare combination with
single agents regimes and regimes of different durations. These have shown that
polychemotherapy is more effective than single agent chemotherapy (Early Breast
Cancer Trialists' Collaborative Group 1988; 1992b). The most extensively studied
cytotoxic regimes consisted of CMF or CMF. The regimes have varied considerably in
their dose and intensity of treatment. No conclusive statement can therefore be made
about the relative efficacy of other regimes and in particular those containing
adriamycin, a drug which is known from advanced breast cancer (Hoogstraten et al
1976; Livingston & Carter 1970) to be one of the most active single agents available
for the control of human breast cancer.
Theoretical and Experimental Evidence for Early Administration of
Systemic Therapy
There is increasing evidence from several biological systems which suggests that the
timing of adjuvant systemic therapy may be crucial; systemic therapy being more likely
to achieve cure if it is administered early in the life history of a cancer. The following
section will review the theoretical, experimental and clinical evidence relating the
potential importance of the timing of systemic therapy.
Chemosensitivity and Tumour Burden
An inverse relationship has been demonstrated between tumour burden and the ability
to obtain cyto-eradication (Goldin et al. 1956; Skipper 1960; Skipper, Schabel &
Wilcox 1964). Drug therapy fails because the tumour cells are resistant. Conceptually
two forms of resistance exist, temporary resistance, due to either pharmacological
sanctuaries or altered cell kinetics, and permanent resistance with the emergence of
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resistant mutant lines. Since both are mass related, the greater the tumour mass or
number of cell divisions the tumour has gone through the more likely a tumour is to be
resistant to anticancer drugs.
Pharmacological Sanctuaries
As a tumour increases in size areas will outgrow their blood supply which are the
source of systemically derived drugs and so can provide sanctuary site in which
otherwise sensitive tumour cells can survive (Devita 1983). Resistance can be also be
imparted by physiological barriers such as the blood-brain barrier (Devita 1983; West
et al. 1980).
Alteration in Tumour Kinetics
The overall growth pattern of the malignant tumour is best characterised by
Gompertzian function, although unpredictable phases of growth early in the life history
of a primary tumour and its micrometastases are suspected (Skipper 1960). With
expansion of overall tumour cell burden, the proportion of cells actively proliferating
will decrease. Since many anti-cancer drugs are specific for cycling cells, tumours
which have a larger cell burden would theoretically be less susceptible to anticancer
drugs.
Noncurative cytoreduction, whether by means of surgery, chemotherapy, or
radiotherapy has been shown in experimental animal models to lead to an increase in the
labelling index of the metastatic deposits (Tyzzer 1973; Gorelik, Segal & Feldman
1978; Simpson-Herren, Sanford & Holmquist 1976; DeWys 1972; Gundez, Fisher &
Saffer 1979; Fisher, Gundez & Saffer 1983). Although the data is not as conclusive
as for animal models, similar kinetic changes have been shown in human malignancies
(El Rifi et al. 1965; Lange et al. 1980). This kinetic perturbation through acceleration
of metastatic growth is potentially harmful. A shift in the proliferation phase from the
flat back to the steep slope of the Gomperzian curve (Ragaz et al. 1985; DeVita 1983,
Lloyd 1975) may explain this phenomenon but the effect can be reproduced in the
tumours of other animals by transfer of serum (Fisher, personal communication). The
burst of proliferative activity may be mediated by, as yet undefined growth factors
(DeWyss 1972) and can be blocked by prior treatment of the donor animal with
chemotherapy (Schabel et al. 1979, Corbett et al. 1981).
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Phenotypic Resistance
Phenotypically resistant mutants arise spontaneously, early in the natural history of
tumours even before exposure to anticancer drugs. The likelihood of a resistant line
developing appears closely related to the number of previous cell divisions (Ling
1978). It has been suggested by mathematical modelling (Goldie and Coldman 1979)
and confirmed in biological systems (Skipper 1960) that within 5 doublings, or less
than a 2-log increase in the microscopic burden, the risk of drug-resistant mutant cells
may increase from 5% to 95%. The doubling time of microscopic tumours may be
shorter than their overt counter parts (Shackney, McCormack & Cuchural 1978)
providing further theoretical argument for systemic treatment to being given as early as
possible.
Acquired resistance
The ability to resist environmental chemical stresses represents a major evolutionary
driving force and a wide variety of defence mechanisms have evolved to protect cells
against such cytotoxic insults. Potential mechanisms including changes in membrane
permeability (Kartner et al. 1983), DNA repair (Karran & Lindahl 1986), gene
amplification (Ozols & Cowan 1986) and drug detoxification (Hayes & Wolf 1988).
Spontaneous genetic mutations occur in all living cells at a rate of between one in lO^-S
new cells. The probability that a spontaneous drug mutant would emerge which was
resistant to two separate drugs is much lower and this has formed the theoretical basis
for combination chemotherapy. Clinical trials have confirmed improved response rates
with combination chemotherapy for the treatment of breast cancer by systemic
chemotherapy in both the adjuvant (Early Breast Cancer Trialist's Collaborative Group
1988) and the advanced disease situation (Carter 1972).
Clinical Studies on the Relationship Between Efficacy and Timing of
Chemotherapy
In theory, timing of the first cycle of chemotherapy may be critical. By observing the
alteration in labelling index associated with noncurative cytoreduction in mouse-
mammary tumours, Fisher and his colleagues were able to investigate the relationship
between interval from primary tumour removal to administration of a single dose of
cyclophosphamide and the effect on growth of residual tumour cells and animal
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survival (Fisher, Gundez & Saffer 1983). The greatest effect was noted when the
cyclophosphamide was given prior to operation when it completely prevented the
increase in labelling index resulting from tumour removal, more effectively suppressed
the growth of residual tumour and prolonged survival to a greater extent than noted
under any other circumstance. Cyclophosphamide given on the day of tumour removal
was more effective than when given 3 days later and least effective if given 7 days
following primary tumour excision.
The literature on the clinical importance of minor delays in starting adjuvant
chemotherapy in operable breast tumours of human patients shows no uniform
consensus. Only two randomised trials compare the efficacy of perioperative to
conventionally timed chemotherapy. In the Scandinavian Adjuvant Chemotherapy
Study a short perioperative course of cyclophosphamide (5mg/kg for 5 days) started
immediately after mastectomy was compared to a 12 month schedule of
cyclophosphamide, methotrexate and 5-flurouracil in 1026 patients. A significant
advantage was noted for relapse-free survival in favour of perioperative chemotherapy
(p=0.002, Nissen-Meyer et al. 1986). This finding was not however confirmed by the
Ludwig Breast Cancer Study Group (Ludwig Breast Cancer Study Group 1989). In
this trial the chemotherapy regime used included cyclophosphamide, methotrexate,
flurouracil and leucoverin. One thousand and twenty-patients with operable node-
positive breast cancer were randomised to one of three treatment schedules. The first
group received a single perioperative course of chemotherapy within 36 hours of
mastectomy, the second received six cycles of conventionally timed chemotherapy
starting 25-32 days after operation and the third received both the perioperative cycle
and the conventionally timed regimen. Tamoxifen was added to the conventionally
timed chemotherapy in postmenopausal women. With a median follow-up period of 42
months, the estimated 4 year disease-free survival was 40% for the group of women
who received a single perioperative cycle, 62% for the longer conventionally timed
regimen and 60% for the combined program (p<0.0001). Overall survival also
favoured longer treatment (p=0.011). The authors concluded from this study that a
single perioperative cycle of adjuvant combination chemotherapy was less effective than
prolonged therapy in patients with operable breast cancer with involved axillary nodes.
Furthermore starting the prolonged chemotherapy in the perioperative period added little
to beginning treatment 4 weeks after mastectomy (Ludwig Breast Cancer Study Group
1989).
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Several groups have retrospectively evaluated the relationship between delay in
initiation of chemotherapy after surgery and disease-free survival (Senn, Jungi &
Amgwerd 1981; Buzdar et al. 1982; Glucsksberg et al. 1982). Because these studies
were not primarily set up to answer this specific question their evidence is less
substantial. In the OSAKO trial (Senn, Jungi & Amgweid 1981) patients with newly
diagnosed cancer of the breast were treated with LMFP (leukeran, methotrexate,
flurouracil, prednisone) chemotherapy regime with or without BCG. A review of the
first 117 patients has shown that the median delay between diagnosis and the first day
of chemotherapy was 32 days in the relapsing and 23 days in nonrelapsing patients
(p=0.05; Ragaz 1986). Other workers (Jones et al. 1984; Brooks et al. 1983) have
also shown that long as opposed to short delays adversely affect outcome. The South
West Oncology Group (Glucskberg et al. 1982) and the M.D. Anderson Hospital
(Buzdar et al. 1982) however have failed to demonstrate any correlation. Buzdar and
his colleagues (Buzdar et al. 1982) subdivided their study of 460 patient with stage II
and III breast cancer into 4 subgroups according to the length of delay in initiation of
chemotherapy following regional therapy. These groups included patients who had
received their chemotherapy <10weeks, 10-13 weeks, 14-17 weeks and >18 weeks
post surgery. Their respective overall four year disease-free survival was 64%, 68%,
60%, and 63%. The Southwest Oncology Group (Glucskberg et al. 1982) in their
randomised trial comparing one year of adjuvant combination chemotherapy with
continuous cyclophosphamide, methotrexate, flurouracil,vincristine and prednisone
(CMFVP) to two years of intermittent L-PAM in women with operable breast cancer
with positive axillary nodes also analysed the relationship between interval from
mastectomy to onset of chemotherapy (between 1-6 weeks) and rate of recurrence. No
correlation was demonstrated. Animal experiments suggest that it is the first 7 days
which are of greatest importance in relation to the effectiveness of perioperative
chemotherapy (Fisher, Gunduz & Saffer 1983) and it must be noted that in both the
study reported by Buzdar (Buzdar et al. 1982) and the Southwest Oncology Group
(Glucsberg et al. 1982) the importance of giving chemotherapy within the first
postoperative week has not been separately analysed .
Thus despite the convincing theoretical and experimental data indicating superiority of
early administration of systemic therapy the value of giving chemotherapy early in the
postoperative period as opposed to 4-6 weeks latter has not yet been sufficiently tested
in human malignancy and requires further definition. The results of further
prospective ongoing randomised trials will be vital (Ragaz 1986).
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Preoperative Chemotherapy
Several workers have demonstrated both increased survival and improved
locoregional control in mice-mammary carcinoma when chemotherapy was
administered before, rather than after surgical removal of the primary lesion. ( Corbett
et al. 1981; Fisher, Gunduz & Saffer 1983; Schabel et al. 1979). Combination
chemotherapy prior to local therapy was first introduced for human breast cancer by the
Milan group (DeLena et al. 1978, 1981).
Investigation of preoperative chemotherapy regimes in breast cancer have until recently
been uncontrolled individual studies concentrating on patients with locally advanced
disease; a group of patients known to have a poor overall survival and early relapse
when treated by surgery or radiotherapy alone. Improved 5 year overall (57% to 73%)
and distant-free (50% to 87.5%) survival was demonstrated for patients with operable
stage III breast cancer (T3, NO-2) receiving 6 cycles of combination chemotherapy
therapy as opposed to radiotherapy after modified radical mastectomy (Grohn et al.
1984). Combination chemotherapy prior to local therapy for human breast cancer was
introduced by the Milan group (DeLena et al. 1981). In 110 patients a 70% objective
response rate (complete response rate of 15%) was achieved with 4 cycles of
adriamycin and vincristine chemotherapy prior to local therapy. This produced an
overall 3 year survival of 53% compared to 41% for a historical control group receiving
radiation alone. In subsequent studies comparing surgery versus radiation after
primary chemotherapy, equivalent findings were achieved with respect to local control,
patterns of recurrence, and overall survival (DeLena et al. 1981). A similar
multimodality treatment strategy has been used in 174 patients with locally advanced
noninflammatory stage III breast cancer at the M D Anderson Hospital (Hortobagyi et
al. 1988). All patients received as their initial therapy 3 cycles of cyclophosphamide,
adriamycin and flurouracil. Local treatment in the form of mastectomy, axillary
dissection radiotherapy or both was then carried out after which chemotherapy was
continued using the induction regime until a total cumulative dose of adriamycin of 450
mg/m2 was reached. Thereafter chemotherapy was continued using
cyclophosphamide, methotrexate and flurouracil for a further 20 cycles. Following
induction chemotherapy, objective remission was achieved in 87.4% (complete
remission 16.7%) of patients and following local therapy all but 6 of the 174 patients
were rendered disease-free. With a median follow-up period of 59 months, the 5 year
disease-free survival was 84% for patient with stage IIIA disease and 33% for patients
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with stage IIIB disease. Five year overall survival rates were 84% and 44%
respectively; 26 patients (15.3%) had locoregional recurrence. The quality of response
to induction chemotherapy correlated prominently with prognosis.
At the department of Medical Oncology of the Salpetriere Hospital and the Department
of Radiotherapy of the Necker Hospital in France, 98 patients with locally advanced
breast cancer (stage IIIA-IIIB) have received intensive induction chemotherapy,
locoregional radiotherapy and maintenance chemotherapy with or without
hormonotherapy (Jacquillat et al. 1988). The chemotherapy used consisted of
vincristine, thiotepa, methotrexate, flurouracil, adriamycin for both induction and
maintenance chemotherapy. In addition tamoxifen was given to all postmenopausal
women; premenopausal women received this drug by random allocation. Mastectomy
was not an integral part of this study. Tumour regression with reduction in tumour size
in excess of 50% was observed in 91% of patients after chemotherapy and complete
clinical remission in 100% of patients after irradiation. The rate of local relapse was
13% at 3 years. The 3-year disease-free survival was 62% with an overall survival of
77%. Again they demonstrated that initial tumour regression of >75% was the main
predictive factor for disease-free survival (Jacquillat et al. 1988).
The National Cancer Institute, since 1977, has given women with locally advanced
breast cancer chemotherapy to the point of maximum objective clinical response in an
attempt to produce considerable tumour regression to enhance the ability to perform
surgical resection or deliver a tumouricidal dose of radiation (Swain et al. 1987).
Concomitant endocrine and chemotherapy were used in such a way so that tamoxifen
and premarin were administered sequentially before the cell cycle specific agents in the
hope of synchronising DNA synthesis in the tumour cells and thus make them more
susceptible to cytotoxic chemotherapy (Weichselbaum et al. 1978; Aitken & Lippman
1982). The chemotherapy regime used included cyclophosphamide, adriamycin,
methotrexate, flurouracil, and leucoverin and initial doses of chemotherapy were
escalated to targeted myelosuppression. Patients were treated to maximum clinical
response before preceding to any local therapy. Patients achieving a complete response
with a negative biopsy received radiation only while patients with residual disease
received debulking surgery prior to irradiation. All patients received at least 6 months
of additional chemotherapy following local therapy. Seventy-six patients with locally
advanced breast cancer have now received this form of management, 31 with stage
IIIA, 41 with stage IIIB and 4 with stage IV disease. The objective response rate to
induction chemotherapy was 93% with 49% complete response , 44% partial response
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and 7% no change. With a median follow-up period of 26.4 months (range 0-
66months), 24 (32%) patients have relapsed with a 14% incidence of locoregional
recurrence. The median time to progression was 35.9 months for stage IIIA and 34.2
months for stage IIIB. The median survival was 35.3 months for stage IIIB and
indeterminate for stage IIIA. The high response rate within this series reported by
Swain (Swain et al. 1987) is due in part to an increased proportion of patients achieving
complete response and relates to the increased number of cycles of chemotherapy given
before surgery.
After the success of preoperative therapy in advanced disease, this approach was
extended to operable tumours, with the aim of downstaging them to facilitate a more
conservative surgical approach. Such a study was started in Milan in 1989 and the
results of 165 patients, with operable tumours of diameter greater than 3 cm have
recently been reported (Bonadonna et al. 1990). Five different chemotherapeutic
regimens were tried with similar effect. In 127 (81%) of patients a reduction in tumour
size to diameter of less than 3cms was achieved allowing a breast-saving procedure.
Mansi and colleagues (Mansi et al. 1989) have also reported results from primary
medical therapy in operable breast cancer. Of the 15 patients treated with primary
chemotherapy, 60% achieved a response and of the 42 patients 47% achieved
regression as defined by UICC criteria. Subsequent mastectomy was only performed
in 18% of patients, 30% had radiotherapy and or conservative surgery and the rest are
still on medical therapy. With a median follow-up of 19 months (range 6- 42 months)
only two patients have had a local recurrence and none have developed uncontrolled
local disease. Eight have developed distant recurrence and 4 (7%) have died of
metastatic disease. In both of these studies therefore, although downstaging of local
disease allowing more conservative surgery has been achieved in a high proportion of
patients, the followup is too short to be sure of the ultimate impact of primary
chemotherapy, used in this way, on local control. In addition given the design of the
study, the impact of primary chemotherapy on relapse-free and overall survival is not
likely to be conclusive.
Interest has also been shown in the initial use of tamoxifen in operable breast cancer of
elderly (>70 years) patients (Gazet et al. 1988; Ashby et al. 1988; Robertson et al.
1988; Gaskell et al. 1989; Horobin et al. 1991). Only two however are prospective
randomised trials comparing primary tamoxifen to surgery. Preliminary data (median
follow-up 3 years) from a study of 116 elderly patients with breast cancer that has
shown no difference in either time to progression or survival and suggested that
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tamoxifen was as effective as surgery (Gazet et al. 1988). In contrast Robertson and
colleagues in a study comparing wedge mastectomy to primary tamoxifen therapy have
demonstrated that with a median follow-up time of 2 years that a high proportion of the
group treated by tamoxifen alone required surgery for local control (Robertson et al
1988). This lead them to the conclusion that optimal treatment for elderly patients
should include both surgery and tamoxifen. The use of tumour characteristics to
predict both an increased likelihood of initial response, by determination of ER status
by immunocytochemical assay (Gaskell et al. 1989), or persistence of response as
shown only in those patients who achieve complete clinical response (Horobin et al.
1991) may help select a subgroup of patients with operable breast tumours in whom
primary tamoxifen is the treatment of choice.
In conclusion, studies of preoperative chemotherapy (Table 4) in advanced disease
have suggested improved survival rates as compared to corresponding figures from
stage matched control populations. Direct evaluation of preoperative chemotherapy can
however only come from randomised control studies. There are at present two ongoing
controlled randomised trials testing the efficacy of pre- versus post- operative
chemotherapy in operable breast cancer. In the NSABP study four cycles of
preoperative adriamycin and cyclophosphamide given at 3 weekly intervals followed by
surgical therapy is being compared to surgery followed by the same chemotherapeutic
regime. This study is still in its infancy and as yet no results as yet available. In 1983
a randomised trial of preoperative therapy was started by Ragaz in British Colombia
(Ragaz 1986). In this study premenopausal women with operable breast cancer are
randomised following a tissue diagnosis of breast cancer (cytological or histological) to
receive either a preoperative course of CMF as soon as the staging investigations are
ordered or to proceed onto initial definitive locoregional surgery. After surgery the
high risk patients (axillary lymph node involvement or histological evidence of vascular
or lymphangitic spread in the primary tumour) from both groups receive eight
(preoperative arm) or nine (no preoperative CMF) courses of CMF at 3 weekly
intervals. The median interval between diagnosis and the first cycle of chemotherapy
was 6 and 24 days respectively. The disease free interval at 2 years followup (n=68 )
has shown no statistically significant difference between the randomised arms.
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Table 4
Overview of the studies of induction chemotherapy in locally advanced breast cancer.
No. of Response 3 Year 5 Year


















1989 (inflammatory) 61 61% ... . 27% 58%
OS = overall survival: DFS = disease-free survival; LR = local relapse rate: CR =







31 - 50% -
41 50% 45% -
4 ...
98 91%(23) 77% 62% 13%
41 - ... 63% 54%
CHAPTER 3
SELECTING APPROPRIATE SYSTEMIC THERAPY
The goal of adjuvant systemic therapy for breast cancer is to effect a significant
prolongation of survival, while maintaining an acceptable quality of life. From
adjuvant studies it is apparent that not all patients benefit equally from systemic therapy
and given the high morbidity associated with cytotoxic therapy (Glass et al. 1981) a
non selective policy is not ideal. One of the most difficult aspects of assessing the
success of any therapeutic approach is in knowing how successful that approach has
been. In no area is the data more confusing than in the assessment of factors which
predict for response to systemic therapy, since not only is the ground confused by
differing therapeutic approaches but breast cancer itself is a heterogeneous collection of
disease patterns with very variable courses. This section reviews current understanding
of factors which will predict for response to systemic therapy in both the advanced and
adjuvant setting.
PREDICTING SENSITIVITY TO ENDOCRINE THERAPY
A critical step forward in our understanding of the mechanism of oestrogen action on
mammary tissue came with the discovery of high-affinity binding sites for oestrogen,
originally in rat mammary tumours (King, Cowan & Inman 1965) and subsequently in
normal (Desphande et al. 1967) and eventually malignant breast (Jensen et al. 1971)
tissue. Oestrogen receptors (ER) can be detected in 60-80% of human breast cancers,
and their concentration is related to age, menstrual status and the degree of
differentiation of the tumour (McGuire et al. 1975). The highest receptor values are
found in more differentiated, highly cellular tumours (Elston et al. 1980) or those from
postmenopausal patients (Hawkins, Roberts & Forrest 1980).
Structure and Measurement of the Oestrogen Receptor
The ER has been characterised by sucrose-gradient centrifugation as an 8S protein
(Gorski et al. 1968; Jensen et al. 1968). The unoccupied receptor sites are loosely
bound within the nucleus. Oestradiol diffuses to the nucleus, where receptor binding
produces a configurational change causing tight binding to genonic DNA and
transcription of messenger RNA (King & Greene 1984).
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Ligand-saturation assays were developed by which unoccupied sites of oestrogen
receptor (ER) could readily be quantified (Hawkins et al. 1975; 1981). These ligand
binding assays have however been associated with certain methodological difficulties
(Raam et al 1981; Leclercq et al. 1975; Thoipe 1987). The development of an antibody
to the oestrogen receptor (Greene, Fitch & Jensen 1980; Greene & Jensen 1982) has
allowed newer and more reliable radioimmune, immunohistochemical and
immunocytochemical assays to be developed. These assays offer several advantages
over the conventional steroid-binding biochemical assay since they are rapid, do not
require complex laboratory materials and can be performed on small tissue samples or
fine-needle aspirates (Flowers et al. 1986; Hawkins et al. 1987; McLelland et al. 1987;
Weintraub et al. 1987). They also provide valuable information concerning the
heterogeneity of ER expression within a tumour population.
Several studies have examined the relative sensitivities and specificities of the
biochemical and immunochemical assay methods. Although in general these have
demonstrated a good correlation, several differences have been noted (King et al.
1985; McCarty et al. 1985; McLelland et al. 1985, 1986: Hawkins et al. 1987).
Recent data has shown that the immunocytochemical ER status also correlates with
mitotic activity of the tumour, patient age and prognosis. (Walker et al. 1988).
Oestrogen Receptor and Response to Endocrine Therapy
The concept that assay of oestrogen receptors may be of value in the clinical
management of breast cancer originates from the work of Folca and colleagues (Folca,
Glascock & Irvine 1961) who related uptake of synthetic oestrogens by tumour tissue
to patient response to simultaneous oophorectomy and adrenalectomy. Experiments in
rat mammary tumours indicated that tumours which contain appreciable concentrations
of ER regressed after endocrine ablative therapy whereas tumours without ER failed to
respond (McGuire, Pearson & Segaloff 1975). That ER concentration predicts for
response to endocrine therapy in human advanced breast cancer has been confirmed in
many studies (McGuire, Pearson & Segaloff 1975; Brooks et al. 1980, Jensen, 1975,
Dao & Nemoto, 1980, Oriana et al. 1986) and the results from over 1800 patients
reviewed by Hawkins (Hawkins, Roberts & Forrest 1980). The chances of tumour
regression in response to endocrine therapy in ER-negative tumours are small (4 -
14%), while tumours with detectable ER have a response rate of between 49-58%. In
the absence of ER data, response to endocrine therapy can be expected in approximately
one third of patients.
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A good correlation between response to tamoxifen and the proportion of tumour cells
which stain with ER antibody has also been demonstrated in patients with advanced
disease (Coombes et al. 1987) and elderly patients treated by primary endocrine therapy
(Gaskell et al. 1989).
The value of ER status in predicting benefit from adjuvant endocrine treatment
however remains controversial. While several studies have demonstrated that only
patients with ER-positive tumours treated by adjuvant tamoxifen have a statistically
significant survival advantage (Hubay et al. 1980; Palshof et al. 1985, Rose et al.,
1985, Fisher et al., 1986, Cummings et al. 1986: Rutquist et al., 1987, Meakin, 1985,
Marshall et al., 1987, Bianco et al., 1988 (disease-free survival only), the NATO trial
(Nolvadex Adjuvant Trial Organisation, 1988) has demonstrated a benefit independent
of ER status. An intermediate view has been suggested by the Scottish (Scottish
Cancer Trials Office 1987) and NSABP trials (Fisher et al. 1986) in which all patients
who received tamoxifen benefitted, but the level of benefit was greatest in those patients
with tumours of ER concentration >100fmol/mg cytosol protein and >9 fmol/mg
cytosol protein respectively (Table 5 ).
When the results of the individual studies are combined in an overview
a significant benefit can demonstrated in recurrence-free survival and overall survival
with adjuvant tamoxifen in both patients with ER-positive (>10 fmol/mg cytosol
protein) and ER-negative (<10 fmol/mg cytosol protein) tumours (Early Breast Cancer
Trialist's Collaborative Group 1992). When recurrence-free survival was analysed,the
level of benefit achieved in ER-positive tumours was significantly higher than for ER-
negative tumours (ER-negative 13% SD 4 versus ER-positive 32% SD3). The
difference in mortality benefit between ER-positive and ER-negative however was not
significant. These data suggests that adjuvant tamoxifen produced a beneficial effect
irrespective of the ER status of the primary tumour but the effect on long-term outcome
was largest when the primary tumour was ER-positive .
Improving the Predictive Value of Oestrogen Receptor
The presence of ER in a breast tumour is thus an indicator but not synonymous with
hormonal sensitivity. Various theories have been proposed to explain why the
correlation between the presence of ER and response to endocrine manipulation is not
more exact. These include tumour heterogeneity of ER concentration both at a cellular
(McClelland et al. 1986; Charpin et al. 1988) and architectural level (Hawkins et al.
1977; Senbanjo, Miller & Hawkins 1986), lability of the ER protein, sensitivity of the
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assay (Thorpe 1987), difficulty with reliable assessment of tumour response in
advanced disease (Hawkins 1985) and possible cytotoxic effects of endocrine drugs
which are not dependent on the ER (Sutherland, Watts & Ruenttz 1986; Etienne et al.
1989).The receptor remains however the primary site of interaction between the cell
and oestrogen. Biochemical detection of the ER however does not provide information
about the function of the receptor and it is possible that some failures of ER-positive
tumours to respond to endocrine therapy are due to a nonfunctioning receptor complex
(Jensen et al. 1982).
Table 5
Summary of the relationship between ER status of the primary tumour and survival









(Nolvadex Adjuvant Trial Organisation 1988)
all levelsNolvadex
Scottish 742 57
(Scottish Breast Cancer Trials Committee 1987)
all levels- >99fmol best
NSABP B09 1079
(Fisher et al. 1986)
82 all levels- ER or PR
>9fmol best
Copenhagen 225
(Pashlof et al. 1985)
59 >9fmol, >60fmol best
ECOG 144
(Cummings et al. 1986)
85 >9fmol only
GUN 308
(Bianco et al. 1988)
71 ER or PR >9fmol
Danish 291
(Rose et al. 1985)
18 >99 fmol only
56
In sensitive breast cancer cells oestrogen is known not only to stimulate cell
proliferation and reduce cell cycle time (Weichselbaum et al. 1978; Lykkesfeldt et al.
1984), but also induce at a transciptional level, the synthesis of specific proteins. Some
of these proteins are thought to coordinate the trophic effect of oestrogens at an
autocrine or paracrine level (Lippman & Dickson 1989). Detection of these oestrogen-
induced proteins, or their messenger RNA, now possible with monoclonal antibodies
and probes, would give at least partial information on the integrity of ER-mediated
pathways and may improve the accuracy for predicting response to endocrine therapy.
The progesterone receptor was the first oestrogen-induced protein to be studied in
breast cancer (Sherman, Corval & O'Malley 1970; Milgrom et al. 1972, Horwitz &
McGuirel977; Horwitz, Koseki & McGuire 1978). Other proteins include a pS2
protein (Masiakowski et al. 1982, Brown et al. 1984), a 52kDa protein precursor of
cathepsin D (Westley et al. 1984; Rochefort et al. 1986), a 160 kDa protein (Westley et
al. 1984), insulin like growth factors IGF-I and n, transforming growth factors TGF-
§l, TGF-j, fibroblast growth factors, and platelet derived growth factors (Lippman &
Dickson 1989).
The Progesterone Receptor
In 1972 Milgrom and colleagues first demonstrated that oestradiol induces progesterone
receptors (PR) in the rat uterus (Milgrom et al. 1972). Several workers have now
confirmed this observation for human breast cancer cells (Horwitz & McGuire 1977;
1978; Horwitz, Koseki & McGuire 1978; Rao & Meyer 1977). PR can be detected in
approximately two thirds of ER-positive tumours, but is exceptional in ER-negative
tumours (8%, McGuire & Horwitz 1977, Hawkins et al.1987). The incidence of PR-
positivity also tends to rise as the ER concentration increases (Hawkins et al. 1987).
The presence of PR has been shown to improve the prediction of objective response to
endocrine manipulation in advanced disease by up to 70 - 80% (Hawkins, Roberts &
Forrest 1980; Siebert & Lippman 1982; Lippman 1988) Interestingly, about 30% of
ER-positive but PR-negative tumours respond to endocrine therapy. It has been
suggested that this may be due to problems in detecting the PR. In postmenopausal
women levels of circulating oestradiol are low and this may account for the failure to
detect PR in some elderly women. In premenopausal women levels of circulating
progesterone during the luteal phase are high and this may mask the receptor sites
(Saez, Martin & Chouvet 1978). These dilemmas may be solved with the recent
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development of antibodies to the PR which bind irrespective of the occupancy of the
receptor (Pertschuk et al. 1988).
The relationship between progesterone receptor (PR) status and efficacy of adjuvant
tamoxifen is shown in Table 5. Analysis of disease-free survival in the Gun study
(Bianco et al. 1988). showed a near significant interaction between tamoxifen-
treatment effect and a PR concentration of >10 fmol/mg cytosol protein (p = 0.11)
which was significant interrelated to ER status (p = 0.04). In the NSABP B09 study
(Fisher et al. 1986) the progesterone receptor content was found to be a stronger
predictor of the effectiveness of PFT (L-phenyalanine mustard, 5-flurouracil,
tamoxifen) therapy than ER status.
PS2 and Response to Endocrine Therapy
The transcription of pS2 mRNA is stimulated by oestrogen (Masiakowski et al. 1982,
Brown et al. 1984) and inhibited by tamoxifen (Westley et al. 1984) in MCF-7 cell
lines. The mature protein is secreted probably as a 58 amino acid peptide, although its
exact function remains unknown (Nunez et al. 1987). A DNA probe is available for
the mRNA (Masiakowski et al. 1982) and a specific monoclonal antibody for the
protein (Nunez et al. 1987).
Not all breast cancers have positive staining for pS2. Ninety-six percent of ER-
negative tumours neither express PR or pS2 (Rio et al. 1987). Around 67% of ER-
positive tumours express the pS2 protein and although expression appears independent
of PR status, an increased likelihood of expression of pS2 in ER-PR-positive tumours
has been noted (Rio et al. 1987). No data is as yet available on its value as a predictive
index for hormonal sensitivity.
Epidermal Growth Factor Receptor and Response to Endocrine Therapy
The relationship between EGF-receptor expression and response of recurrent breast
cancer to tamoxifen has recently been reported in 72 patients (Nicholson et al. 1989).
Tumours which contained >10 fmol/mg cytosol protein were significantly less (8.5%)
likely to respond to tamoxifen than those tumours which were EGF-receptor negative
(30%, p<0.05). The effect was independent and additive to the ER status, such that
EGF-receptor-positive, ER-negative were least likely to respond (11%), EGF-receptor-
negative, ER-positive tumours were most likely to respond (44%) and if both receptors
were either positive or negative the response rate was intermediate at around 30%.
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Correlation Between Local Metabolism and Endocrine Responsiveness
Little direct data is available concerning the relationship of local oestradiol production
and hormone sensitivity but several studies have related the pattern of endogenous
steroidogenesis to the established marker of hormone sensitivity, namely ER-status
(McGuire, Pearson, Segalof 1975).
Sulphokinase Activity
High sulphating activity is invariably associated with ER-positive tumours, whereas
ER-negative tumours usually have low activity (Adams et al. 1979). A direct and
absolute relationship between the presence of steroid sulphurylation and response to
endocrine therapy has been demonstrated in one major study of response to
adrenalectomy and patients with advanced breast cancer (Dao & Libby 1972), but this
has not been confirmed by other workers (Leung et al. 1973).
Aromatase Activity
Aromatase activity can be demonstrated in both ER-positive and ER-negative tumours.
While some studies have failed to demonstrate a significant association between these
two parameters (Varela & Dao 1978, Li & Adams 1981, Tilson-Mallet et al. 1983),
others have demonstrated a positive association. Vermeulen & Deslypere (Vermeulen
& Deslypere 1989) have suggested a higher level of aromatase activity exists in ER-
positive tumours while Miller & O'Neill have demonstrated a higher incidence of
significant activity in ER-positive tumours but a similar level of activity in both ER-
positive and ER-negative tumours (Miller & O'Neill 1987).
Correlation between response to aminoglutethimide therapy and aromatase activity has
been investigated in 23 postmenopausal patients with ER-positive tumours by Miller
(Miller & O'Neill 1989). Of the 5 patients in whose tumours aromatase activity was
undetectable, there were no responders; response was observed in 11 of the 18 patients
whose tumours exhibit significant aromatase activity. It was concluded that while the
detection of aromatase activity in a tumour may not be an absolute marker for response
to aminoglutethimide, it would seem that the drug, which is known to produce at least
some of its effect through aromatase inhibition, is more likely to produce response in
patients whose tumours contain significant aromatase activity. A similar relationship
between aromatase activity and response to oophorectomy in premenopausal women or
tamoxifen in postmenopausal women has not been demonstrated (Miller & O'Neill
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1989). Tumour aromatase activity may therefore be a marker of hormonal sensitivity
specific to the aromatase inhibitors.
17B hydroxysteroid Dehydrogenase Activity
17B hydroxysteroid dehydrogenase activity is significantly higher in ER-positive when
compared to ER-negative tumours (Vermeulen & Deslypere 1989). In ER-positive
tumours the enzyme activity can be induced by progestins and the increase has been
suggested to be a further putative marker for hormonal dependency (Foumier et al
1985).
Rate of Cell Proliferation and Endocrine Sensitivity
Histological Grade
Several methods have been developed for the histological grading of breast carcinomas
(Elston 1988). The best known is that described by Bloom and Richardson (Bloom
1950a, 1950b, Bloom& Richardson 1957), which relies on the subjective assessment
of the number of mitosis present, the level of nuclear pleomorphism and the degree of
tubular formation to classify tumours into three categories; well-differentiated grade 1,
moderately-differentiated grade 2 and pooly-differentiated grade 3. This method was
latter refined by Elston (Elston 1984, 1988) Black (Black, Opler & Speerl955; Black,
Barklay & Hankey 1975) developed an alternative grading system which was derived
from the work of Bloom, but assessed tubular structures and nuclear appearances
separately, with the conclusion that tubular differentiation did not contribute to
prognosis but nuclear appearances did. Fisher (Fisher, Gregorio & Fisher 1975;
Fisher 1977) have advocated a method which combines both systems. All three
methods have been shown to correlate with prognosis (Bloom & Field 1971; Black,
Barklay & Hankey 1975; Fisher, Redmond & Fisher 1980). The distribution of cases
within this grading system which can be expected for any given series of patients is
given in Table 6.
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Table 6
Comparison of the relative percentages of cases in each histological grade from
different studies.
Study Histological grade %
I II III
Bloom & Richardson (1957) 26 45 29
Wolff (1966) 33 33 34
Tough et al. (1969) 11 51 38
Champion et al. (1972) 23 52 25
Fisher et al. (1980) 3 30 67
Fisher et al. (1984) 11 23 66
Elston (1984) 17 37 46
Masters et al. (1987) 4 58 38
An inverse relationship has been demonstrate between the degree of differentiation and
frequency of response to endocrine therapy (Millis et al. 1981, Masters, Millis &
Rubenl986) and survival (Williams et al. 1986) in advanced disease. Response of
advanced breast cancer to endocrine therapy is known to correlate with such features as
a long postoperative disease-free interval, the presence of steroid receptor activity and
elastosis (Masters et al. 1979) within the tumour. These features are all interrelated and
it was not possible to determine, on the small sample study whether the positive
association with grade was independent of the other factors. Williams and colleagues
(Williams et al. 1986), following a study of survival in patients with metastatic breast
carcinoma treated by endocrine therapy, suggested that the addition of low grade to
high ER status could define a subpopulation which had an improved survival when
compared to simply a population with high ER status.
Information relating the importance of histological tumour grade to benefit from
adjuvant tamoxifen is scanty but is available in a subsection of 546 cases from the
NATO trial (Singh et al. 1988). The greatest benefit from adjuvant tamoxifen was
observed in those patients with better differentiated tumours (Grade I and II). No
survival advantage was noted in Grade III tumours which were twice as likely to be
ER-negative than ER-positive. In this trial benefit from adjuvant tamoxifen was
independent of ER status (Nolvadex Adjuvant Trial Organisation 1988) and therefore
the relationship between grade to benefit may be real but requires further definition.
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Similarly the NSABP study (Fisher et al. 1986) has shown that a good nuclear grade
was predictive of a better disease-free and overall survival in patients receiving
chemoendocrine therapy (L-pam, 5 FU and tamoxifen). The effect was independent of
but additive to the predictive value of hormone receptor status.
DNA Analysis and Labelling Indicies
Changes in cell cycle distribution following hormone treatment may be elicited in model
systems for example, MCF-7 breast cancer cell lines which when given oestrogen
show a dose dependent increase in the rate of proliferation, with recruitment of
nondividing cells from the resting G0/G1 phase into the actively dividing population
and also shortening of the cell cycle time due to a decrease in the G1 phase of the cell
cycle (Weichselbaum et al. 1978). Administration of tamoxifen, a competitive inhibitor
of oestrogen for its receptor, causes a dose dependent inhibition of these effects, with
reduction of the cells within the S-phase and accumulation of cells in the growth arrest
phase of G0/G1 (Green et al. 1981; Sutherland et al. 1983; Bruno et al. 1988,
Lykkesfeldt et al. 1984) and G2/M phase (Lykkesfeldt et al. 1984, Bruno et al. 1988).
In vitro the effect of tamoxifen can be detected within 36 hours of challenge and if it
were possible to detect such changes in cell cycle kinetics in vivo it would prove a
useful early predictor of response (Brunner et al. 1984). As yet this has not been
possible (Engleholm et al. 1987) and may relate to the heterogeneity within the tumour.
However information from DNA analysis may relate to likelihood of response. A
higher incidence of complete response to endocrine therapy has been shown in
tumours which are both ER-positive and have a low proliferation rate (Meyer & Lee
1980; Paradiso et al. 1988). Although the time taken to reach maximal response was
shorter with tumours which exhibit a faster proliferation rate, these tumours were more
likely to escape hormonal control (Paradiso et al. 1988). Tetraploid tumours when
treated by adjuvant endocrine therapy have shown improved survival in relation to other
aneuploid tumours and they may represent a distinct entity of endocrine responsive
tumours (Baildam et al. 1987a 1987b; Stuart-Harris et al. 1985). It is unclear whether
this represents an independent effect or is a function of the better prognosis or higher
ER-positivity of tetraploid tumours (Baildam et al. 1987b).
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Efficacy of Adjuvant Tamoxifen in Relation to Patient Characteristics
Age, Menopausal Status and Axillary Node Status
The relationship between age and effect from adjuvant tamoxifen has also been
reviewed by recent meta-analysis. The beneficial effect of tamoxifen on both recurrence
and mortality is highly significant in women over the age of 50 at randomisation (Early
Breast Cancer Trialist's Collaborative Group 1992a). Among women under the age of
50, tamoxifen produced a highly significant delay in recurrence (12% SD 4), but the
size of the benefit was significantly less than for women over the age of 50 (Early
Breast Cancer Trialist's Collaborative Group 1992a). For survival the general pattern
resembles that for recurrence-free survival, but with smaller risk reductions and hence
less statistical significance to the pattern. The effect of tamoxifen on overall survival in
women under the age of 50 was favourable but did not reached statistical significance.
The trend towards less effect in younger age groups only just reaching conventional
significance (2p = 0.04). Improved survival has however been demonstrated in
premenopausal women within several individual trials by subgroup analysis (Pashlof
et al. 1985; Scottish Breast Cancer Trials Committee 1987; Nolvadex Adjuvant Trial
Organisation 1988; Bianco et al. 1988).
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PREDICTING SENSITIVITY TO CYTOTOXIC THERAPY
Sensitivity to anticancer drugs may either be tested directly by in vitro panel testing or
indirectly by relating specific histological and biochemical parameters to response in
vivo. The following section summarises the data which is presently available in relation
to cytotoxic drugs.
Efficacy of Cytotoxic Therapy and Relationship to Patient
Characteristics
Axillary Node Status
The proportional reduction in annual risk for both recurrence-free and overall survival
was similar in extent irrespective of the axillary node status. The absolute benefits at 5
and 10 years however appear greater in node-positive disease and was highly
significant (Early Breast Cancer Trialists' Collaborative Group 1988, 1992b). The
meta-analysis at 10 years has now confirmed that even in node-negative disease the
survival benefit produced is significant. In relation to individual randomised studies
two large series containing over 500 patient, with a followup period in excess of 3
years have been published on the effect of polychemotherapeutic regimes in patients
with high risk (ER-negative or ER-positive diameter >3cms) node negative disease
(Fisher et al. 1989, Mansour et al. 1989). Each have shown a statistically significant
prolongation of disease-free survival in favour of women who received cytotoxic
therapy. As yet no significant difference in survival has been observed but the trials are
still immature in relation to overall survival.
Patient Age and Menopausal Status
Clear survival benefits from cytotoxic therapy were evident in the overview for women
less than 50 years of age (Early Breast Cancer Trialists' Collaborative Group 1988,
1992b). The effect of polychemotherapy on mortality in women > 50 years old was
also significant but appear to be only half as large as the benefit achieved in younger
women (Early Breast Cancer Trialists' Collaborative Group 1992b). A significant
reduction in recurrence rates has been demonstrated with adjuvant cytotoxic therapy
irrespective of age (Early Breast Cancer Trialists' Collaborative Group 1988, 1992b).
Age is related to menopausal status but the relationship was so close that it was not
possible to disentangle the effects of these two factors on the response to
polychemotherapy.
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Oestrogen and Progesterone Status
Controversy exists regarding the relationship between ER content and response to
chemotherapy in patients with advanced breast cancer. Some workers have reported a
negative correlation between ER presence and response to chemotherapy (Jonat &
Maass 1978; Hilf et al. 1980), while others have noted a positive correlation (Kiang et
al. 1978; Young, Ehrlich & Einhorn 1980; Rosenbaum et al. 1980, Samal et al. 1980;
Mortimer et al. 1981) and yet others have been unable to demonstrate any relationship
at all (Rubens et al. 1980; Jonat et al. 1980; Bonadonna et al. 1980; Stewart et al.
1983).
The relationship between hormone receptor status and the value gained from adjuvant
chemotherapy is also illdefined. Padmanabhan (Padmanabhan , Howell & Rubens
1986) in his review of the literature on adjuvant chemotherapy noted that the benefit
gained from adjuvant chemotherapy was equivalent to that obtained by oophorectomy,
with the predominant effect seen in premenopausal women, especially when permanent
amenorrhoea was achieved. Adjuvant chemotherapy induces permanent cessation of
menstruation in 70% of premenopausal patients by 6 months of treatment. This is
accompanied by a concomitant decrease in circulating oestrogens and a a rise in
gonadotrophins (Rubens 1988). Moreover in Rubens study (Rubens 1988) the effect
of chemotherapy was confined to patients with progesterone receptor positive tumours.
These observation lead them to postulate that the major effect of adjuvant chemotherapy
was mediated by ovarian suppression, with only a small contribution from direct
cytotoxicity. Debate on this philosophy continues. Randomised trial are currently
ongoing comparing the effects of oophorectomy directly with that of a CMF regime in
node-positive premenopausal women (Scottish Breast Cancer Trials Committee - Trial
A personal communication). Unfortunately hormonal studies are not an integral part of
this study and so the study may not help to resolve this precise problem.
Two recent studies of chemotherapy however, in oestrogen receptor negative tumours
(Fisher 1988, Bonadonna et al 1987), have shown a significant improvement in
disease-free survival in the treatment arm suggesting some effect independent of the
presence of the ER and therefore not hormonally mediated. Other studies have relied
on retrospective analyses of subpopulations not stratified for ER at the time of
randomisation. In a randomised trial of a single perioperative cycle of combination
chemotherapy with no adjuvant therapy, involving 1275 patients with no axillary
node metastasis, not only was an improvement in disease-free survival noted in pre-
and postmenopausal women but the magnitude of effect was largest among patients
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with no or low oestrogen-receptor content of their primary tumour (Ludwig Breast
Cancer Study Group 1989).
In Vitro Test of Drug Sensitivity - The Clonogenic Assay
The "human tumour stem-cell assay" has been proposed as an in vitro method by which
the activity of anticancer drugs could be tested against tumour cells from the patient and
is analogous to sensitivity testing for antibiotics in patients with bacterial infections.
Tumours contain a small proportion of stem cells which are capable of unlimited self-
renewal and are responsible for tumour growth and metastasis (Mendelsohn &
Dethlefsen 1968; Steel 1977). Inherent drug sensitivity of these tumour stem cells is a
prerequisite for treatment success and a major determinant of clinical response.
Stem cells when grown in enriched semisolid agar will produce cell colonies or clones
(Hamburger & Salmonl977; Courteney et al. 1978; Salmon et al. 1978) against which
a panel of anticancer drugs can be tested. Using this clonogenic assay it has been
shown that human tumours of a single histological type exhibit a pattern of response
in vitro which is similar to their known clinical behaviour (Von Hoff et al. 1981). For
any given histological type however, tumours display heterogeneity in sensitivity
patterns both in vivo and in vitro. Direct comparison of in vitro sensitivity and clinical
response has shown that when the in vitro assay predicts for resistance it is correct in
84-98% of cases, whereas the prediction of drug sensitivity is correct in 40-70% of
cases (Salmon et al. 1980; Von Hoff et al. 1981a; Mann et al. 1982; Meyskens et al.
1981; Hug et al. 1986). Both clinical response rates (Von Hoff et al. 1981b) and
survival (Alberts et al. 1982; Durie, Young & Salmon 1983) have been shown to be
improved by selecting drugs by in vitro panel testing but the majority of these trials
have been retrospective and uncontrolled and to date there is no study which has
unequivocally demonstrated that the assay has benefited the patient.
There are also several technical problems associated with the clonogenic assay which
would make its routine application impracticable. Sufficient in vitro growth for drug
testing can be obtained from less than 50% of tumour biopsies (Selby, Buick &
Tannock 1983; Von Hoff 1983a; 1983b) and Selby (Selby, Buick & Tannock 1983)
has calculated that in only 5% of the total patients tested would an improvement be
achieved in drug selection.
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In summary although this method of testing may have potential for improving the
selection of appropriate chemotherapeutics agents improved methods are clearly still
needed before a definitive trial can be undertaken.
Multidrug Resistance
Multidrug resistance describes the phenomenon of simultaneous resistance to several
structurally and functionally unrelated cytotoxic drugs. A specific form of multidrug
resistance has been identified from tumour cell lines, in which there was
overexpression, due to gene amplification (Gros, Croop & Housman 1986; Chen-Jie
et al. 1986), of a high molecular weight, membrane bound glycoprotein named P-
glycoprotein (Gerlach et al. 1986; Pastan & Gottesman 1987). Resistant cells contain
decrease levels of intracellular cytotoxic drug and it is now thought that the P-
glycoprotein is an energy-dependent membrane transport protein which extrudes toxic
drugs from the cell. This effect is directly inhibited by calcium channel blockers which
may represent a potential method of increasing the sensitivity of tumour cells to
cytotoxic drugs (Tsuruo et al. 1981, 1982).
Monoclonal antibodies are now available against the P-glycoprotein and a cDNA
probe against its gene. These have allowed the relevance of P-glycoprotein to be
studied in a small number of human tumours in vivo. P-glycoprotein has been
identified in around 10-20% of tumours tested and although increased amounts have
been demonstrated with increasing resistance to therapy (Kartner & Ling 1989) no
study has yet demonstrated a clear role for the multidrug resistant phenotype in clinical
drug resistance.
Topoisomerases and Atypical Multidrug Resistance
Cells lines have been developed which display resistance to different classes of
antineoplastic agents in the absence of any apparent P-glycoprotein gene expression
(Marsh & Center 1987; Danks, Yalowich & Beck 1987). In these cells the drug influx
and steady-state intracellular drug concentrations were similar to the parent drug-
sensitive cells. This new pattern of cross-resistance has been termed "atypical
multidrug resistance" and although the precise mechanism is not known, there is
strong evidence implicating altered topoisomerase activity in the resistant cells (Moscow
& Cowan 1988).
Topoisomerases are enzymes which catalyse changes in the secondary and tertiary
structure of DNA and are necessary for DNA replication. Topoisomerase II is thought
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to be the enzyme target of drugs which act as DNA-intercalating agents (Glisson et al.
1986). They may represent the final common pathway of cytotoxicity for several
different classes of antineoplastic agents. No studies have yet determined whether
altered topoisomerase activity plays a role in clinical drug resistance.
Glutathione S-Transferase Enzymes
There is evidence that overexpression of glutathione and glutathione dependent
enzymes are important mechanisms of acquired drug resistance in both normal and
tumour cells (Hirono 1960; Calcutt & Connors 1963; Arrick & Nathan 1984; Fabrer
1984; Wolf et al. 1987; Hayes & Wolf 1988; Lewis et al. 1988, 1989). Although the
direct involvement of these enzymes in the detoxification of anticancer drugs has not
been clearly established, glutathione S-transferase mediated conjugation of melphalan
has been reported (Dulik, Feneselau & Hilton 1986). It is likely that the enzyme will
also be able to inactivate other structurally related nitrogen mustards. Certainly cell
lines resistant to nitrogen mustards, such as chlorambucil and cyclophosphamide
(Wang & Tew 1985; McGowan & Fox 1986; Robson et al. 1987; Buller, Clapper &
Tew 1987), cisplatin (Green et al. 1984) and adriamycin (Green et al. 1984) have been
shown to have elevated levels of GST. Such elevated levels have been shown to be
associated with an amplification of alpha class glutathione S-transferase genes (Lewis
et al. 1989). The role of glutathione S-transferase in clinical drug resistance has yet to
be determined.
Glutathione Peroxidase
Glutathione peroxidase catalyses the reduction of potentially toxic peroxides to alcohols
at the expense of oxidising GSH to its disulphide form. Adriamycin-resistant MCF-7
cells have shown a 13-fold increase in glutathione peroxidase activity relative to the
parent cell line suggesting a possible causal relationship (Sinha et al. 1987).
Rate of Cell Proliferation and Chemosensitivity
Histological Grade
Proliferating cells are known to be more sensitive to the lethal activities of most
cytotoxic drugs than cells which are not proliferating (Valeriote & van Putten 1975).
One would therefore expect that rapidly growing tumours respond more readily to
therapy whereas tumours with a low rate of proliferation very often show no reaction to
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therapy. Clinical studies in human solid tumours (Silvestrini et al 1985) and leukemias
(Hart et al. 1977) have demonstrated that a direct relationship exists between the DNA
labeling index and clinical therapeutic success such that well-differentiated tumours,
with the possible exception of lymphomas and chronic lymphocytic leukemias, are
relatively resistant to chemotherapy, while poorly-differentiated tumours are more
likely to respond (Whitehouse 1984). A study of the relationship between response
to chemotherapy and tumour grade, elastosis, and ploidy, in 125 patients with
advanced breast disease has however failed to confirm any significant relationship,
although there was a trend for patients with tumours which were diploid or had a high
elastosis content to have a higher response rate (Masters et al. 1987).
Nuclear grade was shown to have an independent influence on both disease-free and
overall survival in breast cancer patients receiving adjuvant L-pam, 5 flurouracil with
or without tamoxifen (Fisher et al. 1986). Those having tumours with either receptors
>10 fmol or a good nuclear grade had a better relative 5 year survival. The magnitude
of difference was similar for all three discriminants but the effect was independent for
each and the predictive value improved if more than one marker was used, particularly
in those patients who received tamoxifen.
DNA Analysis and Labelling Indicies
It has been observed that in the treatment of leukemia, patients with tumours which had
a high thymidine labelling index (TLI), were more likely to achieve complete response
(Zittoun et al. 1975). A significant reduction in the TLI of tumours 48 hours post-
therapy has been shown to predict for clinical response to cytotoxic therapy in some
tumours (Murphy et al. 1975;, Zittoun et al. 1975; Thirlwell et al. 1976). A
relationship between labelling index and clinical response in a small number of patients
to combination chemotherapy has been demonstrated (Sulkes, Livingston & Murphy
1979). None of the patients with a labelling index of less than 9% regressed with
therapy, in contrast to 11 of 16 patients with a labelling index greater than 9%.
There has been no evidence to support the value of tumour ploidy or % S-phase as
useful indices of chemoresponsiveness in breast cancer in vivo (Masters et al. 1987).
Thymidine Kinase Activity
Thymidine kinase is the essential enzyme involved in the salvage pathway of DNA
synthesis. Levels within malignant tissue are significantly elevated (Kit 1976) and
correlate directly with the proliferation rate (Kit 1976, Bronzert et al. 1981). A rise in
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thymidine kinase activity can also be demonstrated in ER-positive cells when growth is
stimulated by oestrogens (Bronzert et al. 1981).
In a study of 45 patients with breast cancer treated by combination chemotherapy, a
significant difference was demonstrated in the response rates of tumours containing
greater or less that 80 pmol/mg/min of thymidine kinase activity (86 vs 13%, Zhang,
Kennedy & Kiang 1984). The effect was independent of the ER-status of the tumour.
Within this study, thymidine kinase activity was not useful in determining response to
endocrine therapy but the numbers were small (n=12) and a higher median
concentration was found in those with regression.
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CHAPTER 4
ASSESSMENT OF TUMOUR RESPONSE
The principal aim of new therapies is to improve survival. For the individual patient, to
use survival as an end point is too complex since it takes years of followup, may be
confused by multiple therapies and the biological heterogeneity of breast cancer itself.
For this reason a more objective method of assessment of tumour response has been
sought and if the primary tumour is left in situ during systemic therapy, it can be used
as an assessable parameter of the disease.
The natural course of a solid tumour is to grow. The rate of growth is variable in breast
cancer and doubling times may vary between a week and a year, with a median of
around 60 days (Steel 1977). It is however rare for breast tumours to undergo
spontaneous remission (Wyard 1925; Greenwood 1926; Daland 1927; Everson & Cole
1966) and it is therefore likely that any sustained reduction in tumour size is due to
therapy. Provided an accurate method of determining tumour size can be achieved,
response to therapy could be followed. The problem comes with accurate measurement
of tumour size.
Direct measurement of changes in clinical tumour size
Direct measurement of tumour mass with a ruler or engineers calipers, has been a basic
method of testing the effect of anti-tumour agents in animals. Tumour size has been
shown to correlated with weight and volume in these models (Scholler, Phillips &
Bittner 1955). Using simulated tumour nodules it has been shown that if response is
assessed from measurement of a single diameter, a significant false positive response
rate exists (Moertel & Hanley 1976) such that if a reduction of 25% in diameter was
used, the placebo response rate was 19% if the same observer had measured the tumour
and as high as 25% if the second measurement had been made by a different observer.
When a 50% reduction in diameter was used to define response, the false response rate
due to measurement error was reduced to 7.8%. On the basis of these findings in 1977
guide lines were introduced by the UICC for the evaluation of response to treatment in
advanced disease (Hayward et al. 1977; Ward et al. 1977). In the case with a clinically
measurable lesion, a 50% or greater reduction in diameter was required in order to
specify regression although the exact period of time was not defined. Progression was
defined as a greater than 25% increase in tumour diameter with tumours of intermediate
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response being categorised as no change. A 50 % reduction in diameter however
represents over an 80% reduction in tumour volume and if the measurement error could
be reduced a less stringent index of tumour response may be defined.
Several pertinent points were made by Brindley and his colleagues in their review of
tumour measurements in patients with inoperable breast cancer (Brindley, Markoff &
Schneiderman 1959). They demonstrated that two observers, measuring the same
lesion may differ by a considerable amount in the absolute measurement, but if each
remained consistent in their method, the noted changes in lesion size were very similar.
Measurements taken at frequent intervals also allowed discrimination of transient
changes in tumour size from a real therapeutic effect. Only those lesions which were
discrete and easy to measure gave reproducible results and since an observer may be
influenced by knowledge of their previous values, measurements should be made
without referring to previous results. Other workers (Warr, McKinney & Tannock
1984; 1985) have confirmed that the false positive rate could be reduced if two or
more successive measurements showed a consistent change, or if the pretreatment
diameter of the lesion was greater than 3.2 cm.
By utilising the theory of multiple measurements by the same observer over a period of
treatment, Thomlinson (Thomlinson 1982; 1987) has devised an alternative method of
assessing response based on the statistical regression analysis of the observed changes
in tumour volume. Over 62,000 measurements were made in 239 tumours. The
average number of measurement points in each regression line was 7 and the
correlation coefficient of the exponential regression lines were extremely high. This
represent a more precise method of assessing regression in the individual patient while
also allowing appraisal of the rates of regression.
Imaging
A further objective measurement of tumour size can be gained from imaging the tumour
and the most commonly used technique in breast disease is mammography. The
relationship between clinical and mammographic response to systemic therapy has been
reviewed in 49 patients with primary breast cancer (Cocconi et al. 1984) with some
disagreement being noted in quantifing the magnitude of response. Physical
examination overestimated the overall response rate in relationship to mammography in
22.9% of cases, while in 8.6% of cases the reverse was true . Although physical
examination may be less objective than mammography, a mammographic abnormality
does not allow differentiation between malignant or reactive processes within the
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imaged lesion. It was concluded that both techniques should be used together since the
most favourable response was the best predictor of complete pathological response.
Like clinical examination, mammography only gives a two dimentional view of the
tumour. The developing technique of breast ultrasound may be a potential method of
obtaining estimation of the thud elusive dimension, depth (Nishimura et al. 1988)
Pathological Assessment of Response
Pathological assessment of a change in tumour size is difficult since in order to assess
intial tumour size it would require complete removal of the tumour. Complete
histological disappearance of a tumour is however a definite end point and it has been
suggested that this is a better predictor for survival than complete clinical response
(Feldman et al. 1986).
Survival
It is common practice in cancer literature to compare the survival experience of patients
who respond with those who do not respond to therapy and assume that the difference
is due to the efficacy of therapy (Anderson, Cain & Gelber 1983; Anderson & Davis
1986). This type of direct analysis is invalid since survival may be associated with
response because of some basic underlying factor which merely identifies those more
prognostically favourable patients. To test the efficacy of new therapies properly






Patients were considered for entry into the study if they presented with an invasive
adenocarcinoma of the breast, 4 cms or greater in clinical diameter (T2, T3, NO, Nl,
MO). Patients with evidence of tumour fixation to underlying muscle or chest wall,
skin involvement, breast lymphoedema, or detectable metastasis on routine clinical and
radiological investigations were excluded from the study as were patients with tumours
of classical lobular carcinoma, because of the inherent difficulty in clinical and
mammographic measurement of these tumours. Due to the undetermined effect on the
psychological state of patients undergoing this form of management, patients with a
history of psychological morbidity were not included. Patients required to be medically
fit for and have no history of previous chemotherapy. All patients were Karnofsky
grade 0.
During the 4 year period between April 1985 and April 1989, 136 patients presented
to the Breast Unit of Longmore Hospital with a primary breast carcinoma of clinical
diameter greater than 4cm; 88 have been included in this study. Sixteen patients failed
to fulfil the selection requirements due either to psychological (n = 7) or medical (n = 3)
infirmity, or the wedge biopsy revealed lobular carcinoma (n = 3) or carcinoma in situ
(n= 3). In 5 patients, a large amount of tissue had already been removed to establish
diagnosis so leaving insufficient tissue for reliable measurement; in a further 13
patients the tumour was either multifocal, partly cystic, bilateral or just difficult to
measure reliably. Seven patient were excluded because they lived greater than 50 miles
from the hospital. Only 7 patients refused preoperative therapy, prefening immediate
mastectomy.
The mean age of the study population was 53.1 years (range 33 - 69 years). Thirty-
eight patients were premenopausal (less than one year since their last menstrual period),
50 were postmenopausal. Determination of menopausal status in patients who had
undergone hysterectomy was based on serum gonadotropin levels; patients were




At initial presentation, tumour size was assessed both clinically and
mammographically. The diagnosis of malignancy was made from cytological
examination of a fine-needle aspirate. Staging assessment was performed in all patients
and involved a thorough clinical examination supplemented by haematological
(erythrocyte sedimentation rate, full blood count) biochemical (urea and electrolytes,
liver function tests, serum calcium, phosphate and albumin) and radiological (chest X-
ray and radioisotope bone scan) investigation. Any patient with abnormal liver function
tests had a liver ultrasound to exclude the presence of overt metastasis. The philosophy
of the study was explained to all suitable patients both verbally and by written
document and informed consent obtained.
Pretreatment tumour material for histological and biochemical evaluation, was obtained
by incisional wedge biopsy performed under general anaesthesia. Approximately
0.6cm3 of tumour was removed and a biopsy of 2 grams of peritumour fat also
obtained; all specimens were transported to the laboratory on ice. In order to
standardise the technique this procedure has been performed by one person (EA) in the
last 50 patients and to aid post-therapeutic localisation of the tumour area, the tumour
bed was marked by metal ligaclips. Early in the study an involved axillary node was
excised in preference to biopsy of the primary tumour in 15 patients. Although not




Of the 88 patients included within this study 61 received primary endocrine therapy
(Table 12) and 47 cytotoxic therapy. Twenty patients received both endocrine and
cytotoxic therapy. Systemic therapy was commenced within 10 days of the wedge
biopsy.
Initially a small pilot study was conducted in which all patients (n = 36) received
endocrine therapy; a variety of endocrine agents being assessed. Ovarian function was
ablated in premenopausal women initially by surgical bilateral oophorectomy (n = 5)
and subsequently by means of the lutenising-hormone releasing-hormone analogue
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goserelin (Zoladex ICI 118630, subcutaneous implantation 3.6mg depot preparation at
28 day intervals following 4ml lignocaine local anaesthetic, n = 7). Postmenopausal
women received either tamoxifen (20mg per day, n = 11) or the aromatase inhibitor
aminoglutethimide (500mg plus 40mg hydrocortisone acetate, n = 10 ). Three
postmenopausal patients received goserelin as their primary therapy. Following the
demonstration that no patient with an ER concentration of <20 femtomols/mg cytosol
protein showed significant regression to endocrine therapy (Table ), a more formal
selective policy was instituted on 1st April 1987. Endocrine therapy was reserved only
for those patients with ER-moderate/rich tumours (>20fmol/mg cytosol protein),
patient with ER-poor tumours (ER<20fmol/mg cytosol protein) or those patients with
tumours unresponsive to endocrine therapy received cytotoxic therapy. In this
formalised protocol premenopausal patients received goserelin (n = 9) and
postmenopausal patients received the selective peripheral aromatase inhibitor, 4-
hydroxyandrostenedione (250mg intramuscular injection to alternate buttocks at 14 day
intervals; Ciba-Geigy CGP 32349, n = 16).
Cytotoxic Therapy
Forty-seven patients received cytotoxic therapy. The regime used was 4 cycles of
CHOP (cyclophosphamide lg/m2, adriamycin 50mg/m2, vincristine 1.4mg/m2,
maximum 2g, all by iv bolus and oral prednisolone 40mg per day for 5 days)
administered at 21 day intervals. If cytopenia (white blood count <3,000 ml~3 or
platelet count of < 100,000 ml~3) was present on day 21, therapy was delayed until the
cytopenia had resolved. A dose adjusted course was then given. Twenty-seven
patients, all with tumours of ER concentration of < 20 fmols/mg cytosol protein were
given chemotherapy as their primary treatment. The remaining 20 patients received
chemotherapy following failed endocrine therapy; 10 had ER-negative/poor and 10 had
ER-moderate/rich tumours (Table ).
Assessment of Response to Therapy
Clinical Assessment
Patients were reviewed at weekly intervals by one clinician and serial mean clinical
diameters obtained. Although formal assessment of tumour response was calculated
following completion of 12 weeks systemic therapy, detection of any interim signs of
local progression (n = 16), i.e. de novo breast lymphoedema or increasing size of
tumour, ensured that endocrine therapy was immediately stopped and the patient either
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transferred to cytotoxic therapy or proceeded immediate to mastectomy (n = 2).
Clinical response to therapy was assessed either as clinical progression (de novo
presentation of breast lymphoedema), residual palpable tumour or complete clinical
regression when there was no residual tumour palpable.
Statistical Assessment of Response
Statistical evaluation of response was by linear regression analysis (Apple Mac,
Statview) of the changes in tumour volume between treatment weeks 4 to 12 (earlier
measurements were not considered inorder to allow the reaction caused by tumour
biopsy to subside, Figure 1, 3, 5 and 7).
Mean tumour volume was calculated by assuming that the tumour was a sphere
(4/3th3) and mean clinical tumour diameter was calculated by taking the mean of
measurements performed in 8 differing axes taken at 22.5° angles using engineers
calipers. Care was taken to apply a consistent amount of pressure. All measurements
within the same patient were performed when possible by the same investigator and
without direct knowledge of previous measurements.
Linear regression analysis is a standard statistical test (Rees 1985) which allows
determination of the relationship between two variables (in this case time and log of
tumour volume) drawn on a scattergram. It is based on the linear regression equation
y = a + bx
where y is the variable on the y-axis, x is the variable on the x-axis, b the slope
(gradient or regression coefficient) of the line and a the intercept. By application of this
equation to a scattergram of two variables, a 'best fit' or regression line can be drawn.
This is a line for which the sums of the squares of distances from the points to the line
in the y direction are minimised. Application of regression equations allow not only
estimation of y given x within the allocated range but also by application of hypothesis
testing to the slope of the regression line one can calculate whether it is significantly
greater than 0 (5% level). The designated formula is
t = b
Sr
/ Ex2 - Ex2/n
Where b = slope of the line, Sr is the residual standard deviation (residual is the
distance from the points to the line in the y direction) and n is the number of points.
The significance with which the line deviates from zero is calculated by comparing the
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observed value of t to tables of the Student t distribution with n-2 degrees of freedom.
There are numerous statistical packages for calculation of linear regression of which the
Applemac Statview is only one.
When the scatter diagram shows a nonlinear pattern it may be possible to produce a
linear pattern by transforming one of the variables (Reesl985). If a standard
proportional reduction in tumour volume was to occur for every given period of time a
nonlinear scattergram would be obtained for this reason the volume data has been log
transformed (log 10) when calculating regression.
Response was graded as i) significant regression (reduction in tumour size where the
probability that the regression line deviated from the horizontal was greater than 95%)
ii) progression (significant increase in tumour diameter or signs of local advancement)
iii) no change (regression slope intermediate to significant regression and progression).
Mammographic Assessment
Alterations in tumour size were also assessed radiologically by a single mammogram,
performed at 4 weekly intervals, in the view known to give the best perspective of the
tumour.
Pathological Assessment
Pathological assessment of tumour response was obtained by histological examination
of both the incisional wedge biopsy and the definitively excised specimen. In the latter
the macroscopic size of any residual tumour was measured by ruler. If no macroscopic
tumour was visible the specimen was graded according to whether or not there was any
evidence of microscopic tumour (complete or non-complete pathological response).
Axillary lymph nodes were also examined for the presence of metastatic tumour.
Hormonal Assays
Hormonal assays were performed in patients who received either goserelin or 4 -
hydroxyandrostenedione. Twenty mis of blood (lithium heparin tube) was spun at
4000 rpm. (4°C for 10 mins) and the resulting plasma pipetted off and stored at -20°C
until analysis. In patients who were treated with goserelin, samples were obtained
weekly for the first month and fortnightly thereafter. The samples were assayed for
plasma FSH, LH, oestradiol and progesterone. In patients undergoing treatment with
4-hydroxyandrostenedione plasma samples were obtained before initiating therapy and
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at 14 day intervals just prior to the next depot injection. Plasma oestrone levels were
assayed by gas chromatography-mass spectrometry performed by Dr Mitch Dowsett
and his staff at the Department of Academic Biochemistry of the Royal Marsden
Hospital, London (Dowsett et al. 1989).
Side-effects
Side-effects to therapy were assessed from the weekly clinical interview. The morbidity
associated with cytotoxic therapy was reported using the WHO toxicity grading system
(Miller et al. 1981). Blood was taken when clinically indicated and on day 21 for
patients receiving cytotoxic therapy and day 28 of the cycle in patients receiving
goserelin or 4-hydroxyandrostenedione, to check haematological and biochemical
indices.
Survival
All patients were followed with respect to disease-free survival, distant disease-free
survival and overall survival. Recurrences of tumour in the chest wall, ipsilateral breast
or axillary nodes were classified as local recurrences. Tumour reappearance in any
other area were considered as distant failure. Overall survival was defined as survival
with or without recurrence of disease. The followup period has been expressed from
entry into the study, dating from the time of initiating systemic therapy to the date of
analysis.
Survival has been analysed according to Kaplan Meier life analysis (Kaplan & Meier,
1958) and statistical differences between parameters calculated by the Generalised
Wilcoxon Test.
Definitive Locoregional Surgery
On completion of systemic therapy (3-6 months) mastectomy with extensive skin
removal (3cm clear of tumour) and axillary node clearance (level 3) was performed in
82 patients, of whom 55 have had simultaneous reconstruction by latissimus dorsi
myocutaneous flaps. In 6 patients, with complete clinical response, wide local
excision of the previous tumour site was preferred: this was followed by radical
radiotherapy in 5 cases.
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Postoperative Systemic Therapy
Patients who had shown significant regression to preoperative endocrine therapy were
continued on endocrine therapy following definitive locoregional surgery.
Premenopausal patients proceeded to oophorectomy, postmenopausal patients received




MEASUREMENT OF POTENTIAL PREDICTIVE INDICES
Biochemical Method of Oestrogen Receptor Estimation
In both pre- and post-treatment specimens, a section was cut from the face of the tissue
portion used for receptor analysis, fixed in formol-saline and stained with haematoxylin
and eosin to permit histopathological confirmation of the presence of tumour.
Oestrogen receptor activity was determined by saturation analysis (Hawkins et al.
1975, 1981). In brief, tumour was homogenised in tris-monothioglycerol-glycerol
buffer and centrifuged at low speed; aliquots of tumour cytosol were incubated at 40C
overnight with oestradiol +/_ 8 concentrations of nonradioactive oestradiol (0.031-
62.3 nMolar). After separation of the bound fraction by adsorption with dextran-coated
charcoal, and scintillation counting, the concentration of receptor sites and dissociation
constant of binding were calculated by Scatchard analysis (Scatchard 1949) using a
programmed BBC microcomputer. Protein concentration was determined in a separate
aliquot of each tumour cytosol by the method of Bradford (Bradford 1976); using
serum albumin as a standard, with 5 quality controls. Receptor concentration was
finally expressed as fentomoles of binding sites/mg extract protein.
Correlation of Changes in ER with Changes in Histology
To examine the correlation between any changes in ER concentration and
histopathology, 12 paired (pre- and post-treatment) tumours samples were
independently examined by Dr. T.J. Anderson to exclude major differences in
morphology of the pre- and post-treatment paired specimens.
Statistical analysis
The relationship between pre- and post-treatment specimen ER concentrations was
examined using the paired "t" test after logarithmic transformation of the data.
Determination of Oestrogen Receptor Status by Cytochemical Assay
Smears for cytochemical assay were prepared from the fine needle aspirate for
diagnostic cytopathology, and any material left within the syringe and aspiration needle
was flushed through and into Roswell Park Memorial Institute (RPMI) tissue culture
medium (0.4ml). Distilled water was added to lyse erythrocytes, further medium was
added to restore osmolarity and the remaining cells were harvested by centrifugation (5
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mins at 230g) and resuspended in RPMI (>300ul). Three 100j.il aliquots were then
cytospun (4 min at lOOOrpm) onto slides precoated with polylysine, air-dried for 2
minutes, fixed and later stained with the immunocytochemical assay system (ERICA,
Abbott laboratories). Control slides were processed with each batch of aspirates.
Slides were independently assessed by two observers and following correction for
nonspecific staining, scored for both the proportion of epithelial cells staining,
expressed as a percentage, and the average staining intensity. The staining intensity
was graded visually on an arbitrary scale of 0 (no staining)- 3 (strong staining). To
determine whether correlation with either the biochemically determined ER
concentration or response could be improved by integrating these scores, their product
the "staining index" (% epithelial cells x average staining intensity x 0.01) was also
calculated.
Statistics
The relationship between two variables has been examined using the Spearman's Rank
Correlation Coefficient.
Measurement of 17B-hydroxysteroid Dehydrogenase Activity
Determination of 17B-hydroxysteroid dehydrogenase activity was based on in vitro
assay of the conversion of radioactive labelled androstenedione to testosterone and has
been expressed in pmols testosterone formed/mg protein/hour of incubation.
Harvesting
Breast adipose tissue was obtained from the vicinity of the primary tumour either at the
time of incisional biopsy or at the time of mastectomy. (If complete tumour regression
had occured, tissue was taken from the area surrounding the previous tumour biopsy
site). All biopsy tissue was rapidly processed and kept on ice until stored or fixed.
Adipose tissue was dissected free from breast parenchyma and fibrous tissue by
teasing with a metal forceps and stored in liquid nitrogen until assayed.
Extraction and Incubation
Two grams of fat were homogenised in ice cold buffer (2ml, 0.1M phosphate buffer,
pH 7.4) then centrifuged (800g, 5 mins at 4°C). The soluble fraction below the lipid
layer was extracted and further centrifuged (100,000g 60 mins). The particulate
fraction was resuspended in 600JJ.1 of ice cold phosphate buffer and a lOOql aliquot was
retained for protein estimation. The remaining 500pl was incubated for 3 hours at 37°C
in phosphate buffer (0.1M; pH 7.4) containing in a total volume of l.lmls, an NADPH
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generating system (NAD, ATP, NADP, glucose-6-phosphate, glucose-6-phoshate
dehydrogenase),IB 4-androstenedione(l()6 dpm) and cold androstenedione (final
concentration lOOnM). Blank incubations were also set up using 500(0.1 of bovine
serum albumin (2.0mg/ml) in place of the particulate fraction. The incubation was
terminated by the addition of ice cold chloroform. Testosterone fractions were purified
from the chloroform layer and aromatase activity derived from processing of aqueous
fractions.
Purification of Metabolites
Testosterone fractions were purified by thin layer chromatography and characterised by
chemical derivative formation. "Cold" carrier steroids androstenedione (500|ig) and
testosterone (500|ig) were added at this stage so that losses during purification and
characterisation could be determined.
Chloroform extracts were evaporated to dryness and the residue reconstituted in 2 mis
of ethanol. Two aliquots (40|il) were removed, dried down, reconstituted in Scintol 7
(10ml) and the radioactivity measured in a liquid scintillation counter to check
distribution of radioactivity between organic and aqueous fractions. The metabolites in
the remaining solution were separated by fractionation with thin layer chromatography
(chloroform: acetone 92.5:7.5 on silica gel HF 254/360 for lhour). Testosterone and
androstenedione fractions were identified by exposure to UV light. Both fractions were
eluted but only the testosterone fraction was purified further by sequential acetylation
and hydrolysis. Testosterone was acetylated by the addition of pyridine (3 drops) and
acetic anhydride (6 drops) and incubation for lhour at 60°C. The incubation was
halted by the addition of methanol. The mixture was evaporated to dryness,
reconstituted in ethanol and the derivative fractionated by thin layer chromatography
(cyclohexane: ethyl acetate 70:30). The area corresponding to the testosterone acetate
was identified under UV light, scraped off the plate and eluted with ethanol. Aliquots
were taken for estimation of radioactivity and concentration of testosterone acetate
determined by UV spectrophotometry. The testosterone acetate was then hydrolysed
by incubation overnight with 0.25mls of 2% K2CO3 at 37°C. Steroids were extracted
with ethyl acetate (5ml x 2). The bulked ethyl acetate extracts were evaporated to
dryness, reconstituted in ethanol and run on thin layer silica gel coated chromatography
plates in a solution of chloroform and acetone (92.5:7.5). The hydrolised testosterone
acetate was identified under UV light and eluted before being reconstituted in ethanol.
The resulting testosterone was reacetylated to obtain the third derivative. For each of
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the three derivatives, specimen samples were removed to determine the amount of cold
and radioactive testosterone, and sample specimens were obtained to assess
background radioactivity and steroid contamination. Radioactivity was read in a liquid
scintillation counter and the amount of cold testosterone assessed by U.V. absorbtion at
240 nm against a known standard solution of testosterone. Specific activities were
then calculated for the derivatives from each incubation and results only accepted when
the specific activities for all three derivatives were within a 10% error.
Activity was described as pmol testosterone formed/mg protein/hour incubation.
Formulae Used in Calculation of 17B-Hydroxysteroid Dehydrogenase
Activity
Estimation of radioactive testosterone in disintegrations per minute
= counts per minute X 100 X dilution correction
% efficiency of solvent
Estimation of cold testosterone in nmol
= (reading x - blank) X 694* X dilution correction
reading of standard
* amount of testosterone in 200(il of lmg/ml solution (standard)
Specific activity of derivative
= radioactivity (dpm)
amount of cold testosterone (nmol)
% conversion/3hour incubation
mean specific activity of derivatives X 1736* X 100
total amount of radioactivity
* amount of cold testosterone added in 500gil oflmg/ml.




The relationship between peritumour 17B-hydroxysteroid dehydrogenase activity and
ER concentration of the primary tumour was analysed using the Spearman Rank Test.
Correlation of with menopausal status and clinical response to systemic therapy have
been assessed from nonparametric analysis using the Mann-Whitney U Test. The
changes in 17B-hydroxysteroid dehydrogenase activity following systemic therapy
have been analysed using the Wilcox-signed rank test of log transformed data.
Measurement of Tumour Aromatase Activity
Tumour for assay was obtained from either the pretreatment biopsy or the mastectomy
specimen which had been rapidly transported to the laboratory on ice. A portion of the
specimen was taken to histologically confirm the presence of malignancy. 500mgs of
tumour was finely sliced and incubated for 2 hours at 37°C in Krebs-Ringer phosphate
buffer pH 7.4 containing, in a total volume of 7.5ml, an NADPH generating system
and 7&-3h testosterone (22.5 uCi, 8.9 Ci/mmol). The reaction was stopped by the
addition of methanol and the incubations stored at -10°C until processed.
Determination of protein content was by an adaption of the method of Bradford
(Bradford 1976).
Before extraction, 500pg of non-radioactive oestradiol was added to allow monitoring
of procedural losses. The mixture was then homogenised, centrifuged (2500 rpm for 2
mins) and the resulting supernatant decanted off. The residue was rehomogenised with
2 x 20ml. acetone, centrifuged for a further 2min at 2500 rpm and the acetone
supernatant combined with the aqueous methanol supernatant and evaporated to
dryness. The residue was dissolved in ethyl acetate (20ml) and partitioned with
distilled water (2 x 20ml). The ethyl acetate fraction was evaporated to dryness
dissolved in a few drops of alcohol and spotted onto thin-layer silica gel coated
chromatography plates (TLC). The TLC plates were run in a continuous elution
system with chloroform:acetone (98:2) for 3 hours. The area corresponding to
standard oestradiol was scraped off and eluted with alcohol, evaporated to dryness and
the precipitate redissolved in 4ml ethenpet ether 40-60 (1:1). NaOH (1ml N x 3) was
used to extract the steroid and the organic layer washed with 1ml of water. The NaOH
and aqueous extract were combined and neutralised with 0.56 g NaHC03. The
oestrogen fraction was extracted using ethyl acetate (2x2 ml), dried down and spotted
on to TLC plates and run for 1 hour in benzene: ethlyacetate (4:1). The oestradiol was
eluted with alcohol, evaporated to dryness and then acetylated by incubation for an hour
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at 60°C with acetic anhydride (6 drops) and pyridine (3drops). Methanol was then
added and the mixture evaporate to dryness, redissolved in a few drops of ethanol and
rerun on TCL plates in cyclohexane: ethyl acetate (7:3) for 1 hour. The fraction
corresponding to oestradiol diacetate was eluted with ethanol, evaporated to dryness
and then hydrolysed by incubating overnight (37°C) in 1ml of methanol and 0.25ml
2% K2CO3. Distilled water (3ml) was added and the steroid extracted with ethyl
acetate (2 x 5ml). The purified oestradiol fraction was then rerun on TCL in
benzene:ethyl acetate (4:1) for 1 hour and eluted. This represented the first derivative
and aliquots were taken for counting of radioactivity and estimation of cold oestradiol
by UV spectrophotometry (282nM) using a known oestradiol concentration as a
standard. The specific radioactivity of the derivative was expressed as dpm^H/nmol
oestradiol. The remaining oestradiol was reacetylated, run on TCL plates in
cyclohexane:ethyl acetate (7:3) for an hour, the oestradiol diacetate eluted and specific
radioactivity measured. The third derivative was obtained by hydrolysis as previously
described and the free oestradiol ran in benzene:acetate (4:1) for an hour. The free
oestradiol was eluted and the specific radioactivity measured. If this was not within
10% of that of the diacetate then the derivative formation and characterisation was
continued until it was. A fourth derivative was obtained by methylation of the free
oestradiol. Distilled water (10ml) were added to the dried steroid, followed by boric
acid (0.18g), NaOH (0.8ml, 20%) and dimethylsulphate (0.2ml). The steroid was
dissolved by shaking in a water bath (37°C) and then incubated for 30 mins. A further
0.4mls of NaOH (20%) and 0.2mls dimethyl sulphate were then added, the solution
shaken and reincubated for 30 mins (37°C). The incubation was culminated by the
addition of NaOH (2ml, 20%) and hydrogen peroxide (0.5ml, 30%). The methylated
oestradiol was extracted with 25ml pet. ether, redissolved in a spot of alcohol
and run on TCL in cyclohexane:ethyl acetone (1:1), eluted and its specific radioactivity
determined. This required to be within a 10% error of the specific activity of the third
derivative. When the specific activities were in agreement, the % conversion was
determined using the following formula
% conversion = specific radioactivity x 1838 x 100
dpm added initially
Aromatase activity was calculated from the % conversion based on the measurement of
radioactivity in the purified oestradiol fraction and has been expressed as pmol E2
produced/g/hr. Using these methods, conversions in excess of 0.02% (0.5 pmol
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E^/g/hr) were measurable and values below this figure have been considered as
negative.
Statistics
The relationship between the presense of aromatase and oestrogen receptor activity has
been analysed using the Fishers exact test. The changes in tumour aromatase actiity
following systemic therapy have been analysed using the Wilcoxon-signed rank test.
Determination of Protein Concentration
This was adapted from the method of Bradford (Bradford 1976). Coomassie Blue
Reagent (5ml) was added to 0.1ml blank, standards (10, 20, 30, 40, 50, 60, 70, 80
and lOOmg bovine serum albumin/ lOOmls 0.9% NaCl), quality controls (2 dilutions)
and the samples. Following thorough mixing the solutions were left for lOmins at
room temperature. The absorbance of each sample was read at 595nm in a
spectrophotometer against a reagent blank. A plot of absorbance (595nm) is an almost
linear curve. The protein concentration in each cytosol was established by reading from
the standard curve, correcting for the dilution employed. All samples were measured in
duplicate and the mean estiinated.
Determination of Histological Grade
Tissue for grading was fixed in 10% neutral buffered formalin, routinely processed,
embedded in paraffin wax and 6q sections stained with haematoxylin and eosin.
Grading was carried out on invasive cancer only using the modification to the criteria
of Bloom and Richardson (Elston 1988). In order to check the degree of consistency
all slides were graded by the same reader on two separate occasions without knowledge
of the previous results. In cases of discrepancy the tumours were graded for a third
time and a definitive grade assigned. Histological grading was obtained by analysis of
the following three features, each of which was given a score of 1-3.
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Tubule formation
Care was taken to differentiate between clefts due to tumour tissue shrinkage and tubule
formation.
Score 1 - great majority of tumour composed of tubules with clearly
visible lumina
2 - moderate amount of tubule formation but with areas of solid
tumour growth
3 - little or no tubule formation, the cells mainly growing in sheets
or cords.
Nuclear pleomorphism
The variability of both size and shape of tumour nuclei was assessed and scored.
Score 1 - little variation in size and shape of nuclei
2 - moderate variation without extremes of cell size or shape
3 - marked variation present with large bizzare nuclei and multiple
nucleoli.
Mitotic Rate
Using a magnification of x 300 the number of mitoses per 10 fields were counted.
Score 1- <10 mitoses per 10 fields
2- 10-19 mitoses per 10 fields
3 - > 20 mitoses per 10 fields
To obtain the overall tumour grade the scores for each category were added, giving a
possible score of between 3 and 9 points. Grade was then allocated on the following
basis;
Grade 1 - well differentiated - 3-5 points
Grade 2 - moderately differentiated - 6-7 points
Grade 3 - poorly differentiated - 8-9 points.
Statistics
The relationship between histological grade , ER status,patient menopausal status,
axillary node status and response to systemic therapy has been analysed using x^2 test.
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DNA Analysis
Fresh tumour was transported to the laboratory on ice and processed immediately. A
portion of tumour was submitted for histological analysis and FNA biopsies performed
on the remaining tumour. Using a lcm^ syringe with a 23 guage needle the tumour
was pierced, negative pressure applied and a gentle pumping action used to free cells.
After releasing the negative pressure, the needle was withdrawn and any material held
within the needle tip expelled into and flushed through with 200pl of citrate buffer. The
specimen was rapidly frozen and stored at -40oc until analysis (Vindelov et al. 1983b).
The method used for DNA staining is an adaption of that used by Vindelov (Vindelov,
Christensen, Nissen 1983; Vindelov et al. 1983a). Thawed cell suspension (lOOpl)
was mixed with an internal standard (Vindelov, Christensen, Nissen 1983) of chicken
red blood cells (15pl) and incubated for 10 minutes at room temperature with 0.003%
solution of trypsin (450pl). A solution of trypsin inhibitor (375pl, 0.05%w/w) and
RNAase (0.01 %w/w) was then added and a further 10 minutes incubation carried out.
The cells were then stained with a solution of propidium iodide (250pl, 416pl/ml) and
spermine tetrahydrochloride (1.16mg/ml). Samples were kept on ice and run in the
flow cytometer 30 to 120 minutes after addition of the propidium iodide solution. In
order to break-up any particulate matter the cell suspension was vigorously passed
through a 23 guage needle prior to insertion into the flow cytometer. Cellular DNA
content was measured using an EPICS C flow cytometer (Coulter Electronics Ltd,
Hialeah, Florida). A 5 watt argon laser was used to create a 250mW beam of 488nm
light. Twenty thousand cellular events were acquired on a single parameter red
fluorescence histogram. The chicken red blood cell internal control helped identify the
Go/Gl diploid population. Analysis of the DNA histograms was using the para 2 soft
ware package (Coulter Electronics).
Samples for flow cytometric analysis of paraffin-embedded tumour blocks were
prepared using the method of Hedley and collegues (Hedley, Freidlander & Taylor,
1983). The presence of representitive tumour tissue was confirmed on a 4pm
haematoxylin and eosin section. Adjacent 30pm sections were cut, dewaxed in two
changes of xylene (each for 10 min), rehydrated through decreasing concentrations of
ethanol (100, 95, 70, 50%, each for 10 min) and washed twice in distiled water.
Nuclei were released by cytoplasmic digestion, using 0.5% pepsin in 0.9% NaCl (pH
1.5) for 30min at 37°C. Release of nuclei was enhanced by intermittent vortex mixing.
Samples were resuspended in lpg of 4',6-diamidino-2-phenylindoldihydrochloride
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(DAPI) per millilitre of RPMI tissue culture medium. DAPI is a fluorescent dye that
binds to DNA. The quantity of DAPI bound is directly proportional to DNA content.
Stained nuclear suspensions were filtered through 35pm nylon mesh and analysed on a
the EPICS C flow cytometer, using ultra-violet excitation and blue fluorescent emision
(408nm long pass filter). A total of 20,000 nuclei were analysed in each sample.
The diploid population was given a DNA index of 1.0. DNA content was defined as
aneuploid, if there were 2 discrete Go/Gl peaks, the aneuploid peak containing at least
10% of the 20,000 cell events and there was an associated G2M peak. The aneuploid
populations were subclassified as follows, DNA index (DI)<1.0 = hypodiploid, 1.0<
DI< 1.9 = hyperdiploid, 1.9<DI<2.1 = tetraploid, DI>2.1 = hypertetraploid. By
definition a tetraploid population had at least 20% of cellular events and a corresponding
G2M peak. Tumours with more than one aneuploid peak were designated as
multiploid. Histograms were categorised as "acellular" when there was no distinct
Go/Gl peak or "unassessable" when either the coefficient of variation for the peak was
>5 or the peaks could not be satisfactorily resolved. No attempt was made to determine
% S-phase in aneuploid tumours.
The qualitative reproducibility of flow cytometric DNA analysis, using fine-needle
aspiration (FNA) as a method of biopsy was measured by obtaining 4 separate FNA
biopsies from each of 20 tumours.
Statistics
To express the variation in the measurement DI and % total cell count in aneuploid cell
lines due to measurement error, the pooled variance and standard deviation has been
used. All percentages are absolute figures i.e. % total cell counts.
The relationship between ploidy status and response to systemic therapy has been





ASSESSMENT OF RESPONSE TO TREATMENT
Reproducibility of Clinical Mean Tumour Diameter
In order to assess the reliability of clinical mean tumour diameter, multiple
measurements were performed in forty patient on 4 separate occasions before therapy
had been instituted or a surgical biopsy performed. At least 4 hours were allowed to
elapse between measurements. Results for both mean clinical tumour diameter and
resulting volumes have been analysed in relation to standard deviation and an indication
of variance is given by the pooled standard deviation (Table 7 and Table 8). For mean
tumour diameter the pooled standard deviation was 0.0072 ( SD range 0 - 0.183). For
tumour volume the pooled standard deviation was 9.87 (SD range 0 - 17.1).
Statistical Assessment of Response
The reduction in tumour volumes achieved with systemic therapy in association with
the gradients of the regression lines and corresponding statistical analysis as derived
from linear regression analysis are shown in Table 9 for all 88 patients. Examples of
regression lines are given in Figures 1, 3, 5, 7. The mean reduction in tumour value
of those tumours categorised as having undergone significant regression was 72%
(range 14 - 100%).
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Table 7
Reliability of clinical measurements of mean tumour diameter by comparison of
measurement taken at 4 different occasions from each of 40 tumours. Mean tumour
diameter was calculated by computing the mean of 8 diameters taken at 22.5° angles
with engineers calipers.
Clinical tumour diameter(cm) Mean Standard cv
1 2 3 4 deviation
3.9 4.1 4.1 3.9 4.0 0.115 2.89
5.2 5.3 5.1 5.2 5.2 0.082 1.57
6.5 6.3 6.5 6.4 6.42 0.096 1.49
3.9 4.1 4.0 4.0 4.0 0.082 2.04
4.9 4.9 5.0 5.1 4.97 0.096 1.92
4.3 4.3 4.2 4.4 4.3 0.082 1.89
5.1 5.0 5.0 5.0 5.02 0.05 0.99
5.9 5.7 6.0 5.8 5.85 0.129 2.21
5.0 5.0 5.1 5.0 5.02 0.05 0.99
4.0 4.2 4.2 4.0 4.1 0.115 2.82
6.7 6.5 6.7 6.6 6.62 0.096 1.44
4.0 4.0 4.0 4.0 4.0 0 0.00
6.6 6.5 6.7 6.6 6.6 0.082 1.24
4.0 4.1 4.0 4.0 4.02 0.05 1.24
4.7 4.7 4.8 4.8 4.75 0.058 1.21
4.6 4.6 4.5 4.5 4.55 0.058 1.27
4.7 4.8 4.6 4.8 4.75 0.096 2.03
9.7 10.0 10.0 9.8 9.87 0.15 1.52
5.8 5.5 5.5 5.7 5.62 0.15 2.67
3.8 4.1 4.0 3.9 3.95 0.129 3.27
5.6 5.6 5.8 5.9 5.72 0.15 2.62
4.6 4.6 4.5 4.7 4.6 0.082 1.77
4.3 4.4 4.4 4.4 4.37 0.05 1.14
6.2 6.3 6.3 6.2 6.25 0.058 0.92
4.8 4.9 5.0 5.0 4.92 0.096 1.94
5.2 5.2 5.2 5.1 5.17 0.05 0.96
4.7 4.7 4.8 4.8 4.75 0.058 1.21
4.9 4.7 4.8 4.8 4.77 0.096 2.00
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5.1 5.0 5.0 5.1 5.05 0.058 1.14
4.5 4.5 4.4 4.5 4.47 0.05 1.12
5.1 5.0 5.2 5.1 5.1 0.08 1.60
5.7 5.8 5.7 5.8 5.75 0.058 1.00
4.8 4.7 4.8 4.6 4.75 0.096 2.03
4.3 4.0 4.2 4.3 4.2 0.141 3.37
4.1 4.2 4.0 4.1 4.1 0.083 1.99
4.8 4.6 4.5 4.9 4.7 0.183 3.88
4.8 4.7 4.8 4.7 4.75 0.058 1.21
4.2 4 4.1 3.9 4.05 0.129 3.19
5.6 5.4 5.6 5.7 5.57 0.126 2.26
4.4 4.4 4.4 4.5 4.42 0.05 1.14
Mean 5.03 0.16 2.10
"Pooled" standard deviation = 0.0072
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Table 8
Reliability of clinical measurements of volume as calculated from mean tumour diameter
by comparison of measurement taken on 4 different occasions for each of 40 tumours.
Mean tumour diameter was calculated by computing the mean of 8 diameters taken at
22.5° angles with engineers calipers. Volume was calculated from 4/3;tr3-
'linical tumour volume(cm3) Mean Standard CV
1 2 3 4 deviation
31.0 36.1 36.1 31.0 33.6 2.94 8.78
73.6 77.9 69.4 73.6 73.6 3.47 4.71
143.7 130.9 143.7 137.2 138.9 6.14 4.42
31.0 36.1 33.5 33.5 33.5 2.08 6.21
61.6 61.6 65.4 69.4 64.5 3.72 5.78
41.6 41.6 38.8 44.6 41.6 2.37 5.69
69.4 65.4 65.4 65.4 66.4 2.00 3.01
107.4 96.9 113.0 102.1 104.9 6.94 6.62
65.4 65.4 69.4 65.4 66.4 2.00 3.01
33.5 38.8 38.8 33.5 36.1 3.06 8.46
157.4 143.7 157.4 150.5 152.2 6.56 4.30
33.5 33.5 33.5 33.5 33.5 0 0
150.5 143.7 157.4 150.5 150.5 5.60 3.70
33.5 36.1 33.5 33.5 34.1 1.30 3.80
54.3 54.3 57.9 57.9 56.1 2.08 3.71
50.9 50.9 47.7 47.7 49.3 1.85 3.75
54.3 57.9 50.9 57.9 55.2 3.36 6.08
358.2 392.5 392.5 369.4 378.2 17.1 4.50
102.1 87.1 87.1 96.9 93.3 7.46 8.00
28.7 36.1 33.5 31.0 32.3 3.19 9.86
91.9 91.9 102.1 107.4 98.3 7.73 7.86
50.9 50.9 47.7 54.3 50.9 2.69 5.29
41.6 44.6 44.6 44.6 43.8 1.5 3.42
124.8 130.9 130.9 124.8 127.8 3.52 2.75
57.9 61.6 65.4 65.4 62.6 3.59 5.74
73.6 73.6 73.6 69.4 72.6 2.1 2.89
54.3 54.3 57.9 57.9 56.1 2.08 3.71
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61.6 54.3 54.3 57.9 57.0 3.49 6.12
69.4 65.4 65.4 69.4 67.4 2.3 3.43
47.7 47.7 44.6 47.7 46.9 1.55 3.3
69.4 65.4 73.6 69.4 69.4 3.35 4.82
96.9 102.1 96.9 102.1 99.5 3.0 3.01
57.9 54.3 57.9 50.9 55.2 3.36 6.08
41.6 33.5 38.8 41.6 38.9 3.82 9.82
36.1 38.8 33.5 36.1 36.1 2.16 5.99
57.9 50.9 47.7 61.6 54.5 6.36 11.66
57.9 54.3 57.9 54.3 56.1 2.10 3.70
38.8 33.5 36.1 31.0 34.9 3.40 9.60
91.9 82.4 91.9 96.9 90.8 6.06 6.68
44.6 44.6 44.6 47.7 45.3 1.55 3.42
Mean 73.9 3.72 5.05
"Pooled" standard deviation = 9.76
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Figure 1
Response of a premenopausal woman with a large operable breast cancer of ER
concentration 46 fmol/mg cytosol protein following subcutaneous LHRH analogue
goserelin (3.6mg) at 28 day intervals shown by arrows. Each closed point represents
tumour volume as calculated from the mean clinical tumour diameter, while each open
point is the volume calculated from the mean mammographic diameter. The calculated
regression line had a correlation coefficient of -0.96 and a slope of -9 x 10~3




Response of a premenopausal woman with a large operable breast cancer of ER
concentration 46 fmol/mg cytosol protein following subcutaneous LHRH analogue
goserelin (3.6mg) at 28 day intervals as shown by serial changes in mammographic
tumour size at weeks a) 0,b) 4, c) 8, and d) 12. A significant reduction in tumour
volume was observed (Figure 1).
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Figure 3
Response of a postmenopausal woman with a large operable breast cancer of ER
concentration 81 fmol/mg cytosol protein following intramuscular 4-
hydroxyandrostenedione (250mg) at 14 day intervals as shown by arrows. Each
closed point represents tumour volume as calculated from the mean clinical tumour
diameter, while each open point is the volume calculated from the mean mammographic
diameter. The calculated regression line had a correlation coefficient of 0.24 and a
slope of 1 x 10"^ cm3(log)/day. This indicates non significant regression (p = 0.53
Student's t-test). The patient then went on to receive 4 cycles of the cytotoxic regime
CHOP as shown by the stars. The calculated regression line had a correlation
coefficient of -0.92 and a slope of -6 x 10~3 cm%og)/day. This indicates statistically
significant regression (p < 0.004, Student's t-test).
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Figure 4
Response of a postmenopausal woman with a large operable breast cancer of ER
concentration 81 fmol/mg cytosol protein following intramuscular 4-
hydroxyandrostenedione (250mg) at 14 day intervals for 84 days followed by 4 cycles
of the cytotoxic regime CHOP at 3 weekly intervals, as shown by serial changes in
mammographic size at weeks a) 0, b) 12, c) 16, and d) 24. No change in tumour size
was observed between treatment weeks 0 and 12. There was a significant reduction in
tumour size following chemotherapy (Figure 3).
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Figure 5.
Response of a postmenopausal woman with a large operable breast cancer of ER
concentration 19 fmol/mg cytosol protein following 4 cycles of the cytotoxic regime
CHOP (shown by star). Each closed point represents tumour volume as calculated
from the mean clinical tumour diameter, while each open point is the volume calculated
from the mean mammographic diameter. The calculated regression line had a
correlation coefficient of -0.80 and a slope of -2.4 x 10~2 cm3(log)/day. This indicates
statistically significant regression (p < 0.003, Student's t-test).
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Figure 6.
Response of a postmenopausal woman with a large operable breast cancer of ER
concentration 19 fmol/mg cytosol protein (Figure 5) following 4 cycles of the cytotoxic
regime CHOP as shown by serial changes in tumour size at a) 0, b) 4, c) 8 and d) 12
weeks. This patient achieved significant regression, note the gradual disappearance of























Response of a premenopausal woman with a large operable breast cancer of ER
concentration 8 fmol/mg cytosol protein following 4 cycles of the cytotoxic regime
CHOP (shown by star). Each closed point represents tumour volume as calculated
from the mean clinical tumour diameter, while each open point is the volume calculated
from the mean mammographic diameter. The calculated regression line had a
correlation coefficient of -0.70 and a slope of -4 x 10~2 cm3(log)/day. This indicates
statistically significant regression (p < 0.04, Student's t-test). The patient achieved a
clinically and histologically complete regression.
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Response of a pretmenopausal woman with a large operable breast cancer of ER
concentration 8 fmol/mg cytosol protein following 4 cycles of the cytotoxic regime
CHOP as shown by serial changes in mammographic tumour size at a) 0, b) 4, c) 8




Individual patient details of tumour volumes, regression analysis and clinical response
in relation to systemic therapy. Tumour volume was calculated from 4/3^3 mean
clinical volume.
Tumour volume (cm^)
Day 0 28 84
Oophorectomy
168
gradient "t"a p Clinical
response
33.5 36.1 28.7 - -0.002 2.48 0.04 R
91.9 57.9 26.5 - -0.005 5.83 0.01 R
102 54.3 57.8 - +0.00005 1.07 0.33 NC
Oophorectomy + CHOP
113.1 77.9 107.4 - +0.005 2.85 0.07 NC
- - 107.4 107.4 -0.0002 0.13 0.9 NC
69.4 54.3 50.9* - +0.002 0.89 0.4 P
- - 50.9* 14.1 -0.06 3.1 0.01 R
Zoladex
41.6 24.4 4.2 - -0.017 3.73 0.02 R
96.9 38.8 8.2 - -0.12 6.53 0.0006 R
28.7 15.6 4.8 - -0.009 2.68 0.04 R
239 172 4.2 - -0.029 9.3 0.0007 R
36.1 22.4 12.8 - -0.003 1.57 0.17 NC
41.6 24.4 22.4 - +0.001 0.91 0.4 NC
50.9 44.6 47.7 - +0.001 1.49 0.19 P
Zoladex + Oophorectomy
91.9 50.9 22.4 - -0.006 7.8 0.0001 R
57.9 36.1 1.77 - -0.02 4.75 0.003 R
157 65.4 22.4 - -0.009 5.4 0.003 R
Zoladex + CHOP
33.5 31.0 22.4 -0.002 2.26 0.06 NC
22.4 -0.034 6.13 0.002 CR
106
Tumour volume (cm^) gradient "t"a p Clinical
Day 0 28 84 168 response
92 113 143* - +0.007 1.08 0.47 P
143* 120 +0.002 2.19 0.09 NC
77.9 47.7 73.6 - +0.002 1.87 0.1 NC
73.6 54.3 0.0009 0.938 0.39 NC
44.6 24.4 22.4 - -0.0006 0.40 0.77 NC
73.6 69.4 -0.0002 0.314 0.77 NC
50.9 73.6* - - +0.006 - - P
73.6* 57.8 +0.003 1.27 0.24 NC
143 131 187* - +0.002 1.77 0.14 P
187* 0 -0.06 6.25 0.001 CR
151 195 204* - +0.001 0.16 0.88 P
204* 65.4 -0.009 3.45 0.04 R
57.9 69.4 87.1* - +0.14 0.15 0.67 P
87.1* 0 -0.028 5.46 0.002 CR
41.6 44.6 61.6* - +0.006 1.69 0.189 P
61.6* 8.1 -0.01 5.13 0.004 R
Aminoglutethimide + Hydrocortisone
54.3 41.6 20.6 - -0.005 3.95 0.007 R
77.9 82.4 38.8 - -0.003 3.11 0.01 R
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Tumour volume (cm^)
Day 0 28 84 168
gradient "t"a p Clinical
response
26.5 24.4 8.2 -0.007 2.7 0.03 R
54.3 50.9 24.4 -0.006 7.95 0.001 R
57.9 57.9 57.9 +0.0002 0.221 0.83 NC
87.1 73.6 73.6 -0.0004 0.394 0.72 NC
87.1 38.8 28.7 -0.002 1.47 0.2 NC
Aminoglutethimide + Hydrocortisone + CHOP
47.7 38.8 54.3
54.3 4.2
+0.003 2.21 0.09 NC
-0.015 8.88 0.003 R
96.9 54.3 57.9* - +0.00004 0.04 0.97 P
57.9* 24.4 -0.005 2.3 0.06 NC
50.9 44.6 57.9
57.9 0
+0.004 2.21 0.11 P
-0.023 5.17 0.007 CR
4-Hydroxyandrostenedione
38.8 24.4 8.2 -0.01 4.4 0.004 R
91.9 65.4 44.6 -0.004 3.14 0.02 R
41.6 44.6 18.8 -0.009 8.58 0.0001 R
57.9 18.8 7.2 -0.006 2.48 0.04 R
38.8 33.5 7.2 -0.011 7.25 0.0003 R
31 24.4 14.1 -0.004 7.9 0.0002 R
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Tumour volume (cm^) gradient "t"a p Clinical
Day 0 28 84 168 response
33.5 20.6 8.2 - -0.005 3.14 0.02 R
61.6 33.5 15.6 - -0.007 1.92 0.09 NC
28.7 17.1 17.1 - +0.0005 0.50 0.631 NC
41.6 36.1 26.5 - -0.004 2.1 0.08 NC
33.5 18.8 12.8 - -0.002 1.89 0.11 NC
77.9 47.7 54.3 - +0.0002 0.334 0.75 NC
54.3 33.5 22.4 - -0.002 3.89 0.008 PA
4-hydroxyandrostenedione + CHOP
113 96.9 96.9 - +0.001 0.66 0.53 NC
96.9 22.4 -0.006 5.2 0.003 R
65.4 87.1* - - +0.007 - - P
87.1* 61.6 -0.001 0.468 0.66 NC
73.6 69.4 69.4
_ +0.001 0.82 0.439 P
69.4 65.4 -0.002 0.88 0.42 NC
Tamoxifen
96.9 36.1 0 - -0.03 4.04 0.0001 R
96.9 41.6 10.3 - -0.012 4.15 0.004 R
44.6 38.8 22.4 - -0.003 6.2 0.0002 R
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Tumour volume (cm^)
Day 0 28 84 168
38.8 22.4 14.1
gradient "t"a p Clinical
response
-0.003 3.62 0.02 R
44.6 44.6 38.8 -0.001 0.244 0.82 NC
31 41.6 33.5 -0.0003 2.17 0.7 NC
118.8 77.9 54.3 -0.004 1.8 0.06 NC




-0.002 1.05 0.40 NC
-0.002 1.47 0.1 NC
41.6 38.8 41.6*
41.6* 4.2
+0.0004 0.293 0.79 P
-0.011 4.58 0.006 R
65.4 77.9 64.5*
64.5* 0
-0.006 3.4 0.18 P















0.024 4.0 0.003 CR
-0.04 2.0 0.04 CR
-0.038 6.6 0.0001 CR
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Tumour volume (cm^)
Day 0 28 84 168
gradient "t"a p Clinical
response
44.6 1.44 0 -0.033 6.2 0.0003 CR
523 0 0 0.065 CR
33.5 2.57 0 -0.032 6.3 0.0002 CR
143.7 50.9 0 -0.021 2.93 0.02 CR
82.4 41.6 14.1 -0.008 7.96 0.001 R
69.4 65.4 41.6 -0.004 4.37 0.007 R
125 102.1 50.9 -0.005 6.87 0.001 R
41.6 6.4 1.77 -0.015 4.9 0.006 R
65.4 33.5 24.4 -0.004 5.2 0.001 R
157 61.6 17.1 -0.009 3.9 0.002 R
44.6 22.4 1.8 -0.016 3.1 0.01 R
54.3 28.7 7.2 -0.015 5.7 0.0008 R
57.9 31 18.8 -0.006 3.8 0.004 R
102.1 50.9 14.1 -0.012 6.1 0.0003 R
65.4 6.4 0.52 -0.013 5.7 0.0008 R
57.9 17.1 0.5 -0.022 5.2 0.001 R
36.1 8.2 0.5 -0.028 2.0 0.04 R
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Tumour volume (cm^) gradient "t"a p Clinical
Day 0 28 84 168 response
57.9 17.1 1.2 -0.018 5.2 0.001 R
57.9 4.2 0.52+ -0.038 5.2 0.001 R
33.5 8.2 8.2 -0.0002 0.15 0.89 NC
33.5 15.6 11.5 -0.001 0.8 0.4 NC
33.5 20.6 26.5 +0.00002 0.02 0.98 NC
33.5 22.4 18.8 -0.001 0.02 0.98 NC
a "t" and p values calculated from regression analysis.
* denotes that therapy has been prematurely terminated due to
progression and figures quoted are for tumour diameters at the end
of endocrine therapy.
~ details when regression analysis not possible between weeks 4 and
12 because regression so rapid that no clinical residual tumour by 4
weeks.
A although regression analysis was significant this patient developed a
new mammographic lesion during therapy which was confirmed to be
malignant on histology.
+ patients treatment terminated after 3 cycles due to iliofemoral
thrombosis.
Mammographic Regression
Examples of the changes in mammographic tumour size with systemic therapy are
shown in Figures 2, 4, 6 and 8. Statistical analysis of mammographic changes in
tumour volume was not practicable since measurements were only available for 3 time
points i.e. 4, 8 and 12 weeks. In order to compare clinical with mammographic
changes an arbitary value of 50% reduction in tumour volume between treatment weeks
4 and 12 has been taken and the results tabulated for those tumours achieving statistical
regression and those demonstrating no change (Tables 10 and 11). In 7 patients,
mammograms showed diffuse changes only and the architectural abnormality was not
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measurable. In general there was good agreement between clinical and
mammographic estimation of volume changes. Of the 13 patients who achieved
complete clinical regression all demonstrated a marked reduction in mammographic
tumour size but 7 had some form of residual mammographic abnormality although most
measured less than a centimetre. This did not relate to the presence of residual tumour
on histological examination.
Table 10
Relationship between a demonstrated reduction in clinical and mammographic volume
between treatment weeks 4 and 12 in 58 patients with large operable breast tumours
who on statistical analysis of changes in tumour volume demonstrated significant
regression.
Mammographic volume reduction
Clinical volume reduction <50% >50%
<50% 3 2
>50% 7 40
6 patients had no definite mammographic abnormality.
Table 11
Relationship between a demonstrated reduction in clinical and mammographic volume
between treatment weeks 4 and 12 in 33 patients with large operable breast tumours
who on statistical analysis of changes in tumour volume demonstrated no significant
regression and clinically did not demonstrate progression.
Mammographic volume reduction
Clinical volume reduction <50% >50%
<50% 27 2
>50% 2 0
1 patients had no definite mammographic abnormality.
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DISCUSSION
A semiquantitative method of assessing tumour response has been reported. This is
based on statistical analysis of changes in tumour volume during systemic therapy.
Evidence would suggest that given a single experienced operator measurement of
clinical diameter by estimating the mean of 8 caliper measured clinical diameters gives
reproducible results. This method of measurement has been integral to assessment of
response. The reproducibility studies were however performed on large tumours
(mean diameter 5cms) prior to initiating systemic therapy and the reproducibility of
measurement has been previously documented to be higher in tumours measuring
greater than 3.2 cm (Wan-, Mckinney & Tannock, 1985). As these large tumours
regressed on systemic therapy, exact measurement of clinical size became more
difficult, especially when tumours measured less than 2cm since there was often
residual thickening around the central tumour nidus. This potential increase in the error
rate with response to therapy may in part explain why in 2 cases the slope of the
regression line failed to reach statistical significance at the 5% level despite over a 50%
reduction in tumour volume between treatment weeks 4 and 12. In the remaining case
where there was a significant difference between clinical measurements and eventual
outcome, this was due to clinical evidence of progression with de novo presentation of
breast lymphoedema.
In order to reduce the measurement errors introduced by pretreatment surgical biopsy of
the tumour, clinical diameters taken during the first 4 weeks on treatment were not
included in the statistical analysis of response and the biopsy was performed by a single
committed surgeon in an attempt to standardise the amount of tumour removed from the
tumour core. Although sensitive tumours may have shown a reduction in volume
during this first 4 week period, if clinical relevant then a reduction in volume should
continue. The exception to this were those exquisitally chemosensitive tumours which
had become clinically impalpable by 4 weeks.
Changes in the radiological size of the tumour were not used to define response but
rather to confirm clinical observations. In general there was close but not complete
agreement between the two parameters. Clinical measurement was more likely to
overestimated the degree of reduction (n = 9) than mammography (n = 4). The
reasons for this discrepancy remain obscure. It could be argued that mammography is
more objective than clinical examination but the employment of multiple clinical
114
measurements significantly reduces the intraobserver error. Also it is not possible by
mammography to distinguish between a malignant and benign process hence making it
difficult to differentiate between residual tumour and desmoplastic reaction.
Multiple measurements reduce the false positive error associated with basing
categorisation of response on only two measurements and so the described method is
more sensitive than the routinely used UICC criteria, which demands over an 80%
reduction in tumour volume before regression can be defined (Hayward et al. 1977
Ward et al. 1977). In addition it allows assessment of the rate of regression although
as yet this is of undefined biological significance. If the results are to be meaningful the
method does require multiple regular attendance by the patient to the clinic in addition to




Clinical Assessment of Response
Response to Endocrine Therapy
Twenty-four of the 61 (39.3%) patients treated by primary endocrine therapy
demonstrated significant regression of their tumours at 12 weeks (Table 12). The
overall response rate appeared to be independent of menopausal status or endocrine
therapy used (Table 13), with the exception that none of the 3 postmenopausal patients
who received goserelin therapy achieved significant regression.
Rate of Regression with Endocrine Therapy
The rate of reduction in tumour size which followed endocrine therapy
was variable but was in general slow (Figure 9). Although overlap did
exist in relation to the gradient of the regression slope between some patients who
achieved regression on therapy and others who were categorised as no change, eventual
determination of response was a function of the confidence of the regression slope,
some tumours being more difficult to measure consistently .
The median time taken to achieve half volume (Tl/2) in those patients who showed
significant regression with endocrine therapy was 44 days (range 3-150 days, Figure
11). The rates of regression have been related to the specific endocrine therapy (Table
13). Premenopausal women treated by goserelin appeared to have a slightly faster rate
of regression (median 25 days, range 10-50 days) than other patients but the numbers
within each treatment group are small. No correlation was demonstrated between the
time taken to achieve half volume and the ER concentration of the tumour (Figure 10).
The median Tl/2 for premenopausal women was 33 days (range 10 - 150 days) while
for postmenopausal women it was 50 days (range 3-150 days), the difference is not
significant (Mann -Whitney U Test, U = 43.5, p < 0.05). Only one tumour (treated
with tamoxifen) showed complete clinical regression within the time period of the
study. For various reasons the duration of preoperative antioestrogen therapy was
prolonged beyond 12 weeks in 8 patients. Seven tumours continued to regress at the
same rate, but one tumour previously regarded as static, underwent a rapid reduction in
size at 5 months.
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Figure 9
Relationship between the rate of regression as measure by gradient of regression slope
and response of the primary tumour to endocrine therapy in 61 patient with large
operable breast cancers. The rate of regression was analysed from linear regression




Relationship between response to hormonal therapy and oestrogen receptor
concentration of the primary tumour as determined by the dextran-coated charcoal
adsorbtion method in 61 patients with large operable breast cancer.




oophorectomy 0/2 2/3 2/5
goserelin 0/3 7/13 7/16
POSTMENOPAUSAL
tamoxifen 0/5 4/6 4/11
aminoglutethimide 0/4 4/6 4/10
4-hydroxyandrostenedione - 7/16 7/16
goserelin 0/1 0/2 0/3
TOTAL 0/15 24/46 24/61
* fmol/mg cytosol protein
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Table 13
The relative rates of regression as measure by time to half volume in relation to type of
endocrine therapy employed in the 24 patients who achieved significant regression on
endocrine therapy.
Premenopausal
Oophorectomy (n = 2) - (44 - 150 days)
Goserelin (n = 7) 25 (10 - 50 days)
Postmenopausal
Tamoxifen (n = 4) 101 (3 - 102 days)
Aminoglutethimide (n = 4) 60 (43 - 100 days)
4-Hydroxyandrostenedione (n = 7) 50 (27 - 75 days)
Total (n = 24) 44 (3 - 150 days)
Response to Cytotoxic Therapy
A significant reduction in tumour volume was observed in 34 of the 47 patients
(72.3%) who received cytotoxic therapy (Table 14). Thirteen patients (27.6%) had
complete clinical regression of their tumour. No patient showed evidence of tumour
progression during treatment with chemotherapy.
Table 14
Response rates in 47 patients with large operable cancers of the breast treated with 4
cycles of the chemotherapeutic regime CHOP before definitive locoregional surgery.
No. with significant No. with complete
regression / total clinical regression
Primary cytotoxic therapy
ER <20* 23/27 8
Following failed endocrine
therapy
ER < 20* 8/10 4
ER > 20* 3/10 1
Total 34/47 13





















ER concentration (fmol/mg cytosol protein)
Figure 10
Relationship between the gradient of the regression slope and ER concentration in 24
patients who demonstrated significant regression of their primary tumour to endocrine
therapy. The relationship is not statistically significant (R = 0.22, Spearman Rank Test)
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Rate of Regression with Cytotoxic Therapy
There was a wide variation in the rate at which individual tumours responded to
chemotherapy (Figure 12). The rate of regression was on average more rapid than
that achieved with endocrine therapy, with a median Tl/2 of 20.2 days (range 2.6 -
77.3 days, Figure 11). The correlation between the gradient of the regression slope
and the clinical response as assessed at three months was high . Those patients with
steeper regression slopes were more likely to achieve complete clinical response. The
median time taken to reach 50% of the original pretreatment volume in those patients
achieving complete clinical response was 9.2 days (range of 2.6 - 22.2 days).
Response to therapy measured at 42 days, i.e. after two cycles of chemotherapy, gave a
strong indication of the likelihood of response at 84 days. The rate of regression was





















Comparison of the time taken to achieve half volume in patients demonstration
significant regression in endocrine (n = 24) and cytotoxic therapy (n = 34). The time
taken to half volume was extrapolated from linear regression analysis of changes in

























Relationship between the rate of regression as measured by the gradient of the
regression slope and response of the primary tumour to cytotoxic therapy, in 47
patients with large operable breast cancers. The regression was assessed from linear
regression analysis of changes in tumour volume between treatment weeks 4 and 12.





















ER concentration (fmol/mg cytosol protein)
Figure 13
Relationship between the rate of regression to cytotoxic therapy as measured by the
gradient of the regression slope and the ER concentration of the primary tumour in the
34 patients who demonstrated significant regression to cytotoxic therapy. The
relationship between the two parameters is not significant (R = 0.255, Spearman Rank
Test).
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Histological Assessment of Response
All tumours were ductal carcinoma of no special type although several showed features
of differentiation, these were not thought to be present in sufficient quantity (>90%) to
describe them as being of special type.
All patients, following 12 weeks treatment with endocrine therapy had residual
histopathological disease in their mastectomy specimen. In 8 (17%) of the 13 patients
who achieved complete clinical remission following 4 cycles of CHOP, there was no
histological evidence of residual invasive carcinoma in the post-treatment specimen
although in one of these there was a small focus of intraduct carcinoma. In the
remaining 5 patients there was microscopic evidence of residual invasive carcinoma.
For those patients with residual gross tumour there was little change in the overall
histological pattern .
Axillary Lymph Node Status
Histological assessment of the axillary lymph node status was performed in 46
patients (51%) before and in 86 patients (98%) on completion of systemic therapy.
Metastatic carcinoma was detected in 33 (72%) and 42 cases (49%) respectively.
Overall 56 patients (64%) had axillary metastases detectable at some stage in their
management.
Table 15.
Relationship between the presence or absence of axillary node metastases before and





no metastasis 14 9
Comparison of pre- and post-treatment axillary node status was possible in 43 patients
(Table 15). Of the 33 patients in whom axillary node metastasis were detected
pretreatment, 14 had no evidence of metastases following systemic therapy. Of these 8
had shown significant regression during systemic therapy of which 5 were clinically
complete. Axillary node metastases were found in only one of the 10 patients in whom
the pretreatment axillary node sample had failed to demonstrate metastases. This
125
patient did not response to 4-hydroxyandrostenedione or proceed to chemotherapy and
so may represent a true progression of axillary node status.
Survival
The median time from initiation of systemic therapy to the date of survival analysis was
42 months (range 16 - 72 months); overall and relapse-free survival for all patients
within the study is shown in Figure 14. Twenty-three patients have represented with
recurrent disease while 13 patients have died from their disease. The cumulative overall
survival of those patients surviving greater than 4 years (n = 27) was 77% (+/- 5%),
with 67.2% (+/- 6%) of patients remaining disease free. The site of first tumour
recurrence is shown in Table 16.
A total of 14 patients had pathologically proven local recurrence at the time of analysis
although 6 occured coincidentally with distant metastasis. The local recurrence rate is
shown in Figure 14 and shows that at 4 years 83% (+/- 4%) of the patients had no
evidence of local relapse. Following treatment with radiotherapy and further systemic
therapy in one patient local disease remained uncontrolled at the patients death.
Survival and Prognostic Factors and Response to Therapy
Survival, distant disease-free and relapse-free survival has been related to the presence
or absence of axillary node metastasis (Figure 15 ) and ER concentration of the
primary tumour (Figure 16).
Overall and relapse-free and local recurrence free survival were all significantly better
in that group of patients who had never demonstrated the presence of axillary node
metastases in either their pretreatment or posttreatment axillary node specimen.
Within this series no significant relationship between survival and pretreatment
tumour ER concentration was observed (Figure 16). However in general patients
with a tumour of ER concentration of > 20 fmol/mg cytosol protein fared better
especially if overall survival was considered. In particular patients with endocrine-
sensitive tumours, as a subgroup , exhibited a particularly good prognosis (Figure 17).
To date within this group of 24 patients there have been no deaths although 6 patients
have shown disease relapse. When compared to patients who did not exhibit
significant regression with endocrine therapy, overall survival is significantly improved
(p = 0.01), while both relapse-free survival (p = 0.07) and local disease free survival










































Overall, relapse-free and local relapse-free survival for the 88 patients with large
operable breast cancers who underwent primary systemic therapy. The median time to
survival analysis was 42 months (range 16 - 72 months). The number remaining
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Figure 15
Overall, relapse-free and local relapse-free survival following primary systemic therapy
analysed in relation to axillary node status in the 86 patients for which it was available.
Analysis was on an ever axillary node positive or never axillary node positive basis.
The difference between the two group was analysed by the General Wilcoxon Test).
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Figure 16
Overall, relapse-free and local relapse-free survival following primary systemic therapy
analysed in relation to oestrogen status of the primary tumour. A cut of value of 20
fmoi/mg cytosol protein has been taken to differentiate into those patients with ER
negative/poor tumours and those with ER moderate/rich tumours. The difference
between the two group was analysed by the Generalised Wilcoxon Test. The number
of patients remaining for analysis is shown at yearly intervals.
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Table 16.
Site of first tumour recurrence in 23 of the 88 patients with large operable breast cancer
treated by primary systemic therapy who have demonstrated relapse (median follow-up
period 42 months, range 16-72 months) subdivided for axillary node status.
Axillary Node Status
Site of relapse Ever AN+ Never AN+ Total
Loco-regional alone 7 1 8
Distant alone 7 2* 9
Both Distant and Local 4 2 6
TOTAL 18 5 23
*post-treatment axillary node status
No significant relationship could be demonstrated between clinical response to
cytotoxic therapy and either overall survival (p = 0.37), distant disease free survival (p
= 0.64) or relapse free survival (p = 0.37) (Figure 18) although again as a subgroup
those patients who achieved a complete clinical response faired best. However if the
survival data is reanalysed in relation to those who demonstrated marked
chemosensitivity, that is a a time to half volume less than 20 days, a more obvious
difference can be shown between those patients who had a rapid response to
chemotherapy and those who did not, overall survival (0.08) distant disease free
survival (p = 0.05) relapse free survival (p = 0.3) and local survival (p = 1.00) (Figure
19).



















a) TUMOURS WITH SIGNIFICANT REGRESSION
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Overall, relapse-free and local relapse-free survival is shown for the 24 patients who
achieved significant regression (a) with endocrine therapy and the 37 who did not (b).
The difference between the two response categories is statistically significant for overall
survival (p = 0.01), but just fails to reach significance for relapse-free (0.07) and local
relapse-free (0.08) survival when analysed by General Wilcoxon Testing. The
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Figure 18
Overall, relapse-free and local relapse-free survival is shown in relation to response to
cytotoxic therapy. Three response categories have been defined, those achieving
complete clinical regression (n = 13), those achieving a significant but clinically
incomplete regression (n = 21) and those showing no change (n = 13). No significant
relationship was demonstrated between these three response groups and overall (p =
0.37), relapse-free (p = 0.65) survival although the relationship with local relapse-free
survival just fails to reach statistical significance (p = 0.06; Generalised Wilcoxon
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Overall, relapse-free and local relapse-free survival is shown in relation to the rate of
response to cytotoxic therapy. The median Tl/2 (20days) has been used to define two
groups, those with a more rapid (Tl/2 <20 days) and those with a slower (Tl/2 >20
days) rate of regression. The statistical difference between the two groups as analysed
by the Generalised Wilcoxon test just fails to reach statistical significance for overall
survival (p = 0.08) but is insignificant for relapse-free survival (p = 0.34) and local
relapse-free (p = 1.00) survival. The number remaining available for analysis is shown
at yearly intervals.
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Assessment of Endocrinological Effects of Hormonal Therapy
Endocrinological Effects of Aromatase Inhibitors
The mean serum levels of oestrone before and during treatment with 4-
hydroxyandrostenedione for 8 postmenopausal women are shown in Table 17. The
level of suppression was variable during the first 6 weeks but appeared more stable at
around 50% of the pretreatment level after this time. The levels for individual patients
are shown in Figure 20. Although several patients show high breakthrough peaks of
serum oestrone levels, there was no relationship between clinical response and the level
of suppression of serum oestrone (Figure 20).
Effect of 250mg intramuscular 4-hydroxyandrostenedione given at 14 day intervals on
serum oestrone levels in 8 postmenopausal women with breast cancer. Serum
oestrone levels are expressed as the mean for the 8 patients (+/- standard error of the
mean).
Table 17.



















Effect of 4-hydroxyandrostenedione (250mg i.m. at 14 day intervals) on serum
oestrone levels in 8 postmenopausal women with large operable breast cancers. Those
patients who achieved significant regression are shown by , those who did not
achieve significant regression are shown by .
135
Endocrinological Effects of the LHRH Analogue Goserelin
The effect of goserelin (3.6mg s.c. at 28 day intervals) on serum oestradiol and
progesterone were evaluated in 6 premenopausal women (Figure 21 and 22 ). In
addition the effect on serum gonadotrophin levels were measure for 2 premenopausal
and 2 postmenopausal patients (Figures 23 and 24). Levels of LH were dramatically
reduced by 14 days and by 28 days in all 4 cases had reached low levels. Consistently
low concentrations were found in all subsequent serum samples. FSH levels in
postmenopausal women were similarly reduced, but in the 2 premenopausal patient
studied suppression was not so conspicuous although levels were always below 10
U/l. In premenopausal women castration levels of both serum oestradiol and
progesterone were reached by the fourteenth day of treatment although in several cases
a dramatic rise initially occured. These low levels were maintained while therapy
continued except in three cases where a small transient rises in serum oestradiol was
shown. Despite this rise one of the three patients achieved significant regression.
Levels of serum oestradiol and progesterone within the 2 postmenopausal patients
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Figure 21
Effect of goserelin (3.6mg s.c. at 28 day intervals) on serum oestradiol levels in 6
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Figure 22
Effect of goserelin (3.6mg s.c. at 28 day intervals) on serum progesterone levels in 6




Effect of goserelin (3.6mg s.c. at 28 day intervals) on serum lutenising hormone levels





Effect of goserelin (3.6mg s.c. at 28 day intervals) on serum lutenising hormone levels
( ) and follicule stimulating hormone ( ) in 2 postmenopausal women with




The side-effects experienced during treatment with endocrine agents were minimal.
Goserelin
All side-effects noted with goserelin were attributable to hypo-oestrogenism. In
premenopausal patients menstruation ceased within 4 weeks of initiating therapy. Hot
flushings were noted by 7 patients (37%) and were moderately severe in 2. Vaginal
dryness was a problem with one patient but headaches or mood changes were not
described. Local or general allergic reactions were not noted. There was no clinically
relevant change in any of the haematological or biochemical parameters tested during
the therapeutic period and no patient required to be withdrawn from the study because
of pharmacological side-effects..
4-hydroxyandrostenedione
Of the 16 patients who received 4-hydroxyandrostenedione 8(50%) experienced
some adverse effect. One patient developed a self-limiting erythematous skin rash on
the buttocks and 4 (25%) complained of a tender lump at the site of intramuscular
injection although in the majority of cases this had settled within a week. Hot
flushings were reported by 2 patients. A mild self limiting abnormality of liver
function tests was noted in four patient but this was not clinically significant and did not
require cessation of the drug; it is unclear if this was due to true toxicity or an incidental
finding. Haemotoxicity was not noted and treatment was not discontinued in any
patient because of toxicity.
Tamoxifen
Tamoxifen was well tolerate by all patients. One patient however complained of
moderately severe hot flushings.
Aminoglutethimide
In 6 of the 10 patients no significant side-effect to aminoglutethimide therapy was
noted. Four patients complained of nausea and lethargy on initiation of therapy. No
allergic or haematological reactions were observed.
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Cytotoxic Therapy
The incidence and severity of side effects experienced during treatment with this
combination regimen are shown in Table 18. Alopecia, although transient was noted
by all patients and was severe in 89%. Other principle side effects included nausea and
vomiting (91% WHO grade 2 or greater), stomatitis (68% WHO grade 2) and
neutropenia 26% WHO grade 2 or greater). In addition one fifth of patients developed
symptoms of dyspepsia, 3 requiring H^ antagonists for symptomatic control. Mild
sterile dysuria was noted by 13% of patients. One person developed a dystonic
reaction to the high dose (40mg) metoclopramide anti-emetic regime.
In 2 patients dose adjustment was necessary due to neutropenia. In a further 2 patients
vincristine was omitted from the third and fourth cycles because of autonomic
neuropathy. Premature termination of therapy was required because of nonspecific
toxicity in 2 patients and iliofemoral thrombosis in one patient. Of the 25 patients who
were premenopausal, cessation of menstruation occured in 18.
There were no treatment related deaths and no demonstrable increased morbidity
associated with definitive surgery.
Table 18.
Toxicity associated with the preoperative administration of 4 cycles of adriamycin,
vincristine cyclophosphamide and prednisolone in 47 patient with large operable breast
cancer as defined by the WHO toxicity grading (Miller et al. 1981). The figures given


































Peripheral neurotoxicity 38 2
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P1SCUSSWN
In this study we have been able to observe directly the effect of systemic therapy on
primary breast cancers. Both endocrine and cytotoxic therapies have been used.
Although a variety of endocrine agents were initially tried in the pilot study, these
were found to be of comparable effect and the proportion of patients achieving
regression was similar to that documented using the same agents in advanced disease
(Hawkins, 1985; Coombes, Stein & Dowsett, 1989; Nicholson & Walker, 1989). In
the more formalised protocol interest was centred on the effects of the gonadotrophin-
releasing hormone agonist goserelin in premenopausal women and the peripheral
aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal women with tumour
of ER concentration greater than 20fmol/mg cytosol protein. The cytotoxic regime
remained unchanged at 4 cycles of CHOP.
A study of the endocrinological efficacy of goserelin within this group of patients
mirrors those reported by other workers (Nicholson et al. 1984, 1987) in that low
levels of gonadotrophins, oestradiol and progesterone were reached within 28 days of
initiating therapy, and in the majority of cases these were maintained while treatment
continued. While the rate of decline in serum sex steroids was not as rapid as that
which would be expected following surgical oophorectomy, assessment for response
did not start until 28 days at which time therapeutic hypooestrogenism was achieved.
In some patients an initial transient rise in oestradiol occured but this did not appear to
produce an important clinical effect. Goserelin caused regression of primary disease in
7 of the 16 (43%) premenopausal women with ER-moderate/-rich tumours. This
closely parallels the response rates achieved using surgical or radiation induced
oophorectomy in premenopausal women with advanced ER-positive breast cancers.
However it should be noted that the response was achieved without the morbidity
associated with surgical or radiotherapeutic intervention; side effects being minimal and
mainly related to hypo-oestrogenism. In addition to the drug being well tolerated it had
the added advantage that treatment could be readily discontinued should therapy prove
ineffective. It would therefore appear more suitable for the primary treatment of
premenopausal women with ER-positive tumours, however once response has been
assessed it may be more convenient for economic reasons to offer surgical bilateral
oophorectomy as continuing adjuvant therapy.
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Three postmenopausal women were treated primarily by goserelin but none achieved
significant regression. Although tumour remission has been recorded in 10 % of
postmenopausal women with advanced disease receiving gonadotrophin-releasing
hormone agonists (Nicholson & Walker, 1989), this regression rate is too low to
accept for primary treatment especially with the availability of other drugs, for example
tamoxifen with known higher efficacy.
In postmenopausal women aromatase inhibitors were originally tested because of the
interest in correlation of response with the activity of enzymes responsible for
endogenous oestrogens production. Initially aminoglutethimide was the only
aromatase inhibitor available, but during the study 4-hydroxyandrostenedione became
available for clinical practice as part of a phase 2 clinical trial. Since initial trials had
shown 4-hydroxyandrostenedione to be pharmacologically more active (Brodie &
Santen 1976) and to be associated with fewer side-effects it was decided to use it as the
preferred drug. The optimal clinical dose had yet to be confirmed and a dose of 250mg
intramuscular at 14 day intervals was chosen. Seven of the 16 postmenopausal
women (44%) who received 4-hydroxyandrostenedione achieved significant
regression. The proportion regressing is similar to that demonstrated with other
endocrine agents within this study (Table 12) and that documented by other workers
in postmenopausal patients with advanced ER-positive breast cancers (49-58%;
Hawkins 1985). Indeed Coombes and his colleagues (Coombes, Stein & Dowsett
1989) have demonstrated that increasing the dose over 250mg i.m. at 14 day intervals
does not improve the proportion responding but does increase the incidence of side-
effects.
The major endocrine effect of 4-hydroxyandrostenedione administration is a reduction
in plasma oestradiol concentration (Dowsett et al. 1989). When using a dose of 250mg
at 14 day intervals marginally suboptimal aromatase inhibition had been suggested
during the last few days of the two-week cycle. (Dowsett et al. 1989). In the 8 patients
investigated within this study a fall in plasma oestradiol was demonstrated in all patients
following sustained treatment of greater than 6 weeks but varied between 11 and 82%
of the pretreatment value (mean 50.1 +/- 6.5%). Escape from oestradiol suppression
was more common during the first 6 weeks but did not appear to affect clinical
response. Despite this submaximal suppression of serum oestradiol, in the light of the
maintained clinical efficacy and low incidence of side-effects, 250mg i.m. every 14
days would appear to be an acceptable parenteral dose. Although reports of successful
regression (Coombes, Stein & Dowsett 1989) have been made following treatment
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with oral 4-OHA, the recommended method of administration of 4-OHA is still by deep
intramuscular injection.
Systemic side-effects were not a major problem with 4-OHA but the requirement for
intramuscular injection is a disadvantage and tamoxifen would appear to be preferable
for primary therapy in postmenopausal women.
Within this study cytotoxic therapy with its greater associated toxicity was reserved for
patients in whom endocrine therapy had failed or the likelihood of response to
endocrine therapy was minimal (i.e. patients with ER-poor or ER-negative tumours).
The proportion of such patients with tumours which were chemosensitive was high and
lies within the observed range of 70-93% described with 'neoadjuvant' chemotherapy
in more locally advanced breast cancers (Delena et al. 1981; Jacquillat et al., 1988;
Hortobagyi et al., 1988; Swain et al., 1987). The objective regression rate of
combination chemotherapy in metastatic disease is around 50% (maximum 70%)
(Carter 1972). The response rates achieved with primary cytotoxic therapy are therefore
on average higher than those recorded for treatment of advanced disease. It is difficult
to establish whether this is a function of the more precise method of evaluating
response or whether there is a difference in the response rates of early and metastatic
tumours. The response rates achieved with induction chemotherapy in more locally
advanced disease would suggest that the latter may be so (Rubens et al. 1980), De Lena
et al. 1981, Hortobagyi et al. 1983, Sorace et al. 1985; Swain et al. 1987). There also
exists mathematically (Goldie and Coldman 1979 and experimentally (Skipper 1960,
Skipper et al. 1964, Ling 1978) evidence to suggest that the likelihood of a resistant
line developing appears closely related to the number of previous cell divisions.
Cytotoxic therapy is therefore likely to be more effective the earlier it is given in the life
history of the tumour. The number of patients with non-endocrine responsive tumours
(i.e. ER-poor/negative tumours) who achieved complete clinical (27.6%) and complete
pathological (17%) remission was also impressive. This coincides well with the
complete clinical regression rates (4 - 23%) observer using induction chemotherapy in
locally advanced breast cancer (Rubens et al., 1980; De Lena et al., 1981; Hortobagyi
et al., 1988; Kantarjian et al., 1984).
The rate of regression achieved with systemic therapy was highly variable and
appeared to be a function of the individual tumour responsiveness rather than the
systemic therapy used except that regression on endocrine therapy was on average,
slower than that achieved with cytotoxic therapy. This may reflect the cytostatic as
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opposed to cytotoxic effect of endocrine therapy. Within the period of the study only
one patient achieved complete clinical regression during endocrine therapy and in no
patient was remission pathologically complete. In contrast the response to cytotoxic
therapy was occasionally rapid and in those patients with such a rapid response,
complete clinical (27.6%) and even complete pathological response (17%) was
observed. None of the parameters studied, including tumour size, axillary node status,
patients age or menopausal status were able to define which patients were more likely to
achieve complete remission. The biological significance of the rate of regression to
systemic therapy is as yet uncertain. In a study of the long term follow-up of elderly
patients with locoregional breast cancer treated with tamoxifen alone, survival could be
related directly to the response achieved to tamoxifen, with patients achieving a
complete remission faring best (Horobin et al. 1991). Within the present study the
demonstration of a significant response to endocrine therapy would also appear to
identify a group of patients who have a very good prognosis. It is impossible to tell
from this study whether the improved prognosis is due to biological preselection or
benefit gained from adjuvant endocrine therapy. When survival was analysed against
response for patients receiving cytotoxic therapy, patients achieving a rapid reduction in
tumour volume had a statistically better prognosis. In particular those achieving the
most rapid tumour reduction that is those with complete clinical response did very well
although the difference failed to reach statistical significance and the numbers within the
subgroup were small. It certainly would seem conceivable that if the tumour was
highly sensitive to chemotherapy, there would be less likelihood of residual viable
tumour at the end of therapy. Cure may only be possible in this small subsection on
the patients with very sensitive tumours. However as yet it is not possible to gauge
either the optimum dose or number of cycles of chemotherapy which should be
administered to effect cure. Since the primary tumour is an exquisite marker of
responsiveness, one possible method would be to persue induction treatment to
maximal response. In advanced disease the initial enthusiasm associated with
combination chemotherapy for breast cancer giving complete remission rates in the
20% range, turned to pessimism as the complete remission rates refused to rise (until
recently) and the patients who attained a complete remission almost invariably relapsed
(Bonadonna 1987). These disappointing results may be due to inadequate exploration
of the dose-response curve. As in lymphomas, high dose regimes in advanced breast
cancers with autologous bone marrow transplant programs have finally increased
complete remission rates (up to 49%) with some appearing durable (Peters et al. 1989;
Swain et al. 1987). Recent data from Norton (Norton 1988) suggests that we may
have come closer than we know to to eradicating the last cancer cell in breast cancer in
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adjuvant trials, but our assay systems are to insensitive to detect it. Differences in
survival at 5 years cannot be distinguished between patients whose residual tumour cell
number was reduced to one and patients whose cell number was reduced to a million,
because of differing regrowth characteristics of the remaining cancer cells at different
residual volumes. Primary chemotherapy studies should be designed to offer the
opportunity to overcome these obstacles and take advantage of the near miss while also
identifying those patients in whom further aggressive chemotherapy is unlikely to
produce an improved effect.
Within this study the 4 year local recurrence rate for what is a high risk population was
17 (+/-4)%, with only one case being uncontrolled by subsequent therapy. Historical
series of staged match cases undergoing a radical or modified radical mastectomy quote
the incidence of local recurrence to vary between 24 and 29% at five years in tumours
measuring >4cm at the time of diagnosis (Donegan 1979). It would therefore appear
that leaving the tumour in situ while response is being observed does not compromise
local control. Indeed primary systemic therapy may permit conservative surgery in
patients with large operable tumours which would otherwise require mastectomy and
this is now being explored in several centres (Mansi et al„ 1989; Bonadonna et al.,
1990). Both studies are immature and although significant downstaging of local
disease with systemic therapy was achieved in 51% (29/57) and 81% (127/157)
patients respectively, the follow-up periods are to short to be sure of the impact of
primary systemic therapy on local control when radical surgery is not eventually
performed. Overall within this study a significant reduction in tumour size making
conservation surgery theoretically possible was produced in 66% (58/88) of patients.
Primary systemic therapy however is not yet orthodox for operable disease and it was
not thought justified to perform less than a mastectomy in the majority of patients. In 6
patient with complete clinical response however, wide local excision of the previous
tumour site was performed and supplemented, in 5 cases, by radiotherapy. With a
median follow-up of 42 months only one of the 6 patients has developed local
recurrence, this being adequately controlled by subsequent mastectomy. In future
studies a more conservative approach would be worthy of trial, since the possibility of
being able to maintain an intact breast after aggressive treatment may provide an
important psychological incentive in a population of patients, some of whom initially
delayed seeking medical attention for fear of loosing their breast.
There is theoretical (Goldie and Coldman, 1979; Skipper 1980, experimental (Schabel
et al., 1979; Fisher, Gundez, Saffer 1983) and clinical (Nissen-Meyer et al., 1986;
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Ragaz 1986) evidence, that early administration of systemic therapy in the treatment
schedule of patients with breast cancer may improve survival. The 4 year cumulative
survival rate within this study was 77 (+/-5)%, with 83 (+/-4) % of patients remaining
free of local recurrence. Comparison with historical controls series is fraught with
error but it would appear that the survival rates within this present series compare
favourably to 5 year survival rates achieved with orthodox treatment of large tumours
of similar stage (Table 1) even if the figures are corrected for the beneficial effect of
systemic therapy.
It is possible that the good survival within the present series may simply be a function
of the selection bias and so the prevalence and importance of other prognostic indices
have been studied. The most important biological predictor for tumour recurrence and
survival is the presence of axillary node metastases. Initially axillary node sampling
was not an integral part of the pretreatment assessment. Analysis of the pathological
post-treatment axillary node staging of the first 43 patients demonstrated a lower
incidence (51%) of positivity than would be expected. Since clinical axillary node
staging is notoriously unreliable (Wallace & Champion 1972; Fisher et al. 1975) it was
felt that pathological staging of the axillary nodes should be included in the preoperative
assessment if survival data was to be assessed. Of the 45 patients in whom
pretreatment axillary node status was known there was a higher incidence of lymph
node metastases (73%) which is more in keeping with previous studies for tumours of
similar stage (Carter Allen & Henson 1989). Following therapy however only 20
(44%) of this subgroup of 45 patients had detectable node metastases. Overall 56
patients (64%) had axillary metastases detected at some stage in their management,
although this figure may be lower than the true pretreatment figure and suggests that
sample bias for the study is not a major feature, also within the series axillary node
status persists as a strong indicator of prognosis for both overall, relapse-free and local
relapse-free survival.
The value of ER status as a prognostic index has been argued (Spyratos et al. 1989;
Sutton et al. 1987; Hawkins et al. 1987; Chevalier et al. 1988; Shek & Godolphin
1989; Raemaekers et al. 1985; Knight etal. 1977; Pari et al. 1984; Godolphin,
Elwood & Spinelli 1981; Mason et al. 1983; Todd et al. 1987; Howat et al. 1983;
Williams et al 1987; Alexieva-Figusch et al. 1988; Maki & Hoehn 1989) but survival
results, particularly following adjuvant endocrine therapy may have been scewed if the
distribution of ER status was abnormal. Within the reported literature approximately
70% of primary breast tumours can be expected to be ER-positive (Kvinnsland 1986);
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the proportion of patients with ER-positive tumours increasing with age (Elwood &
Godolphin 1980; Helin et al., 1988; Cooper et al., 1989) such that around 80% of
patients over the age of 60 have ER-positive tumours, whilst less than 60% of patients
under 40 have ER-positive tumours (Elwood & Godolphin 1980). Within this present
study 52% (46/88) of patients (60% [30/50] postmenopausal patients and 42%
[16/38] premenopausal women) had ER-positive tumours. This is at the lower limits of
previously reported series which is probably a function of the higher cut off value as
the criteria for positivity (>20 as opposed to 5 fmol/mg cytosol protein). Although ER
status did not provide a significant prognostic index within the present series patients
with ER-positive tumours tended to survive longer than patients with ER-negative
tumours. This may well have been a function of the subgroup of patients with ER-
positive tumours who regressed on endocrine therapy and demonstrated a remarkably
good prognosis.
This study was undertaken to ascertain whether appropriate long-term systemic therapy
could be selected in the individual patient by direct assessment of primary tumour
response before surgical excision. It has been suggested that in some metastases the
cancer cells are functionally different to those in the primary cancer from which they
arose. Differences in phenotype eg. ER status (Hull et al., 1983; Klinga et al., 1982;
Lee 1982; Kamby, Rasmussen & Kristensen 1989), have been demonstrated. Ninety
per cent of lymph node metastases have the same ER status as the primary tumour,
while corresponding values for liver and bone metastases were 75 and 58%
respectively (Kamby, Rasmussen & Kristensen 1989). Also in general the doubling
times of metastases are more rapid than the primary tumour (Scarckney, McCirmack &
Cuchural 1978). Since all metastases originate from the primary tumour, this may
arise as a result of cloning of tumour cells with a higher metastatic potential ( and
potentially more aggressive biology) or a change in biological characteristics of the
metastasised cells as a result of local environmental growth conditions. Differing
sensitivities to chemotherapeutic drugs have also been demonstrate between some
primary cancers and their metastases (Donelli et al. 1977; Fugmann et al. 1977; Slack
& Bross 1975; Trope 1975). Studies on the differential distribution of
chemotherapeutic agents in vivo suggested that part of this difference in
chemosensitivity between primary tumour and its metastases however may reflect on
blood supply and hence availability of drug to the tumour cells (Donelli et al. 1977).
Within the present series it has not been possible to directly compare the therapeutic
effect on primary and metastatic disease since a prerequisite for entry into the study
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was freedom from overt systemic metastases. However it was possible to compare
axillary node status before and after therapy. A much higher proportion of patients had
axillary node metastases before (72%) compared to after (49%) therapy. No
quantitative relationship however could be demonstrated between response to systemic
therapy and disappearance of axillary node metastases in the 14 patients who were
demonstrated to convert from axillary node positive to axillary node negative. While it
is conceivable that axillary node sampling had simply removed the few lymph nodes
with metastatic disease it is also possible that the systemic therapy has been effective in
eradicating axillary metastases. Certainly all patients who were axillary node positive
prior to chemotherapy and achieved complete clinical regression also had no
demonstrable tumour remaining within their axillary lymph nodes, suggesting a
therapeutic effect on both primary and metastatic tumour in these highly sensitive
tumours.
More impressive is the demonstrable relationship between response of the primary
tumour to systemic therapy and overall survival for both endocrine and cytotoxic
therapy. Overall survival is related to the behaviour of the metastases and so a direct
relationship can be demonstrated between function of the primary tumour and
subsequent behaviour of its metastases. While it is possible therefore that in a small
number of cases the response of the primary tumour may not reflect the effect on
metastatic disease, overall the relationship appears to apply.
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CHAPTER 9
RESPONSE AS A FUNCTION OF POTENTIAL PREDICTIVE
INDICES
BIOCHEMICAL DETECTION OF OESTROGEN RECEPTOR ACTIVITY
Reproducibility of Measurement
Quality controls consisting of pools of minced human uterus or lyophilised powders
were processed at least twice per week. The overall intra-assay precision on a pool of
minced uterine tissue was 15.4% (n = 5). Inter-assay precision on lyophilised powders
(no homogenation step) was 17.8% (n = 10) at low levels (mean 27 fmol/mg cytosol
protein) and 11.7% at high levels (mean 90 fmol/mg cytosol protein); on two pools of
minced uterine tissue (including homogenisation) it was 25.5% (n = 144) at low levels
(mean 48 fmol/mg cytosol protein ) and 17.0% (n = 48) at a higher level (mean 111
fmol/mg cytosol protein).
Biochemical Assay of Oestrogen Receptor Activity and Response to
Endocrine Therapy
Material for biochemical analysis of ER activity was available for all 88 patients. Forty-
six (53%) had an ER concentration of > 20 fmol/mg cytosol protein. The proportion of
postmenopausal women with ER moderate-rich tumours was higher (30/50, 60%) than
in premenopausal women (16/38,42%). The relationship between ER status of the
primary tumour and patient menopausal status for those patients undergoing endocrine
therapy is shown in Table 19.
The relationship between response to endocrine therapy and ER concentration as
measured by the dextran-coated charcoal adsorbtion method is given in Figure 25 and
Table 20. All responding tumours had an ER concentration of >20 fmol/mg cytosol
protein. The overall response rate for patients with tumours of ER concentration of
>20 fmol/mg cytosol protein was 52.2% (24/46) and appeared independent of
menopausal status (p = 0.76, Fishers exact test), relative concentration of ER (i.e. 20-
100 vs >100 fmol/mg cytosol protein; x^ 0.32, p = 0.57) or endocrine therapy used.
Of note is that two third (10/15) of all ER-poor/negative tumours progressed during
endocrine treatment compared to only 13% (6/46) of tumours with an ER concentration
of >20 fmol/mg cytosol protein.
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Table 19
Relationship between ER status of the primary tumour as determined by dextran-coated
charcoal assay and patient menopausal status in relation to the proportion of patients
demonstrating significant regression for 61 patients with large operable breast cancers
treated by primary endocrine therapy. The median ER concentration was higher in
postmenopausal (median 130, range 0-1151 fmol/mg cytosol protein) than
premenopausal (median 30, range 0-174 fmol/mg cytosol protein) women.
Premenopausal Postmenopausal Total
ER Subgroup*
<5 0/2 0/6 0/8
5-19 0/3 0/4 0/7
20-99 7/14 3/7 10/21
>100 2/2 12/23 14/25
Total 9/21 15/40 24/61
* fmol/mg cytosol protein
Table 20
Response to endocrine therapy in 61 patients with large operable breast cancer
subdivided for oestrogen receptor status as measured by the dextran coated charcoal
adsorbtion method.
ER status total significant no progression
no. regression change
ER - poor
<20* 15 0 5 10
ER - rich 46 24 16 6
>20*
Total 61 24 21 16
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Figure 25
Relationship between ER concentration of the primary tumour as determined by
dextran-coated charcoal assay and response to primary endocrine therapy in 61 patients
with large operable breast cancer. The horizontal line marks the level of 20 fmol/mg
cytosol protein. The median values for each response group is shown by a bar.
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Relationship Between Response to Cytotoxic Therapy and Oestrogen
Receptor Status
There was no statistically significant relationship between response to chemotherapy
and the pretreatment variables of age, menopausal status, initial tumour size (Table
21). Of the tumours which had failed to respond to endocrine therapy those with an ER
concentration of >20fmol/mg cytosol protein were significantly less likely to respond to
chemotherapy when compared to those tumours with an ER concentration of
<20fmol/mg cytosol protein (30% vs 80%, p = 0.023, Fishers exact test, 2 tails). The
proportional response of ER poor/negative tumours to cytotoxic therapy was similar
irrespective of prior, failed endocrine therapy or primary therapy (80% vs 83.8%).
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Table 21.
Relationship between pretreatment variables and significant tumour regression
following 4 cycles of preoperative cytotoxic therapy (CHOP). Patients were designated
postmenopausal if it was greater than one year since their last menstrual period.
Pretreatment axillary node status as determined from histological examination of an
axillary node sample was available for 29 patients
No. significant
regression/ total no. x2 p value
TUMOUR DIAMETER
< 5 cm 19/26
5-<6 cm 10/14 0.813 0.67
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Statistical analyses of large controlled randomised trials have shown that survival of
patients with operable breast cancer can be improved by systemic endocrine or
cytotoxic therapy (Early Breast Cancer Trialists' Collaborative Group 1988). These
trials however have not defined which therapy is most suitable for an individual
patient. Given the morbidity of cytotoxic therapy (Glass et al. 1981, Valagussa et al.
1983) an unselective policy is not ideal but as yet here exists no ideal method of
matching individual patients with appropriate adjuvant systemic therapy. Furthermore
the value of tumour oestrogen receptor status (ER) in selecting patients for adjuvant
hormonal therapy remains controversial (Palshof et al. 1985, Rose et al. 1985, Fisher
et al. 1986 Rutquist et al. 1987, Bianco et al. 1988, Scottish Breast Cancer Trials
Committee 1987, Nolvadex Adjuvant Trial Organisation 1988). By removing a small
portion of tumor prior to initiating primary systemic therapy and direct observation of
individual tumour response it has been possible to examine the value of specific
histological and biochemical indices as predictive indices for response to both endocrine
and cytotoxic therapies.
Since endocrine therapy is associated with low morbidity it was decided that all
patients should initially receive primary endocrine therapy. Cytotoxic therapy with its
greater morbidity, was reserved for those who failed to achieve significant regression
with endocrine therapy. Analysis of the results from the initial pilot group of 36
patients demonstrated that none of the patients with tumours of ER concentration less
than 20 fmol/mg cytosol protein showed significant regression and indeed two-thirds
showed evidence of progression. With the direct demonstration of the lack of efficacy
of endocrine therapy in ER-poor/negative tumours, it was no longer considered
justifiable to use an indiscriminant policy and primary endocrine therapy was then
reserved only for those patients with tumours of ER concentration > 20 fmol/mg
cytosol protein. Cytotoxic therapy was administered as primary therapy to those with
ER-negative/-poor tumours or to patients with ER rich tumours when endocrine therapy
had proved ineffective.
This correlation of endocrine sensitivity and ER status of the primary tumour parallels
the situation in advanced disease (Hawkins, Roberts & Forrest 1980; Oriana et al.
1986; Coombes et al. 1986; 1987; Nicholson et al. 1987) and would support the theory
that the ER is central to determining hormone sensitivity in the primary tumour as well
as in the advanced disease situation. Many theories have thus been devised to explain
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the discordance between the value of the ER in predicting efficacy in the adjuvant and
therapeutic trials, these include inadequate quality control in the assay of ER and
subgroup analysis of small sub-populations in adjuvant studies not stratified for ER.
However within the NATO trial, the observed to expected biological value of ER status
and histological grade as prognostic indicators was maintained, suggesting further
explanation is required (Nolvadex Adjuvant Trial Organisation 1988).
Analysis of the relationship between ER status and benefit from adjuvant endocrine
therapy have been based totally on utilising tamoxifen as the therapeutic agent. There is
now increasing evidence that tamoxifen has anti-tumour actions which are independent
of the ER. Two distinct mechanisms of growth inhibition have been demonstrated in
human breast cancer cell lines (Sutherland, Watt & Ruenitz 1986; Etienne et al. 1989);
both effects appear confined to the G1 phase of the cell cycle. In addition to the ER-
mediated oestrogen-reversible growth inhibition, high concentrations of tamoxifen
produce an oestrogen-irreversible cytotoxic effect which can be distinguished from
nonspecific toxicity by its cell cycle specificity (Sutherland et al. 1983; Etienne et al.
1989). Several potential sites of action include inhibition of protein kinase C (O'Brian
et al. 1986) or calmodulin a substance known to play an important role in cell cycle
progression (Lam 1984). Tamoxifen also stimulates the secretion of TGF-B by the
ER-positive cell line MCF7 (Knabbe et al. 1987) and fibroblasts (Baum et al. 1989).
This may act by paracrine or autocrine action to inhibit the growth of surrounding
tumour cells irrespective of their ER content (Knabbe et al 1987). It is uncertain how
significant these non-oestrogen receptor dependent inhibitory actions are in vivo but
because of these findings the relationship between the predictive value of ER status and
benefit from adjuvant tamoxifen cannot necessarily be extrapolated to other forms of
endocrine therapy.
Within this study, response to preoperative chemotherapy has shown that
chemosensitivity was independent of the tumour size, axillary node status or
menopausal status or age of the patient. This suggests that the inherent
chemosensitivity of the tumour may well be more important than these factors in
determining response.
Of those individual tumours directly demonstrated as endocrine-resistant the
proportion of ER-poor/negative tumours regressing with chemotherapy parallelled that
of primary chemotherapy (~80%) but the efficacy in ER-rich tumours was much lower
(30%). This may reflect either preselection of a subgroup of patients with biological
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nonresponsive tumours or an inherently chemoresistance of ER-positive tumours. A
positive correlation is known to exist between proliferation rate and efficacy of
cytotoxic therapy (Valeriote & van Putten 1975) while tumours with significant
amounts of the ER tend to have lower proliferating indices (Meyer & Lee 1980,
Olszewski et al. 1981, Kallioniemi et al. 1987, Dressier et al. 1988). ER-positive
tumours would in theory therefore be expected to be more chemoresistant to cytotoxic
agents. This has not been uniformly held up in clinical practice for cytotoxic therapy in
advanced breast cancer (Rubens et al. 1980; Jonat et al. 1980; Bonadonna et al. 1980;
Stewart etal. 1983).
It has been argued (Padmanabhan, Howell & Rubens 1986) that the principal
beneficial effect of adjuvant cytotoxic therapy is through its ability to produce a medical
oophorectomy. This study has directly demonstrated that chemotherapy is effective in
postmenopausal patients, in patients with ER-poor/negative tumours and ER-positive
tumours which have been directly shown to be endocrine resistant. The effect is rapid
and occurs before the onset of full suppression of ovarian function. The recent
demonstration that a significant improvement in disease-free survival can be obtained in
ER-negative tumours (Bonadonna et al. 1987) following adjuvant chemotherapy
supports the argument that the principal effect, particularly in ER-negative tumours is
by direct cell kill. It is difficult to determine the clinical implication of ovarian
suppression in the long term for premenopausal patients with ER-positive tumours,
when it is possible that ovarian suppression may have an additional effect It does
however seem suboptimal to use cytotoxic therapy as a method of inducing ovarian
ablation.
In summary the ER of the primary tumour can be used to differentiate a group of
patients for whom initially treatment with endocrine therapy is futile, namely those with
an ER concentration of less than 20 fmol/mg cytosol protein. Such patients should
receive primary cytotoxic therapy. Response to endocrine therapy within patients with
ER-moderate/rich tumours can be expected in around 50% patients. Response in the
individual patient however can only reliably be determined by direct observation of the
effect of therapy. In this way those patients in whom continuing endocrine systemic
therapy is appropriate have been selected and survival data would suggest that such
patients have an excellent prognosis. Similarly direct objective assessment of tumour
response to systemic therapy allows cessation of endocrine therapy where it has been
demonstrated to be of no value with initiation of chemotherapy if desired.
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The effect of cytotoxic therapy is not dependent on the presence of the ER and indeed
a subpopulation of patients with endocrine-resistant, ER-positive tumours can be
identified which are less likely to be sensitive to cytotoxic agents.
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CYTOCHEMICAL ASSAY OF OESTROGEN RECEPTOR ACTIVITY
Material for cytochemical analysis of ER activity was available for 50 patients. Of
these, thirty patients (ER < 20 fmol/mg cytosol protein n = 5, ER > 20 fmol/mg
cytosol protein n = 25) received primary hormonal therapy (goserelin n = 9, tamoxifen
n = 3, aminoglutethimide n = 9, 4-hydroxyandrostenedione n = 9) and twenty patients,
all with ER-poor/negative ( < 20 fmol/mg cytosol protein) tumours received primary
cytotoxic therapy.
Reproducibility of Cytochemical Staining and Correlation with
Biochemical Oestrogen Receptor Activity
Biochemical ER activity was determined in all 50 patients. In 13 patients ( 26.0% ),
the ERICA was not assessable either because the aspirates were acellular (n = 10) or
the cells were too badly damaged during processing (n = 3). Comparison of
biochemical and cytochemical ER assays was therefore possible in only 37 tumours.
The range of ER concentration using the DCC adsorption method was 0-584 fmol/mg
cytosol protein; 28 of the 37 tumours (75.7%) had an ER concentration of > 5 fmol/mg
cytosol protein. Using ERICA, 62.2% of tumours had positive staining (range of
"staining index" 0.04 - 2.9).
The correlation between two observers scoring the same ERICA specimen
independently was high for all three measured parameters, that is % cell staining (r =
0.98, Figure 26), staining intensity (r = 0.95, Figure 27 ) and staining index (r = 0.97,
Figure 28 ).
The biochemical ER concentration was related to the cytochemical percent cells staining
(r = 0.90, Figure 29a), and staining intensity (r = 0.90, Figure 29b). Integrating these
values as a "staining index" did not improve this already high correlation (r = 0.89,
Figure 30). No tumour with an ER concentration of < 5 fmol/mg cytosol protein had
significant cytochemical staining while all tumours with an ER value of >20 fmol/mg
cytosol protein by DCC showed cytochemical staining. Three tumours had an ER
concentration of between 5 and 10 fmol/mg cytosol protein but only one (ER 8 fmol/mg
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Figure 26
Correlation of interobserver scoring of % cells staining on fine-needle aspirates with the
ERICA kit in 37 patients with large operable breast cancers. The Spearman's Rank




staining intensity - observer 2
Figure 27
Correlation of interobserver scoring of staining intensity on fine-needle aspirates
stained with the ERICA kit in 37 patients with large operable breast cancers. The
Spearman's Rank Correlation Coefficient was 0.95.
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staining index • observer 2
Figure 28
Correlation of interobserver scoring of staining index on fine-needle aspirates stained
with the ERICA kit in 37 patients with large operable breast cancers. The Spearman's
Rank Correlation Coefficient was 0.95.
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Relationship Between Biochemical and Cytochemical ER Status and
Response to Endocrine Therapy
Thirty patients received endocrine therapy. Although response data was available for
all patients, assessment of ERICA activity was only possible for 20 tumours. Of
these, 11 showed regression, 6 exhibited no change, and in 3, there was evidence of
progression.
Biochemical ER concentration was related to response (Figure 31) and showed a
statistically significant correlation (r = 0.48, p < 0.05). The cytochemical "staining
index" also related significantly to hormone responsiveness (r = 0.54, p < 0.02, Figure
31). When however subdivided into its constituent parts, this correlation appeared
primarily to be a function of the percent cells staining (Figure 33a, r = 0.55, p < 0.02);
mean staining intensity showed a poor association with subsequent response to
endocrine therapy (Figure 33b, R = 0.38 p > 0.05) and did not improve the predictive
value over that obtained from analysis of the proportion of cells staining alone. This
was evaluated by considering the association between response and staining intensity
only in those tumours in which staining was present (r = 0.05, p > 0.10).
All tumours responding to therapy had greater than 20% cells staining for ER, or a
"staining index" in excess of 0.3. Although there was overlap between the response
categories, a gradual step-wise increase in the median "staining index" and the percent
cells staining was demonstrated between those tumours which progressed (0.00, 0%
cells staining), those remaining static (0.7, 32% cells staining), and those which
regressed (1.35, 68% cells staining) (Figures 32 and 33). In general, the higher the
staining index or percent cells staining, the greater the likelihood that the patient would
respond to therapy (<20% cells staining 0% response, 20-50% staining 50% response,
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biochemically detected receptor sites (fmol/mg protein) ,
Figure 29
Relationship between the two indices a) % cells staining and b) average staining
intensity of immunocytochemical staining for ER in a fine needle aspirate and ER
concentration, as determined by DCC assay, in 37 large, operable, primary breast
cancers. The Spearman Rank Correlation Coefficient of both graphs was 0.90, giving a
p value < 0.001.
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Figure 30
Relationship between the staining index of immunocytochemical staining for ER in a
fine needle aspirate and ER concentration, as determined by DCC assay, in 37 large,
operable, primary breast cancers. The Spearman's Rank Correlation Coefficient was
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Figure 31
Relationship between ER concentration, determined by DCC assay and response of the
primary tumour to endocrine therapy, in 20 patients with operable breast cancer. The
Spearman's Rank Correlation Coefficient was 0.48, giving a p value of < 0.05. The
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Figure 32
Relationship between the "staining index "(ERICA) of a fine needle aspirate and
response of the primary tumour to endocrine therapy, in 20 patients with operable
breast cancer. TTie Spearman Rank Correlation Coefficient was 0.54, giving a p value
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Figure 33
Relationship between the two indices a) % cells staining and b) average staining
intensity of immunocytochemical staining for ER within fine needle aspirates and
response of the primary tumour to endocrine therapy for 20 patients with operable
breast cancer. The Spearman Rank Coerrelation Coefficient for the relationship
between % cells staining and response was 0.55, giving a p value of < 0.02, and for
average staining intensity was 0.38, giving a p value of > 0.05. The median value
within each group is shown by a horizontal bar.
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DISCUSSION
The development of an antibody to the oestrogen receptor (Greene, Fitch & Jensen
1980; Greene & Jensen 1982) has led to the introduction of a commercially available
immunocytochemical assay for the ER protein (ERICA, Abbott laboratories). This
cytochemical assay offers several advantages over the conventional steroid-binding
biochemical assay currently employed in clinical practice since it is rapid, does not
require complex laboratory materials and can be performed on small tissue samples
obtained by fine-needle aspiration (FNA, Flowers et al. 1986; Hawkins et al. 1988).
Several previous studies have examined the relative sensitivities and specificities of the
biochemical and immunocytochemical assay methods. Although in general these have
demonstrated a good correlation, several differences have been noted (King et al.
1985; McCarty et al. 1985; McLelland et al. 1985,1986; Hawkins et al. 198; Charpin
et al. 1988).
Biochemical assay of ER is performed on homogenised tumour, and while measuring
the total receptor content, fails to demonstrate either the proportion of cells which
contain ER or the amount of ER contained within individual cells. Cytochemical
immunoassay allows assessment of this heterogeneity and in our hands gives consistent
and reproducible results with a high interobserver correlation (r = >0.95). This is
consistent with the reproducibility demonstrated by Kinsel and her colleagues who
report an intraobserver correlation of 0.94 and an interobserver correlation of 0.91
when comparing ER activity measured biochemically to ERICA staining in fixed tissue
sections (Kinsel et al. 1989).
This study also confirmed the reports of others who have suggested that cytochemical
staining of aspirates by the ERICA kit accurately reflects the ER content of the tumour
since there was a good correlation between cytochemical staining of both the
proportion of cells staining, and their relative staining intensities with biochemical
assay. Integrating the cytochemical scores as a "staining index", did not improve this
already high correlation. A few tumours of moderate/high biochemically measured
receptor value were identified which showed a low staining index (<1.0). The reasons
for the low degree of staining within these aspirates have not fully realised since these
specimens were not of lower cellularity or higher blood content than those showing a
stronger correlation between cytochemistry and biochemistry. Nevertheless the finding
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of a correlation coefficient of 0.9 (n = 37) is in fact higher than those reported by other
workers when comparing ERICA staining on aspirates and receptor concentration in
biopsies (Flowers et al. 1985, r = 0.74, n = 33; Cavailles et al. 1987, r = 0.76 n =
35). These correlations are higher than that of 0.48 (n = 95) found by McLelland et al.
(1987) but their series included some comparisons between ERICA staining and DCC
assays on different tumour deposits. A similar order of magnitude of correlation has
also been found when comparing ERICA staining in frozen or paraffin sections with
biochemically determined receptor concentration (King et al. 1985, r = 0.76, n = 38;
McCarty et al. 1985, r = 0.79, n = 38; Andersen, Orntoft, Skougaard Poulsen 1986, r
= 0.91, n = 35; Hawkins, Sangster & Krajewski 1986, r = 0.87, n = 34; Kinsel et al.
1989, r = 0.63, n = 257). Ultimately however, validity of the immunoassay system
must be based on a direct comparison with its predictive power for response to
endocrine therapy.
A positive association was demonstrated between ERICA staining and response to
endocrine therapy such that tumours with a high proportion of cells staining for ER( >
20%) were more likely to be hormone responsive than those with a lower score.
Consideration of the semiquantitative estimation of mean staining intensity seemed to
add little to the information gained from assessment of % cells staining alone.
However only a small series of patients were available for analysis and due to a
necessary change in treatment protocol a high proportion of these patients had ER
positive tumours. Similar results have however been demonstrated in a cohort of 52
elderly patients treated primarily with tamoxifen (Gaskell et al. 1989) in whom 40%
had ER-poor/negative tumours. This study also indicated that the best predictor of
regression was the proportion of tumour cells which stained for ER (Gaskell et al.
1989). In 9 patients without demonstrable activity the tumour rapidly progressed whist
on tamoxifen. Coombes et al. (1987) have similarly reported a positive association
between cytochemical staining for ER and hormone-sensitivity in advanced breast
cancer.
It is interesting to speculate why intensity of staining may not add to % cell staining in
prediction of response to hormonal therapy. Although the technical assessment of
intensity was more subjective than that of percent cells staining, both parameters related
equally well to the biochemical ER concentration and so an alternative explanation must
be sought. In another hormonally controlled organ, the testis, it is well documented that
response to luteinising hormone (LH) can be elicited with occupancy of only 1% of
cellular LH receptors and is maximal when 10% of receptors are occupied (Genuth
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1983)- If the threshold for the cytochemical detection of ER within a cell corresponded
to that required for hormone responsiveness, a further increase in the number of ER
within the cell and hence intensity of staining for ER, would be of no biological
importance. One could then expect a direct relationship between the proportion of cells
staining and the likelihood of response to exist. Although the numbers are small within
this study, the pattern of response is in keeping with this hypothesis.
The discrepancy in sensitivity between cytochemical and biochemical detection of ER,
at low levels of ER (5-20 fmol/mg cytosol protein ) may be of scientific concern, but
previous studies (Jensen 1975, McGuire et al. 1974) as well as the present data have
shown that a tumour is unlikely to respond to endocrine therapy if the ER concentration
is < 20 fmol/mg cytosol protein. An ER activity of 20 fmol/mg cytosol protein would
appear to be within the limits of detection of the cytochemical assay. The proportion of
tumour cells staining for ER is at least as good as biochemically determined ER status,
in predicting hormone responsiveness.
Despite the potential value of the staining of breast aspirates by ERICA, it is important
to remember several limitations. Measurement of ER was only possible in 74% of fine-
needle aspirates within this study. This proportion may be improved by performing a
second aspiration (which is still less invasive than surgical biopsy) but the figure is
lower than would be expected given an experienced aspirator. This may relate to the
minimum number of tumour cells (around 20) required before the specimen was
considered adequate for assessment. Although staining may be visible in a lesser
number of cells, a cell count of less than 20 was thought to be insufficient to take
account of possible tumour heterogeneity. This is to be contrasted with Rowers et al.
(1985) who consider 5 cells as adequate. Secondly the method of cell staining
produces some morphological damage to the aspirated cells but interpretation of cell
type can be obtained from the concomitant smear which has been fixed directly.
In summary immunocytochemical determination of the proportion of tumour cells
staining for ER is a simple, reliable and reproducible technique which can be performed
without surgical intervention and the results correlate well with hormone
responsiveness. The technique thus has a potential role in determining the value of
hormone therapy in those patients in whom systemic therapy is the preferred treatment
option i.e. the elderly patient or those with advanced local or metastatic disease. In
those patients with operable disease, early determination of the ER status of their
172
tumour may in the future facilitate preoperative counselling of the patient in relation to
appropriate systemic therapy.
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RELATIONSHIP BETWEEN LOCAL STEROIDOGENESIS AND
RESPONSE TO SYSTEMIC THERAPY
TUMOUR AROMATASE ACTIVITY
Aromatase activity was measured in a total of 62 tumours; 32 tumours before starting
systemic therapy and 30 tumours on completion of 12 weeks (or if both endocrine and
cytotoxic therapy was given 24 weeks) systemic therapy. All tumours were from
postmenopausal women. Significant aromatase activity (>0.5 pmol E2 produced/g/hr =
>0.02% conversion) was detected in 21 of the 32 pretreatment tumours (65%). Levels
varied from < 0.5 to 19.77 pmol E^ produced/g/hr (median 0.62 pmol E2
produced/g/hr). No significant relationship was observed between tumour aromatase
and ER activity (Table 22).
Reliability of Tumour Aromatase Activity
Due to the large amount of tumour required for assay of tumour aromatase it was not
possible to obtain formal measurement of tumour aromatase activity in multiple
samples from the same tumour.
Tumour Aromatase Activity and Response to Systemic Therapy
Pretreatment tumour aromatase activity was directly related to clinical response in 32
postmenopausal patients; 25 patients received an aromatase inhibitor (4-
hydroxyandrostenedione (n = 12), 4-hydroxyandrostenedione and CHOP (n = 3),
aminoglutethimide and hydrocortisone (n = 7), aminoglutethimide and hydrocortisone
plus CHOP (n = 3); 6 patients received the chemotherapeutic regime CHOP alone and
one patient was given tamoxifen. All patients who received
4-hydroxyandrostenedione had tumours with an ER concentration of >20 fmols/mg
cytosol protein, 4 of the patient who were treated with aminoglutethimide however had
ER-poor tumours. The relationship between tumour aromatase activity and clinical
response is shown in Table 23.
When response to aromatase inhibition was analysed in relation to the presence or
absence of detectable levels of tumour aromatase activity (cut of level 0.5 pmol E2
produced/g/hr), no significant relationship was demonstrated (Table 23 )
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Table 22
Relationship between the oestrogen receptor concentration of the primary tumour as
measured by the dextran coated charcoal method and tumour aromatase activity in 32
patients with large operable breast cancers, (p = 0.67, Fishers exact test).
Tumour aromatase
negative positive
ER status <0.5* >0.5*
<5 fmol/mg protein 3 4
>5 fmol/mg protein 8 17
If however a higher level of activity at 0.85 pmol E2 produced/g/hr is taken, then
although not absolute, a statistically significant relationship between response to
aromatase inhibition and the presence of high levels of tumour aromatase activity was
detected (Table 24). Significant regression was seen in 7 out of 10 tumours with
higher activity (>0.85E2 produced/g/hr) whereas only 4 of 15 tumours with lower
levels demonstrated significant regression. There was no relationship between
response to chemotherapy and aromatase activity of the primary tumour (Table 24).
175
Table 23
Relationship between clinical response to aromatase inhibitors and tumour aromatase
activity in 32 large operable breast cancers. The relationship has been analysed using
the Fishers exact test.
Tumour Aromatase Activity
negative positive
<0.5* >0.5* p value
Aminoglutethimide
Significant regression 1
No significant regression 3
4-hydroxyandrostenedione
Significant regression 3
No significant regression 3
Aromatase Inhibitor - Total
Significant regression 4
Non significant regression 6
Chemotherapy (CHOP)
Significant regression 1
No significant regression 1
Tamoxifen













Relationship between clinical response to aromatase inhibitors and tumour aromatase
activity in 32 large operable breast cancers. The relationship has been analysed using
the Fisher exact test.
Tumour Aromatase Activity





































17B-hydroxysteroid dehydrogenase activity was measured before therapy in 24
patients; 10 were premenopausal and 14 were postmenopausal. Thirteen patients had
tumours with an ER concentration of >20 fmol/mg cytosol protein. Systemic therapy
within the 24 patients was as follows, 6 received 4-hydroxyandrostenedione therapy
alone, two patient underwent therapy with goserelin followed by surgical
oophorectomy, 11 patients received combination chemotherapy (CHOP), and 5 patients
received both endocrine (4-hydroxyandrostenedione n = 2, goserelin n = 3) and
chemotherapy (CHOP).
Relationship Between 17B-hydroxysteroid Dehydrogenase and Patient
and Tumour Characteristics
Enzyme activity was detected in all samples assayed but there was a wide variation
between individual patients (range 0.27 - 21.7; median 2.9 pmol/mg protein/hr). No
relationship could be demonstrated between 17B hydroxysteroid dehydrogenase
activity and menopausal status of the patient (Mann-Whitney U Test; Figure 34) or the
oestrogen receptor status of the tumour (Spearman Rank Test; Figure 35).
Comparison of pretreatment 17B-hydroxysteroid dehydrogenase activity and
pathological axillary node status was only possible for 12 patients, no obvious
relationship could be demonstrated (Mann-Whitney U Test; Figure 36).
Relationship Between 17B-Hydroxysteroid dehydrogenase Activity and
Response to Systemic Therapy
The relationship between pretreatment peritumour fat 17B-hydroxysteroid
dehydrogenase activity and response to systemic therapy is shown in Figure 37.
There was no significant difference in the mean activity of those patients who did
(mean 1.95, range 0.28-5.42 pmol T/mg protein/hr) and did not (mean 1.39, range
0.27 - 2.88 pmol T/mg protein/hr) achieve significant regression with systemic therapy
(Mann-Whitney U Test). The lack of correlation was obvious irrespective of whether
endocrine, cytotoxic or both methods of treatment were considered.
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Figure 34
Relationship between 17B-hydroxysteroid dehydrogenase activity in peritumour fat and
menopausal status in 24 patients with large operable breast cancers. Bars denote























17B hydroxysteroid dehydrogenase activity
(pmol T/mg protein/hour)
Figure 35
Relationship between the oestrogen receptor concentration of the primary tumour and
the 17B-hydroxysteroid dehydrogenase activity of the peritumour fat in 24 operable
breast cancers. No signficant correlation was demonstrated (Spearman Rank Test, R =























Relationship between 17B-hydroxysteroid dehydrogenase activity in peritumour fat and
axillary node status in 12 patients with large operable breast cancers. Bars denote






Relationship between 17B-hydroxysteroid dehydrogenase in peritumour fat and clinical
response to systemic therapy in 24 operable breast cancers. Patients treated with
endocrine therapy are shown by open circles, and those treated with primary
chemotherapy by solid squares. The horizontal bars denote median values. The




The involvement of steroid hormones in the natural history of breast cancer has long
been recognised. Although the level of circulating hormones has been extensively
investigated no specific abnormality has been related to an increased risk of developing
breast cancer, castration at an early age however is associated with a reduced risk of
breast cancer (Feinleib 1968). The circulating levels of oestrogens and their precursors
do not accurately reflect levels within breast cancers (Van Landeghem et al. 1985;
Vermeulen et al. 1986) and local steroidogenesis may have considerable biological
significance. The relationship between hormone responsiveness and the activity of
two of these enzymes, namely aromatase and 17B-hydroxysteroid dehydrogenase has
been studied.
A positive association has been demonstratedbetween the presence of high aromatase
activity in a tumour and an increased likelihood of response to anti-aromatase therapy.
The addition of an aromatase activity of greater than 0.85pmol E2 produced/g/hr to ER
concentration improved the prediction for response to aromatase inhibition from 50%
(11/22) to 70% (7/10). Miller (personal communication) has not been able to
demonstrate any relationship between tumour aromatase activity and clinical response in
either premenopausal women treated by surgical castration or postmenopausal women
treated with tamoxifen. This suggest that tumour aromatase has a particular predictive
association with anti-aromatase agents. The absence of significant levels of tumour
aromatase was not synonymous with resistance to aromatase inhibitors presumably
because these tumours derived their oestrogen as a result of aromatase activity in other
tissues e.g. fat.
Tumour aromatase activity can be regulated by autocrine and paracrine hormones
produced by the tumour itself (Lippman et al. 1986, Knabbe et al. 1987) and this
represent a possible mechanism of growth control for hormone responsive tumours.
Although no relationship was demonstrated in this study between ER-status and tumour
aromatase activity, tumour aromatase activity may only be of clinical importance in ER-
positive tumours.
17B hydroxysteroid dehydrogenase is a pivotal enzyme in the interconversion of both
androgens and oestrogens from the relatively inactive precursors androstenedione and
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oestrone to the biologically active testosterone and oestradiol. Within this study 17B
hydroxysteroid dehydrogenase activity has been assessed by measuring the conversion
of androstenedione to testosterone. It has been established however that essentially the
same order of enzyme activity can be detected whether IB 3H androstenedione or
2,4,6,7 3H oestrone is used as a substrate although interconversion of androgenstends
to be greater than that of oestrogens (Miller & O'Neill 1987).
The levels of 17B -hydroxysteroid dehydrogenase activity detected within the presented
group of patients was similar to that described by other authors for breast cancers of
greater than 3 cm in diameter using a similar methodology (median 1.9, range 0.3 - 7.8
pmol testosterone/mg protein/hour; Miller & O'Neill 1987). The spectrum of activity
was similar irrespective of patient menopausal status confirming previous published
work (Santen et al. 1986).
Although no direct evidence is yet available, it has been postulated that tumours with a
higher level of endogenous oestradiol production are more likely to be hormone
sensitive. It has been suggested that ER-positive tumours (indirect measure of
hormone sensitivity) have a significantly higher 17B-hydroxysteroid dehydrogenase
activity than ER-negative tumours (Vermeulen and Deslypere, 1989). Despite an
equivalent sample size this relationship has not been reproduced in this study.
Similarly no direct relationship between 17B-hydroxysteroid dehydrogenase activity
and tumour response to endocrine therapy was demonstrated. Results from only 13
patients were available for analysis and the failure to demonstrate any relationship may
be a function of small population size. As a discriminating index for hormone
sensitivity however 17B hydroxysteroid dehydrogenase activity would appear to have
little value in routine practice.
In summary, tumor aromatase activity >0.85 pmol E2 produced/g/hr has a predictive
association for response to anti-aromatase agents but the relationship is not absolute.
No relationship was apparent between the endogenous ability to produce oestradiol and
response to either endocrine or cytotoxic therapy.
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Relationship Between Response and Histological Grade
Consistency of Grading
Grading was available for a total of 147 tumour specimens; 80 pretreatment and 67
post-systemic treatment. When the specimen were regraded blind by the same
pathologist, in only 9 of the 147 tumours was a discrepancy in tumour grade noted
giving an overall 92.5% concordance. When a discepancy occured the specimens
were regraded a third time.
Histological grading of the pretreatment biopsy was available for 80 of the 88 patients
within this study, of these 7(9%) tumours were classified as grade I, 26(32%) as grade
II and 47(59%) as grade III.
Relationship Between Histological Grade and Other Prognostic
Parameters
An inverse relationship between histological grade and ER concentration was noted
within this cohort of patients (Table 25). This trend however failed to reach statistical
significance. The relationships between histological grade, menopausal status and
axillary node status of the patient are shown in Table 26 and 27 respectively. No
significant correlation was demonstrated.
Relationship between histological grade and oestrogen receptor status of the primary
tumour as determined by dextran-coated charcoal adsorption method, in 88 large
operable breast cancers. The relationship does not reach statistical significance ( x2 =
Table 25.
3.71, p = 0.16).
Histological
grade











* fmol/mg cytosol protein
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Table 26.
Relationship between histological grade as defined by Bloom and Richardson criteria
and menopausal status in 88 patients with large operable breast cancers. The









Relationship between pretreatment histological grade and axillary lymph node status in
88 patients with large operable breast tumours. The relationship is not significant (x)-2
= 0.364, p =0.833).
Histological Axillary node status
grade positive negative unknown
14 12
II 10 3 13
III 16 7 24
unknown 3 14
TOTAL 33 12 43
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Relationship Between Pretreatment Histological Grade and Response to
Systemic Treatment
Direct comparison of pretreatment histological grade and response was available for 55
patients receiving endocrine and 25 patients receiving primary cytotoxic therapy. No
significant relationship was demonstrated between response to endocrine therapy and
histological grade but patients with grade III tumours appeared less likely to respond to
endocrine therapy (Table 28). This trend was no longer obvious when only those
patients with tumours of ER concentration of >20 fmol/mg cytosol protein were
considered (Table 28).
There was also no correlation between grade and response to primary cytotoxic therapy
(Table 29). The proportion of tumours within grades II and III which achieved




Relationship between histological grade of the primary tumour as judged by Bloom and
Richardson criteria, oestrogen receptor status (dextran-coated charcoal adsorption
assay) and response to endocrine therapy in 61 large operable breast cancer. No
significant relationship exist either when all patients receiving endocrine therapy are
considered (x^= 0.778, p = 0.68) or only those with tumours of ER concentration >
20 fmol/mg cytosol protein (x^ = 0.153, p = 0.93).
TOTAL ER > 20*
Histological Proportion of patients Proportion of patients
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Table 29
Relationship between histological grade of the primary tumour as judged by Bloom and
Richardson criteria and response to primary cytotoxic therapy in 27 patients with large
operable breast cancer. No significant relationship exists ( x^= 0.24 p = 0.89).
Histological Proportion of patients








Histological grading is based on a subjective assessment of microscopic appearances.
Difficulties in consistency and reproducibility are possible. Within this series a high
degree of consistency was achieved on the first assessment. The figure of 92.5%
compares very favourably with that reported by the Nottingham/Tenovus study (Elston
1988) who report a 90% agreement on first assessment when sections were graded
independently by two experienced histopathologists, and by Fisher (Fisher et al. 1975)
who report a 94% agreement by the same reviewer on different occasions.
Within this series of patients the distribution of tumours with respect to histological
grade was within the limits of previously reported series (Table 6) although the number
of patients with grade I tumours at 9% was within the lower limits of the range. This
has acted to reduced the statistical power of the results in relation to response.
Within this study an inverse relationship between histological grade and response to
endocrine therapy was observed (50% grade 1,42% grade II and 33% grade III),
although this failed to reach statistical significance. Previously reported studies have
demonstrated a significant relationship (Millis et al. 1981, Masters et al. 1987,
Williams et al. 1986) and the failure to do so within this study may be a function of the
smaller number of patients particularly those with grade I tumours.
A positive correlation between tumour grade and ER concentration has previously been
demonstrated such that the more differentiated, lower grade tumours are more likely to
be ER-positive (Fisher et al. 1987; Kamby et al. 1988; Singh et al. 1988). Response
to endocrine therapy is known to occur more frequently in ER- positive tumours
(McGuire et al. 1975; Hawkins Roberts & Forrest 1980). The relationship observed
within previous studies between grade and response to endocrine therapy may therefore
simply be an indirect function of the relationship between grade and ER concentration
although an additional predictive effect of grade to ER status has been suggested
(Williams et al. 1986). The proportion of ER-positive tumours responding within this
latter series was however low at 32%. Most other series report response rates of 49-
58% for patients with ER-positive tumours (McGuire et al. 1975, King et al. 1982;
Hawkins, Roberts & Forrest 1980). Had these higher rates been found then the small
additional effect of grade may not have been obvious. Certainly when the response
rates were recalculated within this study to consider only those patients with tumours
of ER concentration >20 fmol/mg cytosol protein (overall response rate 52%) the
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predictive effect of grade was diminished (60% grade I, 50% grade II and 53% grade
III).
Well differentiated tumours with the exceptions of lymphomas and chronic lymphocytic
leukemia tend to be relatively resistant to chemotherapy with poorly-differentiated
tumours more likely to respond (Whitehouse 1984). This study has suggested that
histological grade has no such predictive value in breast cancer and confirms the finding
in advanced breast cancer of other authors (Masters et al. 1987). The overall response
rate to primary chemotherapy within this study was high at 85% and given the small
number of patients it was unlikely that anything other than a dramatic difference would
have been obvious.
Within this study estimation of tumour grade did not give any useful additional
information in relation to hormone-responsiveness over that provided by measurement
of the ER concentration alone. Similarly tumour grade was not a useful predictor of
response for cytotoxic therapy.
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RESPONSE TO SYSTEMIC THERAPY AND DNA ANALYSIS
Fine-needle aspiration as a Method of Cell Yield for Flow Cytometry
To determine the qualitative reproducibility of flow cytometric DNA analysis, using
fine-needle aspiration as the method of biopsy, 4 FNAs were taken from each of 20
excised tumour specimens. On histological examination, all tumours were primary
breast adenocarcinomas of no special type. From the total of 80 FNA specimens, 12
(15%) were acellular and 2 (2.5%) were unassessable; DNA histograms were therefore
evaluable in a total of 66 FNAs (82.5%). Since in one tumour, all 4 FNAs were
acellular, DNA analysis was eventually possible in 19 tumours (95%), although in only
17 was a comparison between FNAs from the same tumour possible. Three tumours
(15.7%) were diploid, the remaining 16 (84.3%) were aneuploid (hypodiploid
1(6.2%), hyperdiploid 7, multiploid 1, tetraploid 6, hypertetraploid 2).
All three diploid tumours maintained their diploid character in all FNAs examined.
Similarly all aneuploid tumours conserved their aneuploid status and there was good
concordance between the DIs of the aneuploid cell line(s) within specimens from the
same tumour (pooled standard deviation 0.078, range 0.017 - 0.19, Table 30). There
was however a discrepancy in the aneuploid subclassification of 3 of the 16 aneuploid
tumours. These tumours remained consistantly aneuploid, but in two a second
aneuploid cell line appeared in one of the 4 aspirates, while in the other, two aneuploid
cell lines were detected in 3 of the 4 aspirates. In all three cases, the deviation occured
in only one of the 4 specimens available for analysis and in each the abnormal cell line
constituted only approximately 11% of the total cell count.
There was a discrepance in ploidy status in 5 of the 19 tumours when the FNA sample
was compared to paraffin tissue sections of the same tumour specimen (Table 32). In
4 cases the FNA reproducibly detected an aneuploid cell line not picked up on the
paraffin sections. The reverse being true for only one case. The presence of tumour
cells was confirmed cytologically in the FNA specimens.
For any given tumour however, the difference between the relative proportion of cells
with diploid and aneuploid DI was much greater (Figure 31). The pooled standard




Variability of the DNA index of 17 aneuploid cell lines within 4 separate FNAs taken



























1.34 1.31 0.021 1.57 0.00043
1.29 1.31 0.064 4.87 0.0041
- 1.35 0.085 6.30 0.007
1.43 1.51 0.063 4.19 0.004
- 1.71 0.19 11.43 0.038
1.73 1.67 0.079 4.69 0.006
1.72 1.74 0.017 0.98 0.00029
- 1.83 0.021 1.16 0.00045
1.91 1.92 0.027 1.41 0.0007
1.92 1.94 0.031 1.598 0.0091
- 1.95 0.116 5.95 0.013
1.96 2.0 0.080 3.96 0.006
- 2.03 0.078 3.847 0.0061
2.03 2.04 0.120 5.65 0.013
2.37 2.37 0.026 1.11 0.0007
2.58 2.53 0.056 2.1 0.003






Variability of the proportion of aneuploid cells of 17 aneuploid cell lines within 4 FNAs







47.2 37.7 47.4 44.6 44.2 4.53 10.25 20.55
19.1 14.9 18.5 16.0 17.12 2.00 11.68 4.00
35.2 36.7 52.4 33.4 39.42 8.78 22.20 76.64
26.6 27.4 11.6 44.0 27.40 13.24 48.30 175.28
68.8 61.3 73.2 56.6 64.40 7.44 11.45 55.31
11.1 9.8 12.9 - 11.27 1.56 13.82 2.42
47.3 45.4 52.7 58.7 51.00 5.98 11.72 35.74
51.5 61.1 65.3 64.3 60.55 6.29 10.39 39.61
51.3 25.6 21.0 39.1 34.25 13.72 40.06 188.20
19.0 58.8 64.6 64.5 51.72 21.98 42.50 483.32
87.4 24.2 90.8 - 67.47 37.51 55.60 1406.80
18.9 87.7 21.1 - 42.57 39.10 91.80 1528.97
59.8 53.4 47.2 50.7 52.78 5.33 10.09 28.38
77.5 70.1 72.6 69.6 72.4 3.61 4.99 13.06
58.6 41.1 67.7 - 55.8 13.52 24.23 182.77
21.9 24.6 - - 23.25 1.91 8.21 3.64
92.9 88.4 89.5 91.5 90.57 2.01 2.22 4.05
Mean 24.68
Pooled variance = 213.7
Pooled standard deviation = 15.81
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Table 32
The relationship between the detection of an aneuploid cell line in FNA compared to the
same tumour on histological tissue section is shown for 19 tumours in which
reproducibility was measured.
Of the three diploid tumours, only two had more than one specimen available for
analysis. The standard deviation for % S-phase was 6.3% (range 8.3% - 22.5% total
cell counts).
Relationship Between Ploidy, DNA Index and Response to Systemic
Therapy
FNA material from the primary tumour before treatment was available in 53 patients,
29 received endocrine therapy and 24 primary cytotoxic therapy. Of the 29 aspirates
from patients who received endocrine therapy 3 (10%) were acellular. Of the remaining
26,18 (69%) were aneuploid and 8 (31%) were diploid. Significant regression was
noted in 5 of the 8 patients with diploid tumours (62.5%) but in only 6 of the 18
patients with aneuploid tumour (33.3%). With the small numbers of patients studied
the relationship does not reach statistical significance (Table 33). The proportion of
tumours showing significant regression was similar for both tetraploid and
hyperdiploid tumour (Table 34). All patients who received endocrine therapy within
this subgroup had tumours with an ER >20 fmol/mg cytosol protein.
Twenty of the 24 patients who received primary cytotoxic therapy had sufficient cells to
allow DNA analysis on the FNA. Of these 16 (80%) had aneuploid tumours and
4(20%) had diploid tumours. The relationship between ploidy status, DNA index and
response to cytotoxic therapy is shown in Tables 35 and 36 respectively. No obvious
relationship between regression with cytotoxic therapy and either lpoidy status and
DNA index was demonstrated. All patients who received cytotoxic therapy within this













Relationship between ploidy measured by flow cytometric analysis of FNA biopsy of
the primary tumour before therapy and response to endocrine therapy in 26 patients
with large operable breast cancers. The relationship is not significant (p = 0.22,
Fishers exact test).
Diploid Aneuploid
Significant regression 5 6
No significant regression 3 12
Table 34
Relationship between DNA index of the 18 patients with aneuploid tumours as
measured by flow cytometric analysis of FNA biopsy of the primary tumour before



















Relationship between ploidy measured by flow cytometric analysis of FNA biopsy of
the primary tumour before therapy and response to cytotoxic therapy in 20 patients with
large operable breast cancers. The relationship is not significant (p = 1.00, Fishers
exact test).
Diploid Aneuploid
Significant regression 3 11
No significant regression 1 5
Table 36
Relationship between DNA index of the 17 patients with aneuploid tumours as
measured by flow cytometric analysis of FNA biopsy of the primary tumour before














Fine-needle aspiration biopsy was first introduced in 1930 (Martin & Ellis 1930) but its
potential as a method for harvesting cells for both diagnostic cytopathology (Zajdela et
al. 1975; Dixon et al. 1983, 1984) and flow cytometric analysis (Levack et al. 1987;
Remvikos et al. 1988) has only been realised more recently. The method has several
obvious advantages over other biopsy methods in that it is relatively atraumatic and
easily performed as an outpatient thus potentially allowing sequential tumour biopsies.
There are however more subtle advantages. When different paraffin block sections
from the same tumour are assessed intratumour variation in DNA ploidy and index
have been observed in 21% of ovarian, 24% of breast cancers with still higher rates
reported for colorectal (Quirke et al. 1985; Hiddeman et al. 1986; Petersen, Lorentzen
& Bichel 1980) and renal cell carcinoma (Ljungberg, Stenling & Roos 1985). The
usual technique of multiple (X10) passages through the tumour in varying directions
ensures that the sample contains cells from a wide area of the tumour. It may therefore
represent a potentially more reliable method for harvesting cells for DNA analysis
(Hartley et al. 1988).
This study confirms previous reports that FNA will in the majority of cases (82.5%),
provide sufficient tumour cells to allow good quality flow cytometric DNA histograms
(Levack et al. 1987). The technique therefore compares favourably in this respect to
the results obtained when fresh homogenised solid tissue is used as the tissue source
(Dressier et al. 1988). The majority of acellular aspirates were from 3 tumours and this
may reflect the cellularity and structure of those tumours. The frequency of
aneuploidy and the distribution of aneuploidy subclassification, both fall within
previously observed ranges (Dressier et al. 1988; Harvey et al. 1987; Barlogie et al.
1983).
The high reproducibility of ploidy within this study means that by using FNA as a
biopsy technique one would be unlikely to misclassify ploidy status. Although there
was a discrepancy in the detection of a cell population in 2 of the 66 evaluable
specimens this did not ultimately affect the classification to either a diploid of aneuploid
tumour type. The conflict occured when the cell line constituted only 11% of the total
cell population and may therefore be at the lower limits of detection for an aneuploid
cell line. If only a simple estimate of ploidy status is required, FNA can be employed
as a biopsy technique.
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For a specific tumour however the proportion of cells within any given aneuploid
population was not so reproducible suggesting that changes in the relative proportions
of cell lines may be difficult to detect reliably. Serial FNA would therefore not appear
to be an acceptable biopsy technique by which to follow the response of cell lines to
therapy. Tumours may also be genetically unstable and undergo spontaneous loss or
acquisition of new cell clone populations unrelated to therapy and so such studies may
have their own intrinsic difficultyirrespective of the mehod of measurement of DNA
indices.
Within the two diploid tumours for which multiple FNA samples were available
examined no direct comment can be made on the reproducibility of FNA in measuring
%S phase except to say that a wide range was observed. Significant intratumour
variation in cell proliferation of diploid tumours has been documented by other workers
using TLI (Lambert 1986; Norton 1985; Smallwood, Cooper & Taylor 1983) and %S-
phase (Kallioniemi 1988). For such diploid tumours, the variation may be related to
the inability to discriminate by flow cytometry between diploid tumour and nontumour
cells. Calculation of %S phase in aneuploid tumours is complex and so with the
software available no attempt has been made to look directly at this variable in
aneuploid cell lines.
In summary FNA would appear to be a reliable method for determining ploidy and DI
of aneuploid cell lines although cell lines which constitute a low proportion of the total
cell population may be difficult to identify consistently. FNA would not appear to be
a reliable method by which quantitative changes in specific cell populations can de
detected by flow cytometric analysis. Within this small study no attempt has been made
to distinguish the major source of error whether it be tumour heterogeneity, sampling
technique, method of assay or a combination of all three.
Previous reports on the relationship between ploidy and response to systemic therapy
have suggested that tetraploid tumours may represent a specific subgroup of endocrine
responsive tumours in which response could be expected in as high as 74% (34/46)
compared to 50% (26/52) in diploid tumours and 39% (15/38) in aneuploid tumours
(Baildam et al. 1987b). Patients with diploid or tetraploid tumours have also been
shown to survive longer and stay in remission longer following treatment with
endocrine therapy than other tumours (Baildam et al. 1987a, 1987b; Stuart-Harris et al.
1985). Closer analysis of these results however showed that over 85% of the tetraploid
tumour were ER-positive tumours compared to a significantly lower proportion in the
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other tumour types and this may account for the difference observed. Within the
present study all tumours had an ER concentration of >20 fmol/mg cytosol protein.
Although the numbers are small the response rate for diploid tumours did appear higher
(5/8) when compared to aneuploid tumours (6/18). When response of the aneuploid
tumours was analysed by DNA index the proportion of tumours regression within the
tetraploid group was similar to that within the hyperdiploid group at approximately one
third. This study would suggest that when the confounding factor of ER status is
controlled, response can be observed in about 62% of diploid tumours. Response in
aneuploid tumours is lower with about one third achieving significant regression
irrespective of the DNA index of the aneuploid cell line. The reason for this difference
remains unclear.
Within this study no relationship was demonstrated between DNA ploidy of the
primary tumour and response of the primary tumour to chemotherapy with equivalent
response rates of approximately 75% being observed for diploid and aneuploid
tumours. Similarly no relationship between response and DNA index was observed.
Other workers (Masters et al. 1987) have also failed to demonstrate any positive
correlation although a trend toward better response in diploid tumours was noted.
Selection of patients for cytotoxic therapy will not therefore be assisted significantly by
assessment of DNA ploidy in the primary tumour.
Cytotoxic therapy has a direct effect on mitosing cells. There is some clinical evidence
to suggest that cytotoxic therapy is likely to be more effective in tumours with high
mitotic activity (Zittoun et al. 1975; Hart et al. 1977; Sulkes, Livingston & Murphy
1979; Zhang, Kennedy & Kiang 1984). Although ploidy and grade do relate to indices
of proliferation (Steel 1977; Meyer & Connor 1977; Haag 1984; Dressier et al. 1988),
it may be that they are too insensitive a measure of tumour kinetics. A more direct
measurement of cell kinetics may be required to further investigate any possible
association . The proportion of cells present within the S-phase can be directly
computed from quantatative analysis of a flow cytometric DNA histogram but a
practical problem exists for aneuploid tumours. Several computer programs have now
been developed to circumvent this problem. Recently specific methods have been
described using antigens incorporated or present within cycling cells and detected by
simple immunocytochemical techniques. Such techniques include the use of
bromodeoxyuridine (Gratzner 1982; Sasaki et al. 1988; Khochbin et al. 1988; Lacombe
et al. 1988; Wilson et al. 1988) and Ki 67 (Gerdes et al. 1984; 1986; Lelle et al. 1987;
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EFFECTS OF SYSTEMIC THERAPY ON PREDICTIVE INDICES
Biochemical Assay of Oestrogen Receptor
ER concentration was measured before and after systemic therapy. Of the 88 patients
within this study, one had bilateral tumours and in twenty-eight patients the post-
treatment specimen (as assessed by the pathologist) contained <10% tumour. Thus 60
patients (with 61 tumours) were available for study.
Changes in ER Concentration According to Type of Systemic Therapy
The changes in ER concentration following therapy are shown for the 60 patients
according to the form of systemic therapy in Figure 38. Although the changes in
individual tumours varied considerably, even within one treatment group, when
analysed as atreatment group, no consistent change in the direction of the ER
concentration was seen (Table 37). Only the three patients treated with tamoxifen alone
showed a significant (99%) fall in ER concentration after 3 months.
Changes in ER concentration According to Response to Therapy
If the 5 patients receiving tamoxifen are excluded (tamoxifen only n = 3, tamoxifen &
chemotherapy n = 2), no significant difference between pre- and post-treatment ER
concentration can be demonstrated irrespective of response to systemic therapy (Table
38). Examination of the relationship between changes in ER and changes in tumour
volume in individual patients did not reveal any consistent pattern.
Changes in ER Concentration in Relation to Tumour Morphology
Although, on average, most treatments were without significant effect on ER
concentration, in some individual patients there were large changes in tumour ER. In
order to see if these related to tumour heterogeneity and sampling, the histological
sections from 12 paired (pre- and post-treatment) tumour specimens were examined by
a pathologist in the absence of any knowledge of the ER concentration.
Of 6 paired specimens showing a 'large' change in receptor concentration, four showed
major differences in morphology between the pre- and post-treatment specimens. By
contrast, none of the six paired specimens from patients showing little or no change in
ER concentration exhibited any striking difference in histopathological appearance.
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Relationship between ER concentration as measured by the dextran-coated charcol
method, before and after systemic therapy with surgical/medical oophorectomy (n =
11), aromatase inhibitor (n = 17), tamoxifen (n = 3), cytotoxic therapy (CHOP, n =
17), or combined endocrine and cytotoxic therapy (n = 13). Patients who achieved
significant regression are shown as — , patients who did not achieve significant




Changes in oestrogen receptor concentration in 61 large primary breast cancers with
systemic therapy.
Oestrogen receptor conc. a
i Pre- Post- Difference Sigb
Surgical/medical 49 60 0.92 n.s.
oophorectomy
(n = 11)
Aromatase inhibitors 163 163 0.98 n.s.
(n = 17)
Tamoxifen 186 2 6.3 p<0.05
(n = 3)
Chemotherapy 4 4 0.98 n.s
(n = 17)
Endocrine 24 18 1.02 n.s
+ Chemotherapy (n = 13)
a Geometric mean calculated after logarithmic transformation of receptor concentration
+ 1.




Changes in receptor concentration and tumour volume in 56 large primary tumours
according to response to systemic therapy.
Oestrogen receptor conc. a
Pre- Post- Difference Sigb
Regression (n = 33)
Endocrine^ (n = 17) 102 127 0.90 n.s.
Chemotherapy (n = 13) 3 4 0.94 n.s.
Endocrine 43 34 1.1 n.s.
+ chemotherapy (n = 3)
No significant regression (n = 23)
Endocrine^ (n = 11) 79
Chemotherapy (n = 4) 8
Endocrine^ + 33




a Geometric mean calculated after logarithmic transformation of receptor concentration
b Significance calculated from the paired't' test, n.s. = not significant,
d Patients on tamoxifen have been excluded.
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DISCUSSION
Studies on the effect of systemic therapy on the oestrogen receptor (ER) concentration
of breast cancer have previously relied upon examination of different tumour deposits
(Taylor et al. 1982; Hamm & Allegra 1988). Since these deposits may differ in
biological characteristics, including the concentration of ER (Hoehn, Plotka & Dickson
1979: Hawkins etal. 1981), this may lead to erroneous conclusions. The treatment of
patient with large operable breast cancer by primary systemic therapy, with direct
observation of response and eradication of local disease by planned locoregional
surgery after 3-6 months of systemic therapy has allowed the study of the concentration
of ER, both before and following systemic therapy within the same tumour mass.
This study has demonstrated that, on average, tumour ER concentration is little changed
by most forms of systemic therapy. Large changes in tumour ER concentration in
individual patients were probably related to tumour heterogeneity (Hawkins et al.
1977a; Van Netten 1985; Senbanjo et al. 1986). Patients on tamoxifen, however did
show a marked fall in receptor concentration during therapy; this was almost certainly
due to interference by tamoxifen or its metabolites in the ligand-binding assay, as noted
by Hull et al. (Hull et al. 1983). In the present study, patients treated by medical of
surgical oophorectomy showed only a slight but insignificant rise in tumour ER
concentration. In a larger number of patients with fibroids, treated with the LHRH
agonist, zoladex, however a similar but significant rise in concentration of ER in uterine
tissues has been observed (Lumsden et al. 1989).
Previous studies in patients with breast cancer (Taylor et al. 1982; Hamm & Allegra
1988; Toma et al. 1986) and in experimental animals (Vignon & Rochefort 1976;
Hawkins et al. 1977b; Cho-Chung et al. 1978) have shown a decrease in receptor
concentration after endocrine manipulation or as in the present study no consistent
change (Hull et al 1983; Mobbs et al. 1987). The conflicting results in human breast
cancer may derive from the inclusion of patients on tamoxifen (Taylor et al. 1982)
which as discussed previously cause an apparent reduction in ER concentration or from
the difficulties of comparing different tumour deposits (Taylor et al 1982; Hamm &
Allegra 1988).
In summary, ER concentration in breast tumours changed little after most forms of
systemic therapy, even in regressing tumours. Thus a marked change in ER
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concentration does not appear to be a component of the mechanism by which tumours
are initially influenced by systemic therapy and in particular does not seem to be due to
a relative reduction in the ER-positive cell population. In order to confirm this direcdy
the study would need to be repeated using immunocytochemical techniques.
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Effect of Systemic Therapy on Enzymes Involved in Local
Steroidogenesis
Effect of Systemic Therapy on Tumour Aromatase Activity
The effect of systemic therapy on tumour aromatase activity is shown in Figure 39 and
Table 39. Of the 12 patients treated with 4-hydroxyandrostenedione, 8 had
demonstrable pretreatment levels of aromatase activity. Following 3 months of
treatment, 7 showed a marked decrease and 4 demonstrated no change in the aromatase
activity of their tumour. Overall there was a significant fall in tumour aromatase
activity irrespective of the response to therapy. In one patient however, with no
demonstrable pretreatment activity a marked rise in activity occured during treatment
with 4-hydroxyandrostenedione.
The general trend of aromatase activity in patients who had received aminoglutethimide
and hydrocortisone was paradoxically upwards with 6 of the 7 patients showing a rise
in aromatase activity in vitro: this occured irrespective of patient response. One patient
exhibited a marked fall in activity following treatment. Of the patients who received
chemotherapy, marked variations in aromatase activity were demonstrated during
therapy but no specific trend was obvious.
17B-Hydroxysteroid Dehydrogenase Activity Before and During
Systemic Therapy
The effect of systemic therapy on 17B-hydroxysteroid dehydrogenase activity is
interesting (Figure 40 and Table 40). There was on average a 70% rise in the 17B
hydroxysteroid dehydrogenase activity following systemic therapy (p < 0.01) although
changes in activity did vary between individual cases. The elevation in 17B-
hydroxysteroid dehydrogenase activity was most significant in the group of patients
treated with CHOP. Within the other treatment groups although the mean level of
activity following treatment was higher than the pretreatment value, the difference was
not statistically significant. The rise in 17B -hydroxysteroid activity appears to occur




Relationship between tumour aromatase activity before and after systemic therapy with
4-hydroxyandrostenedione (4 OHA, n = 12), 4-hydroxyandrostenedione and cytotoxic
therapy (4 OHA + CHOP, n = 3), aminoglutethimide and hydrocortisone (AMG + HC,
n = 7), aminoglutethimide and hydrocortisone and cytotoxic therapy (AMG + HC +
CHOP, n = 1), cytotoxic therapy (CHOP, n = 6) and tamoxifen (TAM, n = 1).
Patients who achieved significant regression with therapy are shown as — , patients
who did not achieve significant regression are shown by . The lines join pre and
post-treatment samples from the same patient.
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Table 40
Changes in tumour aromatase activity in 30 large operable breast cancer during
systemic therapy.
Tumour aromatase activity3 *
Pre-treatment Post-treatment Difference Sig.b








4-OHA + CHOP (n = 3) 0.49 0.89 0.70
Significant regression (n = 1)
no regression (n = 2)





AMG + HC + CHOP 0.22
















a figures quoted are the geometric means of log transformed data in pmol/mg protein/hr




Relationship between peritumour 17B-hydroxysteroid dehydrogenase activity before
and after systemic therapy with 4-hydroxyandrostenedione (4 OHA, n = 5),
oophorectomy (OOX, n = 2), cytotoxic therapy (CHOP, n = 9) and endocrine and
cytotoxic therapy(endocrine + CHOP, n = 4). Patients who achieved significant
regression with therapy are shown as , patients who did not are shown as
The lines join pre- and post-treatment values for the same tumour.
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Table 40
Changes in 17B-hydroxysteroid dehydrogenase activity of peritumour fat in 20 patients
with large operable breast cancers following systemic therapy.
17B-hydroxysteroid dehydrogenase activitya
Pie-treatment Post-treatment Difference Sig.b
40HA (n = 5) 1.23 1.86 0.84 n.s.
significant regression 0.97 1.12 0.95
(n = 2)
no regression 1.45 2.60 0.78
(n = 3)
Oophorectomy (n = 2)
significant regression 1.60 3.02 0.75





3.53. 0.70 < 0.02
3.35 0.69 < 0.25
3.54 0.72
Endocrine + CHOP
(n = 3) 0.84 2.38 0.66
significant regression 0.73 1.48
(n = l)
no regression 1.58 3.02 0.62
(n = 2)
Total 1.30 2.61 0.73 <0.01
a figures quoted are the geometric means of log transformed data in pmol/mg protein/hr




Suppression of plasma oestrogen levels is a function of the inhibition of aromatase
activity in all the peripheral tissues but little information exists concerning the direct
effect of aromatase inhibitors on local oestrogen biosynthesis within breast cancers in
vivo. By obtaining tumour tissue both before and during systemic therapy we have
been able to study this. In general treatment with 4-hydroxandrostenedione was
associated with reduced tumour aromatase activity. This reduction was more marked in
patients who responded to therapy but the trend did not reach statistical significance,
probably due to the small number of patients involved. These findings are consistent
with the demonstrated effect of 4-hydroxandrostenedione on aromatase activity in in
vitro studies (Miller & O'Neill 1987). James and colleagues (James et al. 1989) have
also reported the effect of 4-hydroxyandrostenedione on tumour aromatase and DNA-
polymerase activity in 6 postmenopausal patients with breast cancer. They report a
marked reduction in tumour activity in 5 of the 6 patients.
Within this study for one patient no aromatase activity was detected in the pretreatment
sample but a high level of activity was detected in the post-treatment sample. Failure of
4-hydroxyandrostenedione to produce a fall in the aromatase activity of tumours with
significant pre-treatment activity has been noted in vitro (Miller & O'Neill 1987) and
indeed in one of the six patients in James's series a paradoxical rise in tumour
aromatase and DNA polymerase activity was also noted following treatment with 4-
hydroxyandrostenedione (James et al. 1989). The reason for this rise remains obscure
but it has been suggested that there exists a subset of tumour with significant levels of
aromatase activity which are intrinsically resistant to the effect of 4-
hydroxyandrostenedione. This patient within this series however achieved a highly
significant reduction in tumour volume with therapy and serum oestradiol levels fell to a
mean of 54.6% (SEM +/- 8.9%) of the pretreatment values suggesting that the drug
was functional. The reason for this exception is not evident since tumour was
histologically present in the material incubated from both the pretreatment and post-
treatment specimens.
The increase in tumour aromatase activity observed in patients treated with
aminoglutethimide and hydrocortisone is clearly incongruous for a drug which when
incubated with breast tumour in vitro markedly inhibits aromatase activity (Miller,
Smith & Telford 1987). This rise occured irrespective of the patients clinical response
to therapy and may be due to the concomitant effects of hydrocortisone. In vitro
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studies in MCF7 breast cancer cell lines have shown that Cortisol at a concentration of
10~6 M induces aromatase production (Killinger et al. 1987; Simpson et al. 1981).
Treatment with aminoglutethimide and hydrocortisone is associated in vivo with
depression of plasma oestrone, oestradiol and oestrone sulphate to between 30 - 55%
of their pretreatment values (Harris et al. 1983; Santen et al. 1982; Vermeulen ,
Paridaens & Heusonl983; Dowsett et al. 1985; Lpnning, Johannessen & Thorsen
1989). Urinary excretion of oestrogen metabolites is increased in patients receiving
aminoglutethimide due to the increased activity of hepatic mixed function oxidases
(Lpnning & Skulstad 1989). Both inhibition of oestrogen production and an increase
in plasma clearance of oestrone and oestrone sulphate can be demonstrated in vivo
(Lpnning, Johannessen & Thorsen 1989). Aminoglutethimide can therefore influence
oestrogen disposition by mechanisms unrelated to aromatase inhibition and such effects
might be at least in part responsible for its mechanism of action in breast cancer.
Dramatic differences in aromatase activity between sequential tumour samples taken
before and during treatment could be detected in patients who received the
chemotherapeutic regime CHOP. No definite pattern emerged however and why this
should be so remains unclear. Although the chemotherapeutic regimen did contain
prednisolone this was only administered during the first 5 days of every cytotoxic
cycle. Since surgery was not performed until 4 weeks from the last cytotoxic cycle it
is unlikely that the steroids would have had any effect on the post-treatment aromatase
activity unless the half life of the enzyme was long.
The increase in activity of 17B-hydroxysteroid dehydrogenase activity following
treatment with systemic therapy was highly significant and unlikely to be a spurious
finding. None of the agents used are known to directly affect the activity of this
enzyme and the increase in 17B-hydroxysteroid dehydrogenase activity occured
independent of clinical response to systemic therapy. There was in general a reduction
in tumour size post-treatment. Smaller tumours are associated with a lower peritumour
fat 17B-hydroxysteroid dehydrogenase activity (Beranek et al. 1985) but the findings
are paradoxical to what would be expected if the difference in activity was simply a
function of the change in tumour size. Homogenates from breast cancer cells have been
demonstrated to alter 17B-hydroxysteroid dehydrogenase activity in favour of
reduction (McNeill et al. 1986; James et al. 1989). Interference with tumour cell
growth equilibrium may cause the tumour cells to release nonspecific growth
substances into its surrounding mileau and so effect changes in 17B-hydroxysteroid
dehydrogenase activity. A reduction in tumour size is a complex balance between the
213
rate of cellular regeneration and cell death, increased cell death may still occur without
an obvious reduction in tumour size. It would therefore be possible to affect changes in
17B-hydroxysteroid dehydrogenase activity without being able to demonstrate a
significant change in tumour size.
In summary, tumour aromatase activity is significantly reduced following the in vivo
administration of 4 -hydroxyandrostenedione. This reduction in activity is most
marked in tumours which demonstrated significant regression suggesting a direct causal
relationship. Tumour aromatase was paradoxically raised following the administration
of aminoglutethimide and hydrocortisone although this did not affect clinical response.
The effect of the chemotherapeutic regime CHOP on tumour aromatase was variable
and no definite pattern emerged.
17B-hydroxysteroid dehydrogenase activity was significantly elevated following
systemic therapy irrespective of type of therapy or tumour response. The reasons for
this remain obscure but may relate to local growth control mechanisms.
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Relationship Between Pre- and Post-treatment Histological Grade.
Sufficient residual tumour was available to allow grading in 67 of the 75 post-treatment
specimens in which there was residual tumour. In 60 of these patients pretreatment
grading was also available allowing the effect of therapy on grade to be assessed (Table
41, 42 and 43). In 44 of the 60 tumours studied (73%) no change in grade was noted
with therapy. In those tumours in which a change was observed, the shift was small
and did not relate to response.
Table 41.
Tumour histological grade, as judged by Bloom and Richardson criteria, before and
after primary systemic therapy in 60 patients with large operable primary breast cancer.
Clinical response
Post-treatment progression no change significant
grade regression
reduced - 2 9
unchanged 2 16 25
increased - 1 5
Table 42.
Tumour histological grade, as judged by Bloom and Richardson criteria, before and





progression no change significant
regression
reduced - 1 6
unchanged 2 9 12
increased - - 3
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Table 43.
Tumour histological grade, as judged by Bloom and Richardson criteria, before and

















In vitro cell cycle analysis of hormonally-responsive tumours has demonstrated that
oestrogen deprivation reduces the number of cells undergoing mitosis with reduction of
the cells within the S-phase and accumulation of cells in the growth arrest phase of
G0/G1 (Sutherland et al. 1983, 1986; Lykkesfeldt et al. 1984; Bruno et al. 1988).
Mitotic rate forms an integral part of assessment of grading and so it may have been
expected that a reduction in grade would have occured with those tumours which
responded to endocrine therapy but no such change was observed in this study. It
may be that mitotic counting and grading are too insensitive a parameter of cell
proliferation to detect these subtle changes. Cytotoxic therapy directly kills cells







This study has described a method for direct, in vivo assessment of primary human
breast cancer in response to systemic therapy. By combining a measuring system
based on the mean value of eight clinical diameters taken at weekly intervals for 12
weeks, a method of response analysis has been devisedwhich was both sensitive and
reproducible. The application of statistical analysis to the changes in tumours volume
during therapy meant that not only could response be objectively assessed but also the
rate of regression could be determined. Although this parameter is as yet of
undetermined biological significance, initial survival analysis at least in relation to
response to chemotherapy suggest that the most sensitive tumours may have a better
survival. This would be of relevance in selecting out patients whose tumours are
highly chemosensitive and for whom continuing cytotoxic therapy to the point of
cytoeradication is legitimate. The method of assessment as presented is however time
consuming and dependent on a single committed observer. A more arbitary method of
measurement of clinical size such as ultrasound would reduce interobserver error and
therefore make the system more universally acceptable. This was not available at the
outset of the study.
By using the developed 'human tumour model system' the predictive value for
response of several pretreatment tumour indices has been explored. This was made
possible by performing a biopsy of the tumour before initiating systemic therapy. It
was however important that not too much tumour was removed at the time of biopsy so
that sufficient tumour remained on which to assess response. This severely limited the
number of parameters which could be assessed. Of those parameters studied in
relation to endocrine therapy, the ER concentration proved to be of most value. It was
possible to define a group of patients in which endocrine therapy was highly likely to
fail (ER < 20 fmol/mg cytosol protein) and for whom primary cytotoxic therapy despite
its higher morbidity should be recommended. Of those patients with tumours of ER
concentration > 20 fmol/mg cytosol protein approximately one half showed significant
regression with endocrine therapy but response of the individual patient could only be
assessed on a personal basis. The proportion of cells staining for ER as measured by
immunocytochemical methods was at least as good as the biochemically determined ER
status in predicting hormone responsiveness.
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For those patients who received an aromatase inhibitor, measurement of tumour
aromatase had some predictive merit, in that the absence of high levels (> 0.85 pmol
E2 produced/g/hr) was associated with a low likelihood of response to the aromatase
inhibitor (4/15, 27%). The presence of high levels of tumour aromatase was not
synonymous with response to an aromatase inhibitor but around 70% (7/10) of those
tumours did show significant regression. No significant relationship was
demonstrated between tumour grade or peritumour fat 17B hydroxysteroid
dehydrogenase activity and response to endocrine therapy.
Of the indices of tumour grade, tumour size, axillary node status, menstrual status or
patient age studied in relationship to regression with cytotoxic therapy none showed
predictive potential. Those patients however with tumours of ER concentration > 20
fmol/mg cytosol protein which had failed to regress on endocrine therapy also had a
significantly higher failure rate on cytotoxic therapy. The reason for this remains
obscure, it is unclear whether this is a function of the ER concentration alone or a
preselection of tumours with a resistant phenotype.
In summary of the predictive indices examined within this study, only ER
concentration and possibly tumour aromatase activity have been of any value in
preselecting a group of patients with an increased likelihood of responding to endocrine
therapy. The other parameters studied have been uniformly disappointing in their
prophetic potential. For the individual patient however it is not yet possible to predict
with a high degree of certainty those who will benefit from a specific form of systemic
therapy. For this reason there is theoretical value in giving systemic therapy as the
preferred first line treatment, since it would allow response to therapy to be assessed on
an individual basis and hence determination of appropriate systemic therapy. Although
there may be some evidence to suggest that the cells in metastases may differ
functionally from the primary tumour, within this study results indicate that the
response of the primary tumour to systemic therapy does reflect overall survival
patterns.
By using this principal and the information gained in the pilot study in relation to value
of ER in determining response to endocrine therapy a selective protocol for adjuvant
systemic therapy was devised. Patients with an tumours which had an ER
concentration < 20fmol/mg cytosol protein were given primary cytotoxic therapy.
Patients with tumours of ER concentration > 20 fmol/mg cytosol protein received
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primary endocrine therapy. Individual response could then be assessed, endocrine
therapy being continued in those showing significant regression but stopped when it
has been demonstrated to be of no value with initiation of chemotherapy if desired.
Preoperative systemic therapy would also allow selection of those patients for whom
chemotherapy is highly effective and in whom dose-intensification may increase the
probability of cure while also demonstrating those in whom further cytotoxic therapy is
unlikely to be of value in the adjuvant setting. Although determination of ER
concentration was reliant on a wedge biopsy if the policy was to be more uniformly
adopted the increasing acceptance of fine-needle aspiration techniques for diagnosis
(Dixon et al., 1984) and more recently ER assay (Coombes et al., 1987; Hawkins et
al., 1988; Gaskell et al., 1989) would lend feasibility to this approach avoiding the
need for open biopsy.
The administration of systemic therapy as first line treatment has also the potential of
reducing primary tumour size, such that breast conservation could become technically
possible in patients with tumours previously requiring mastectomy because of their size
at initial presentation. A similar approach, with some success, has been pioneered in
locally advanced breast carcinoma (DeLena et al., 1978: Hortobagyi et al., 1985 ;
1988; Swain etal., 1987, Jacquillatet al., 1988), osteogenic sarcoma (Rosen, 1982;
1985; Eilber et al. 1987), squamous carcinomas of the head and neck (Schuller et al.
1984; Price and Hill, 1986). Certainly within this study a significant reduction in the
size of the primary tumour was achieved in a high proportion of patients (66%; 58/88),
making breast conservation theoretically possible. It remains uncertain whether such
treatment compromises eventual local control since it assumes that tumour shrinkage is
uniform and does not leave residual tumour scattered at the periphery. It is vital
therefore that before such a policy of conservation becomes routine there is adequate
investigation into the resulting local and overall survival. Such studies are at present
ongoing but are as yet immature.
A disadvantage of preoperative systemic therapy is the potential psychological
morbidity induced by leaving the tumour in situ while initial systemic therapy is
undertaken. In general this did not prove to be a problem even in patients with
nonresponsive disease. This was probably due to the fact that surgical removal of the
tumour, regarded by many patients as the critical step in their management, was still
possible. Formal examination of psychological morbidity was not however undertaken
during this study, but should be part of any future work.
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By obtaining a biopsy of tumour tissue both before and after systemic therapy, it
was possible using this tumour model system to evaluate directly the effect of
systemic therapy on potential indices of response within the same tumour.
Although changes in the indices examined within this study would not appear to
be of value as an early predictive index for response, the changes have been of
some value in identifying the mode of action of the administered drugs.
Within this study the ER concentration of a primary breast cancer was changed little by
systemic therapy irrespective of tumour response. This suggests that an alteration of
tumour ER concentration is not integral to the mechanism of regression within
responding tumours. The reduction in ER concentration as measured by the dextran-
coated charcoal method in patients treated by tamoxifen, is likely to be artificial since
tamoxifen or its metabolites interfere with the ligand-binding assay (Hull et al. 1983).
For a true analysis of the effect of tamoxifen on ER concentration an alternative method
of ER assay would have to be used.
This study has confirmed in vivo, that 4-hydroxyandrostenedione administration is
associated, in the majority of patients with a reduction of tumour aromatase activity.
This reduction was most marked in patients who achieved significant regression,
suggesting a linked effect. In contrast patients treated with aminoglutethimide, a drug
which in vivo markedly inhibits aromatase activity (Miller, Smith & Telford 1987),
showed a paradoxical rise in tumour aromatase activity irrespective of tumour
response. Patients receiving aminoglutethimide ( and hydrocortisone) have be shown
by other workers to have increased plasma clearance of oestrogens due to increased
activity of hepatic mixed function oxidases (Lpnning & Skulstad 1989) in addition to
depressed of plasma oestrogen levels (Harris et al. 1983; Santen et al. 1982; Vermeulen
et al. 1983; Dowsett et al. 1985; Lpnning, Johannessen & Thorsen 1989). In vivo
therefore aminoglutethimide would appear to effect oestrogen metabolism by
mechanisms unrelated to the inhibition of tumour aromatase activity. The rise in
tumour aromatase activity observed in vitro following the in vivo administration of
aminoglutethimide is thought to be due to the concomitant administration of
hydrocortisone.
The increase in activity of 17B-hydroxysteroid dehydrogenase activity following
systemic therapy was highly significant and almost universal. The reason for this effect
remains obscure since none of the agents used are known to directly effect the activity
of the enzyme and the effect was independent of clinical response.
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In the majority of patients (73%) studied no change in histological grade was observed
following systemic therapy. When a change was observed, the shift was small and did
not relate to response. Since it is known from in vitro studies that tamoxifen reduces
the number of cells undergoing mitosis one might have expected to demonstrate a
reduction of grade in responding tumours. However it is likely that because of in vivo
heterogeneity, tumour grade is too insensitive a parameter to detect this phenomenon.
Finally there is theoretical (Goldie and Coldman, 1979; Skipper 1980), experimental
(Schabel et al., 1979; Fisher, Gundez, Saffer 1983) and clinical (Nissen-Meyer et al.,
1986; Ragaz 1986) evidence to suggests that systemic therapy when administered early
in the treatment of patients with breast cancer improves survival. A direct comparison
of pre- and post-operative chemotherapy in operable breast cancer is at present under
trial in the USA (NSABP trial protocol B-19). Chemotherapy is toxic however and
may patients appear to obtain an adequate adjuvant effect from endocrine therapy.
Certainly using the selective policy for systemic therapy described above the overall
survival, disease-free survival and local disease-free survival compares favourably with
that achieved with orthodox treatment of tumours of similar stage in which the adjuvant
therapy is given following definitive surgery. Comparison with historical control series
is fraught with error and proof of the value of preoperative therapy requires a controlled
randomised trial in which this selective approach is assessed against conventional
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Randomised Controlled Trial of Primary
Systemic Therapy versus Conventional
Therapy in Operable Breast Cancer
On behalf of the Longmore Breast Group and The




1. Analyses of data accrued from large controlled trials now indicate that the long-
term survival of patients with operable breast cancer can be improved by the
systemic administration of anti-oestrogens and, in the case of premenopausal
women, by giving cytotoxic therapy1-2. However, the benefit gained by these
forms of therapy is not uniform. An unselected treatment policy, therefore is not
cost effective and in the case of chemotherapy may lead to needless morbidity.
2. While the concentration of oestrogen receptor (ER) within the tumour is a valuable
indicator of the likelihood of response to endocrine therapy in patients with
metastatic disease34, the role of ER determination in the planning of adjuvant
treatment in patients with operable breast cancer whose primary tumour has been
removed remains uncertain5"11.
3. Studies conducted to date in the Longmore Breast Unit, Edinburgh, have shown
that the prior administration of systemic therapy in 88 patients with large (diameter
> 4cm) but operable breast cancer have allowed direct assessment of tumour
response before mastectomy.
Of 15 patients with tumours having an ER concentration of <20 fmol/mg cytosol
protein, all failed to benefit from anti-oestrogen therapy, whereas of those with
tumours of higher ER concentration, 52% (24/46) showed evidence of tumour
regression.
27 patients, all with ER poor tumours received cytotoxic therapy (4 cycles of
CHOP; cyclophosphamide, adriamycin, vincristine and prednisone) as the primary
therapy; a further 20 patients received cytotoxic therapy following failed endocrine
therapy - 10 had ER poor tumours and 10 had ER>20. 79% (37/47) of the patients
receiving cytotoxic therapy showed significant regression of tumour size.
Preliminary analysis of survival data suggests that the overall survival rate
(actuarial survival rate at 36 months = 86%) may be superior to that to be expected
from the literature12-13-14.
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B. AIMS OF TRIAL
1. To assess the value of selected preoperative systemic therapy by comparing the
local recurrence rate, distant disease free interval and survival of patients with large
but operable breast cancer,randomised to treatment by either primary selected
systemic therapy followed by mastectomy, or mastectomy and unselected adjuvant
systemic therapy.
2. To test feasibility by first conducting a pilot trial in the Longmore Breast Unit with
a view to subsequent expansion into a multi-centre trial.
C. DESIGN OF TRIAL:
This is summarised in Figure 41.
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D. PATIENTS TO BE INCLUDED
1. All patients under the age of 70 with operable breast cancer of clinical diameter
greater than 4cm as measured by calliper.
2. Entry requires that neither the primary tumour nor any palpable lymph nodes be
fixed deeply on clinical examination (ie neither partially to fascia or completely to
muscle) and that the tumour does not directly involve overlying skin. (Paget's
disease of the nipple or dimpling of the skin overlying the tumour is acceptable).
3. No evidence of distant metastases.
E. PATIENTS TO BE EXCLUDED:
1. Patients of 70 years of age or more.
2. Patients with tumours 4cm or less in diameter on clinical measurement.
3. Patients with T4 lesions.
4. Patients with fixed axillary nodes (N2).
5. Patients with bilateral primary breast cancer.
6. Patients with evidence suggestive of metastatic spread.
7. Patients with in-situ carcinoma only.
8. Pregnant, lactating or premenopausal patients who are anxious to become pregnant
at a later date.
9. Patients with any other condition which precludes adequate surgery, adjuvant
therapy or follow-up.
10. Patients for whom adequate follow-up is likely to be difficult owing to their
residence being at a distance or abroad.
11. Previous malignant disease other than adequately treated basal- or squamous- cell
carcinoma of the skin or carcinoma-in-situ of the cervix.
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F. PRE-OPERATIVE INVESTIGATIONS:
1. Fine needle aspiration cytology to confirm the presence of carcinoma.
2. Sample of aspirate to be sent for oestrogen receptor measurement by the ERICA
method.
3. Bilateral 2-view mammography.
4. Investigations to exclude metastatic disease:
a) FBC + ESR. Bone marrow if indicated by blood count.
b) Urea, serum electrolytes, serum calcium and liver function tests.
c) Chest X-ray, isotopic bone scan with X-rays of any suspicious areas of
increased uptake and ultrasound or CAT scan of the liver if clinically indicated
or if liver function tests abnormal.
5. Plasma oestradiol, oestrone, FSH and LH estimations in women of uncertain
menstrual status (see para G.2c below).
6. Serum sample to be taken and stored frozen for future marker studies.
G. REGISTRATION, STRATIFICATION AND RANDOMIZATION:
1. All potentially eligible patients to be registered and the reason why those not
randomised for therapy within the trial recorded (unsuitable or unwilling).
2. Patients will be classified as premenopausal or postmenopausal, according to the
following definition:
a) postmenopausal patients are those whose last menstrual period was at least
12 months previously or who have had a previous unrelated bilateral
oophorectomy.
b) premenopausal patients are those having regular periods and those whose
most recent menstrual period was within the preceding 3 months.
c) patients under the age of 50 years who have had a hysterectomy without
bilateral oophorectomy and those whose last menstrual period was more
than 3 months but less than 12 months earlier will require to have
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estimations of plasma oestradiol, oestrone, FSH and LH and a pregnancy test
performed to define menstrual status.
3. Randomisation will be carried out at the Scottish Cancer Trials Office. The
following will be required on all trial patients for the initial data base and should be
forwarded to SCTO as soon as possible:
a) Completed registration form with, if indicated, the results of tests to determine
menstrual status.
b) Completed surgical record form.
c) Copies of relevant pathology reports.
d) Oestrogen receptor results with methods of determination. 4. Patients will be
randomised to one of the following two options (see below and section C).
4. Patients will be randomised to one of the following two options:
a) Primary systemic therapy followed by mastectomy.
b) Conventional therapy by mastectomy followed by adjuvant systemic therapy.
H. PRIMARY SYSTEMIC THERAPY GROUP:
i. wedge biopsy: Patients randomised to this arm of the trial will first have a
wedge biopsy of their tumour. This can be done under local anaesthetic though
some might prefer a GA. The skin incision should be made transversely directly
over the tumour and the incisional biopsy performed removing approximately 0.6
cm3 of the primary tumour. A liga-clip should be placed at the tumour site and the
specimen sent on ice to the pathology laboratory for histological examination and
ER assay by the research laboratory. Any remaining tumour tissue should be
stored in liquid nitrogen.
2. systemic therapy: This should commence within 10 days of the wedge
biopsy and be according to the menstrual and receptor status as follows:
a) Premenopausal women with tumours of ER level 20 or more fmols/mg
cytosol protein or equivalent should be commenced on gorserelin (Zoladex
ICI 118630) 3.6 mg by subcutaneous implant at 28 day intervals.
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b) Postmenopausal women with tumours of ER level 20 or more fmols/mg
cytosol protein or equivalent should be commenced on tamoxifen 20 mg
daily.
c) All patients with tumours of ER level less than 20 fmols/mg cytosol protein or
equivalent should be commenced on CAP chemotherapy, based on a 3 week
cycle, as follows:
Cyclophosphamide lgm/m2 I.V.on day 1
Adriamycin 50mg/m2 I.V. on day 1
Prednisolone 40mgs daily for 5 days orally.
d) Those in categories "a" and "b" above in whom a significant reduction in
tumour diameter (see para J below) is not achieved by 12 weeks of endocrine
therapy should be changed to CAP chemotherapy as described in "c" above,
(ie those classified as no change as well as those deemed to have progressed).
3. MASTECTOMY: Within 6 weeks of the 4th course of CAP or as soon as
progression of disease on CAP takes place, whichever is earlier, or after 3 months
when responding to endocrine therapy, ALL patients should have a mastectomy
and axillary clearance. At least 3 cm of skin around the tumour should be
removed. In cases where the tumour has regressed, skin removal should be
planned to be according to the site and size of the original tumour mass. A
latissimus dorsi myocutaneous flap can be used to provide the necessary skin
cover and can usually be combined with breast reconstruction. Axillary surgery
should be a full level 3 axillary dissection with division of the pectoralis minor
muscle.
4 . RADIOTHERAPY: Where adequate skin (as defined above) cannot be excised or
when the tumour is found at surgery to be tethered to the pectoral fascia or muscle,
breast reconstruction should not be performed and radiotherapy should be given to
the skin flaps, (see appendix 1 for radiotherapy guide-lines).
5. POST-MASTECTOMY SYSTEMIC THERAPY: This should be carried out as
follows:
a) Premenopausal patients whose tumours responded to gorserelin should have a
bilateral oophorectomy as soon as is practicable after mastectomy.
Gorserelin should be continued until the ovaries have been removed.
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b) Postmenopausal patients whose tumours responded to tamoxifen should be
continued on tamoxifen after mastectomy until relapse supervenes.
J. ASSESSMENT OF RESPONSE:
1. Response of the tumour to systemic therapy will be assessed from changes in the
mean of 8 calliper measured diameters taken at 22.5° axes, converted to log
volume, at weekly intervals between treatment weeks 4 and 12.
2. By using linear regression analysis the response will be graded as follows:
a) Significant reduction - when the probability that the regression line has
deviated below the horizontal is greater than 95%.
b) Progression - when there is a significant increase in tumour diameter or any
other clinical sign of tumour progression.
c) No significant change - when the slope of the regression line is intermediate
between the slope of a significant reduction and the slope of a significant
progression.
K. CONVENTIONAL THERAPY GROUP:
1. local therapy: Mastectomy and axillary clearance should be performed as
described in para H,3 above and postoperative radiotherapy to the chest wall given
if indicated as in para H,4 above.
2. Adjuvant systemic therapy:
a) Premenopausal patients with involved axillary lymph nodes should be given




b) All other patients should be commenced on continuous tamoxifen 20mg daily
within 10 days of surgery.
L. FOLLOW-UP:
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1. Patients on primary systemic therapy should be seen weekly from weeks 4-12
inclusive to evaluate response.
2. After mastectomy, patients in both groups should be reviewed at 3 monthly
intervals for 3 years. Thereafter patients should be reviewed 6 monthly.
M. ETHICAL CONSIDERATIONS:
1. Although none of the treatments are novel, as a result of the experience already
gained in the use of primary systemic therapy in the management of the larger
operable breast cancers, we believe that it is important that this approach be tested
now in a randomised way.
2. Approval of the protocol by local ethical committees before patients are entered is
mandatory.
3. Verbal and written explanation of the trial must be given to patients and consent to
entry obtained prior to randomization.
N. STATISTICS:
1. It is anticipated that approximately 50 patients per annum will be eligible for entry
to the trial from the Longmore breast unit. The initial feasibility study should thus
be completed within 2 years.
2. If initial piloting of the trial proves successful, the trial will be opened for
participation by other specialist units until a total entry of 300 cases is reached.
This sample size will have a 75% power to detect differences in long-term survival
of 65% and 50%, in the two arms of the trial, at the 5% level of statistical
significance.
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Confirmed Operable Breast Cancer











MX + AN CL at 3 months
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CMF X 6 Tamoxifen 5 years
or until relapse
Postmen
MX + AN CL at 3 months
or disease progression






Protocol for randomised controlled trial of primary systemic therapy versus
conventional therapy in operable breast cancer. Premen = premenopausal, Postmen =
postmenopausal, Mx = mastectomy, AN CL = axillary node clearance, CMF =
cyclophosphamide 600mg/m2 i.v., methotrexate 50 mg/m2 i.v., 5 flurouracil 600
mg/m2 i.v., CAP = cyclophosphamide 1 gm/m2 i.v. on day 1, adriamycin 50mg/m2
i.v. on day 1, prednisolone 40 mgs daily for 5 days orally, N +ve = histologically
proven axillary node metastasis, N -ve = axillary node histologically proven free of
metastasis
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Response to endocrine manipulation and oestrogen receptor
concentration in large operable primary breast cancer
E.D.C. Anderson, A.P.M. Forrest, P.A. Levack, U. Chetty & R.A. Hawkins
University Department of Surgery, The Royal Infirmary, Edinburgh EII3 9YW, UK.
Summary Forty-three patients with large (^4cm) but operable carcinoma of the breast have been treated by
endocrine manipulation before definitive local surgery. This has allowed the study of the relationship between
response to therapy and pretreatment oestrogen receptor (ER) concentration, as measured by a dextran-
coatcd charcoal adsorption method. Premenopausal patients (17) were treated by surgical (4) or medical (13)
oophorectomy. Post-menopausal patients (26) received either tamoxifen (10) or an aromatase inhibitor (16).
Response was assessed from statistical analysis of the changes in tumour size. On completion of 12 weeks of
endocrine therapy, there was significant regression of tumour size in 18 of the 43 patients. All 18 patients had
tumours with ER concentrations of >20fmolmg_1 cytosol protein. Conversely all patients except one
progressing on treatment had tumours with ER concentrations of <20fmolmg_1 cytosol protein. This
relationship applied for both premenopausal and post-menopausal patients. The overall response rate of
patients with tumours of ER concentration > 20 fmol mg ~1 cytosol protein was 60%.
The likelihood of response to endocrine treatment in patients
with metastatic breast carcinoma is related to the concent¬
ration of oestrogen receptor (ER) protein within that tumour
(McGuire et al., 1975; Brooks et al., 1980; Jensen, 1975; Dao
& Nemoto, 1980; Oriana et al., 1987). The value of ER
status in predicting benefit from adjuvant endocrine treat¬
ment remains controversial. While several studies have
demonstrated that only patients with ER-positive tumours
have a significant survival advantage (Rose et al., 1985;
Fisher et al., 1986; Rutquist et al., 1987; Meakin, 1986;
Marshall et al., 1987; Bianco et al., 1988), the Nato trial
(Nolvadex Adjuvant Trial Organisation, 1988) has indicated
that the benefit is independent of ER status. An intermediate
view has been suggested by the Scottish (Scottish Cancer
Trials Office (MRC) Edinburgh, 1987) and Copenhagen
(Palshof et al., 1985) trials, in which all patients who
received tamoxifen benefited but the level of benefit was
greatest in those patients with tumours of an ER concent¬
ration of 3* 100 fmol mg~1 cytosol protein. Thus the rela¬
tionship between ER concentration and response of primary
operable breast cancer to endocrine treatment remains
uncertain.
We have previously reported (Forrest et al., 1986) that the
response of large but operable breast cancer to systemic
therapy can be measured with precision. By obtaining a
small piece of tumour before initiating systemic therapy,
response can be related to the specific biochemical and
histological parameters of an individual primary tumour.
This paper describes the relationship between the ER con¬
centration of large primary operable breast cancer and their
response to endocrine treatment.
Materials and methods
Patient population
Between April 1985 and December 1987, 43 patients with
primary operable breast cancer of mean clinical diameter
greater than or equal to 4cm were given endocrine therapy
for 3 months before definitive local surgery, Initially all
patients (« = 35) were given endocrine therapy irrespective of
the ER concentration of their tumour. In April 1987,
however, there was a change in policy resulting from review
of the results and only those patients with tumours of ER
concentration of greater than 20fmolmg~' cytosol protein
received primary hormonal manipulation (n = 8). Patients
Correspondence: E.D.C. Anderson.
Received 13 October 1988, and in revised form, 9 March 1989.
with tumours of ER concentration 20fmolmg_1 cytosol
protein or less were given four cycles of the chemothera-
peutic regime CHOP (cyclophosphamide 1 gm~2, adriamycin
50mgnW2, vincristine 1.4mgm~2, prednisolone 40 mg orally
5 days).
Patients over 70 years of age, with a history of psychiatric
instability or evidence of metastatic disease on clinical,
haematological, biochemical or bone scintiscan investigation
were excluded from the study. Seventeen patients were
premenopausal, 26 were post-menopausal, i.e. more than I
year since their last menstrual period.
Initial assessment
At initial presentation, tumour size was assessed from both
clinical and radiological examination. The mean clinical
diameter was calculated from the mean of eight caliper-
measured diameters taken at 22.5° axes. An incisional wedge
biopsy was performed under general anaesthesia and 0.6 cm3
of tumour removed and sent for histological and biochemical
evaluation.
The determination of oestrogen receptor concentration
The ER concentration of the excised tumour specimen was
determined using the dextran-coated charcoal adsorption
method (Hawkins et al., 1981). In brief, tumour was homo¬
genised in tris-monothioglycerol-glycerol buffer and centri-
fuged at low speed; portions of tumour extract were
incubated at 4°C overnight with eight concentrations of 3H
oestradiol + non-radioactive oestradiol (0.031-62.3 nM).
After separation of the bound fraction by adsorption with
dextran-coated charcoal and scintillation counting, the con¬
centration of receptor sites and dissociation constant of
binding were calculated by Scatchard analysis (Scatchard,
1949) using a programmed BBC microcomputer. Protein
concentration was determined in a separate portion of each
tumour extract by the method of Bradford (Bradford, 1976)
using serum albumin as a standard, with five quality
controls. Receptor concentration was finally expressed as
femtomol of binding sites per mg extract protein. Quality
controls consisting of pools of minced human uterus were
processed at least twice per week. Intra-assay precision was
3.9% but inter-assay precision was modest (25.1%, 33.6%
on two tissue pools (Hawkins et al., 1987a)).
Endocrine treatment
In premenopausal patients («=17), suppression of ovarian
function was achieved by cither surgical bilateral oophorec¬
tomy (n = 4) or the administration of the gonadotrophin
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releasing-hormonc agonist gosereliu (Zoladcx; ICI 118630,
subcutancsus implantation of 3.6 mg depot preparation at 28
day intervals, w=13).
Post-menopausal patients (n = 26) received either tamoxi¬
fen (20 mg oral nocte, « = 10), or an aromatase inhibitor
(n = 16). Initially aminoglutethimide 500mg plus hydrocorti¬
sone 40 mg orally per day (n = 9) was used, but recently the
selective peripheral aromatase inhibitor 4-hydroxy-
androstencdione (Ciba-Geigy CGP 32349, 250 mg intramus¬
cular injection at 14-day intervals, « = 7) has been preferred.
Assessment
During treatment, the patients were reviewed weekly by
either EA or PL and the mean clinical tumour diameter was
estimated. Single view mammography, in the plane known to
give the best view of the tumour, was performed every 4
weeks.
Calculation of response
Assessment of response was carried out at 12 weeks by
analysis of the change in mean tumour diameter, as des¬
cribed previously (Forrest et al., 1986) with one refinement:
the measurements recorded between treatment weeks 1 and 3
were disregarded to minimise any error introduced by the
wedge biopsy. In brief, a regression line was calculated by
least square analysis of the logs of the mean clinical
diameters measured between treatment weeks 4 and 12
(Figure 1). The statistical difference between the regression
line and the horizontal was ascertained by application of
Student's t test. Response was said to have occurred when
there was a reduction in tumour size, and the probability
that the regression slope deviated from the horizontal was
>95%. The appearance of lymphoedema, or a statistically
significant increase in tumour size, indicated progression.
Tumours with regression slopes which lay between response
and progression were categorised as 'no change'.
Local therapy
Those patients who had shown a response to endocrine
treatment proceeded on to mastectomy with extensive skin
removal (3 cm clear of original tumour site), axillary node
clearance and a latissimus dorsi myocutaneous flap recon¬
struction when required. Patients whose tumour remained
static or in whom treatment required to be prematurely
terminated due to progressive disease received four cycles of
Time (days)
Figure I Response graph of a premenopausal patient with a
primary operable breast cancer of ER concentration
23 fmol mg"1 cytosol protein following the administration of the
gonadotrophin-hormone releasing-hormone Zoladex. This was
given by subcutaneous implantation of a depot preparation at
28-day intervals as indicated by the arrows. Each point repre¬
sents a mean clinical diameter while each square is the mean
mammographic diameter calculated from a single view mammo¬
gram. The calculated regression line had a correlation coefficient
of —0.8 and a slope of —3x 10"3cm(log)day~'. This indicates
statistically significant regression (P<0.01, Student's t test).
the chcmothcrapeutic regime CHOP before also proceeding
to mastectomy.
Results
The spectrum of tumour ER concentrations in these
patients is shown in relation to four subgroups (ER-negative
0-5 fmol mg"1 cytosol protein, ER-poor 5-19 fmol mg"1 cyto¬
sol protein ER-moderate 20-99 fmol mg"1 cytosol protein
and ER-rich >100 fmol mg"1 cytosol protein) in Table I. The
median ER concentration in premenopausal patients was
lower (30 fmol mg"1 cytosol protein) than in the post¬
menopausal group (158fmolmg~' cytosol protein), a reflec¬
tion of the higher fraction of post-menopausal patients with
ER-rich tumours. The proportion of patients within each
menopausal group with ER-negative or ER-poor tumours
was similar at around 30%.
Response rates
Eighteen of 43 patients (42%) had significant regression of
their primary tumour following endocrine therapy (Tables II
and III). The overall response rate for post-menopausal
patients was slightly higher than for premenopausal patients
(46% vs35%) (Table I) but this difference was not significant
(y2=0.09, P=0.8). The relationship between ER concen¬
tration and response is shown in Figure 2. Although there
was considerable overlap between groups, a significant rela¬
tionship between ER concentration and the likelihood of
response to endocrine therapy existed (Spearman rank corre¬
lation coefficient r = 0.65, P<0.0001). All patients who res¬
ponded to treatment had tumours with an ER concentration
of greater than 20 fmol mg"1 cytosol protein. Conversely all
Table I Response to endocrine therapy in relation to ER concent¬




subgroup Premenopausal Post-menopausal total
<5 0/2 0/5 0
5-19 0/3 0/3 0
20-99 6/11 2/4 53
>100 0/1 10/14 67
Total 6/17 12/26 42
"fmol mg"
1 cytosol protein.
Table II Clinical mean tumour diameters at treatment weeks 4 and
12 of the 18 patients who responded to endocrine therapy
Clinical mean tumour diameter (cm)
Probability of
Patient Week 4 Week 12 regression
E.F. 4.75 3.7 0.01
M.H. 3.6 2.0 0.003
M.W. 4.0 3.1 0.05
M.F. 3.6 2.9 0.05
J. McF. 3.1 2.1 0.03
i.e. 5.4 4.2 0.01
A.P. 4.6 3.6 0.002
M.D. 3.6 2.5 0.04
J.C. 4.3 3.4 0.02
A.A. 3.6 2.5 0.004
P.G. 4.0 2.4 0.00008
E.A. 5.0 4.2 0.01
H.C. 4.1 2.9 0.001
J.A. 4.1 0 a
E.B. 4.3 2.7 0.004
W.S. 3.5 3.0 0.03
J.E. 4.2 3.6 0.00008
M.F. 6.9 2.0 0.0007
"Denotes no P value available due to too few degrees of freedom
but tumour clinically impalpable at treatment week 12.
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patients who progressed on treatment, except one, had
tumours with an ER concentration of less than 20fmolmg_l
cytosol protein (Figure 3). This relationship held true for
both premenopausal and post-mcnopausal patients.
Relationship between response and disease-free survival
With a mean follow-up period of 40.6 months, eight patients
have developed recurrent disease; two patients who res¬
ponded to endocrine therapy and six patients who did not.
Clinical response is related to disease-free survival in Figure
3. Using the generalised Wilcoxon (Breslow) survival test,
there was a statistical significant difference in survival
between those patients who showed a response to endocrine
treatment and those who did not (/> < 0.05).
Table 111 Response rates of 43 patients with large operable breast
carcinoma treated with primary endocrine therapy
ER <20" ER^20°
Total (no. patients (no. patients
no. of responding/ responding/
patients total) total)
Premenopausal
Oophorectomy 4 0/2 1/2
GnRH analogue 13 0/3 5/10
Total 17 0/5 6/12
Post-menopausal
Tamoxifen 10 0/4 4/6
Aminoglutethimide 9 0/4 4/5
4-Hydroxyandrostenedione 7 - 4/7
Total 26 0/8 12/18
Grand total 43 0/13 18/30











Regression No change Progression
Clinical response
Figure 2 The relationship between the pretreatment ER con¬
centration in 43 patients with primary operable carcinoma of the
breast and clinical response to 3 months' treatment with endo¬
crine therapy. The ER concentration was determined by the
dextran-coated charcoal adsorption method. Response was
assessed from statistical analysis of the regression slope (Student's
t test, see text). The median ER concentration in each response
group is shown by a bar. Open circles have been used to denote






















Figure 3 The relationship between disease-free survival and
response to endocrine therapy in 43 patients with large but
operable primary carcinoma of the breast. With a mean follow-
up period of 40.6 months (range 7-43 months), there is a
statistically significant difference in the survival of those patients
who responded to treatment when compared to those who did
not (P<0.05, generalised Wilcox (Breslow) survival test).
Discussion
This report confirms and expands our previous reports
(Forrest et al., 1986; Hawkins et al., 1988; Anderson et al.,
1989) of the relationship between ER concentration and
response to endocrine therapy in primary operable breast
cancer. Primary tumours with an ER concentration of less
than 20fmolmg_1 cytosol protein did not respond to endoc¬
rine therapy, while 60% of those with higher ER values did.
Using an immunocytochemical assay we have observed a
similar relationship between ER status and response of
primary tumours in elderly women treated with tamoxifen
(Gaskell et al., 1989). Considering that this relationship also
exists for metastatic disease (McGuire et al., 1975; Brooks et
al., 1980; Jensen, 1975; Dao & Nemoto, 1980; Oriana et al.,
1987), it is reasonable to expect that ER concentration
should be of value in selecting appropriate adjuvant endoc¬
rine therapy. We have already discussed the confusion which
surrounds the value of ER activity in predicting benefit with
adjuvant tamoxifen. In vitro studies have suggested that
tamoxifen may have antitumour actions which are indepen¬
dent of the oestrogen receptor (Sutherland et al., 1986) and
can be distinguished from nonspecific cytotoxicity by its cell
cycle specific nature (Sutherland et al., 1983). Thus results
obtained using adjuvant tamoxifen cannot necessarily be
extrapolated to other forms of endocrine therapy, e.g.
oophorectomy. Further definition of the role of ER activity
in predicting the benefit from adjuvant endocrine therapy is
obviously required. This can only come from well conducted,
controlled randomised trials designed specifically to answer
this question and in which the performance of ER assays is
of uniform high quality.
Systemic therapy is of major importance in the long term
control of invasive breast cancer because of the high possi¬
bility of micrometastatic disease at the time of initial presen¬
tation (Brinkley & Haybittle, 1984). Since it is not yet
possible to predict, on an individual basis, those patients
who will benefit from a specific form of systemic therapy,
there is theoretical value in giving systemic therapy as the
preferred first line treatment. This would enable the response
of the individual's tumour to be assessed and allow selection
of appropriate systemic therapy. The availability of fine-
needle aspiration techniques for diagnosis (Dixon et al.,
1984) and more recently ER assay (Coombcs et al., 1987;
Hawkins et al., 1988; Anderson et al., 1989; Gaskcll et al.,
1989) should lend feasibility to this approach, avoiding the
need for open biopsy.
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Does the oestrogen receptor concentration of a breast cancer change
during systemic therapy?
R.A. Hawkins, A.L. Tesdale, E.D.C. Anderson, P.A. Levack, U. Chetty & A.P.M. Forrest
University Department of Surgery, Royal Infirmary of Edingburgh, Edinburgh EH3 9YW, UK.
Summary The effect of systemic therapy on tumour oestrogen receptor (ER) concentration has been studied
in 88 patients with large, operable, primary tumours (total 89) of the breast. In 26 patients, tumour was not
available for study on one occasion (usually post-treatment). Forty-five patients were treated initially by
endocrine therapy but, of these, 13 who had failed to respond went on to receive chemotherapy also.
Seventeen patients with low concentrations of ER (<20 fmol mg-1 protein) were treated directly by
chemotherapy. Patients underwent an incisional biopsy for confirmation of diagnosis and determination of
pre-treatment ER by radioligand binding assay, followed by systemic therapy for 3 months (or 6 months for
both endocrine and cytotoxic therapies). Response was assessed clinically and mammographically before
mastectomy. ER concentration was then determined in the post-treatment tumour specimen. No significant
change in ER concentration was seen in any treatment group except when the patients had received tamoxifen;
there, receptor concentration fell to very low levels, presumably due to interference with the assay. There was
no relationship between tumour response to systemic treatment and change in ER concentration. It is
concluded that changes in ER concentration are unlikely to play a major role in the early response of breast
tumours to systemic therapy.
Studies of the effect of therapy on the oestrogen receptor
(ER) concentration of breast cancer have previously relied
upon examination of different tumour deposits (Taylor et al.,
1982; Hamm & Allegra, 1988). Since these deposits may
differ in biological characteristics, including the concentration
of ER (Hoehn et al., 1979; Hawkins et al., 1981), this may
lead to erroneous conclusions. We have previously reported
the treatment of patients with large operable breast cancers
by primary systemic therapy, with direct observation of res¬
ponse and eradication of residual local disease by planned
locoregional surgery 3-6 months later (Forrest et al., 1986;
Anderson et al., 1989). This method of treatment has allowed
the study of the concentration of ER, both before and after




We attempted to measure oestrogen receptor concentration,
both before and after systemic therapy, in 88 patients with
large (mean clinical diameter >4 cm) operable (T2 or T3, N0
or N, and M0) cancers of the breast: one patient had two
tumours and thus there was a total of 89 tumours. In 26
patients, the tumour specimen was inadequate (see below) on
one or more occasions: this left 62 patients (with 63 tumours)
for study. These patients form part of a larger series which
will be reported in full elsewhere (Anderson et al., in prepara¬
tion).
Twenty-six patients were premenopausal and 36 were post¬
menopausal in that it was greater than one year since their
last menstrual period. The mean age of the population was
53 years (range 34-69).
Method
Before administration of systemic therapy, tumour was
obtained from 62 patients for histological and biochemical
studies, including ER assay, by an incisional wedge biopsy
performed under general anaesthesia. Forty-one patients with
ER- moderate/rich tumours (ER >20 fmol mg-' cytosol
Correspondence: R.A. Hawkins.
Received 19 October 1989; and in revised form 9 January 1990.
protein) and four with ER-poor/negative tumour
(ER <20 fmol mg-1 protein) were initially treated by endo¬
crine therapy. Ovarian function was ablated in
premenopausal patients either surgically (n = 4), or
medically, using the luteinising hormone releasing hormone
agonist, goserelin (ICI 118630 or zoladex, 3.6 mg sub¬
cutaneous depot preparation at 28-day intervals, n=16).
Tamoxifen (20 mg per day, n = 3) or an aromatase inhibitor
(aminoglutethimide 500 mg plus 40 mg hydrocortisone
acetate, n = l, or 4-hydroxyandrostenedione, Ciba-Geigy
CGP 32349, 250 mg intramuscular injection at 14-day inter¬
vals, n =15) were the endocrine therapies used in post¬
menopausal patients. Thirteen patients who failed to respond
to endocrine therapy subsequently went on to receive
cytotoxic therapy (four cycles of 'CHOP': cyclophosphamide
I gm"2, adriamycin 50 mgm"2, vincristine 1.4mgm"2 and
oral prednisolone, 40 mg per day for 5 days, at 21-day
intervals).
A further 17 patients with tumours of low ER concentra¬
tion (<20 fmol mg-1 cytosol protein) were given cytotoxic
therapy (CHOP x 4) as initial treatment.
During treatment, the tumour was measured weekly by
clinical examination and monthly by mammographic assess¬
ment. Response was classified on the basis of linear regres¬
sion analysis (Apple Macintosh Statview program) of
changes in clinical tumour diameter as previously described
(Anderson et al., 1989) but the results have been presented in
terms of a calculated tumour volume in order to give a better
indication of 'tumour bulk'. Three response categories were
defined: significant regression, when the probability that
significant reduction in tumour size was >95%; progression,
when there was a significant increase in tumour size or signs
of local advancement; and no change, when no significant
difference in tumour size could be demonstrated.
Following 3 months of systemic therapy (6 months when
patients received both endocrine and cytotoxic therapies),
patients proceeded on to mastectomy and axillary lymph-
node clearance. When residual tumour was present within the
mastectomy specimen, a portion was selected for ER assay
by the pathologist.
In both pre- and post-treatment specimens, a section was
cut from the face of the tissue portion used for receptor
analysis, fixed in formol-saline and stained with haematoxylin
and eosin to permit histopathological confirmation of the
presence of tumour. Twenty-six patients in whom either the
pre- or post-treatment specimen contained <10% tumour, as
assessed by the pathologist, have been excluded from the
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study: these include, for example, 11 patients who achieved a
complete clinical response to chemotherapy. Thus of the
whole group, both pre- and post-treatment specimens were
available in 62 patients (63 tumours).
Correlation of changes in ER concentration with changes in
histology
To examine the correlation between any changes in ER
concentration and histopathology, 12 paired (pre- and post-
treatment) tumour samples were independently examined by
Dr T.J. Anderson, Department of Pathology, and graded as
to whether they showed major differences in morphology or
not between the pre- and post-treatment specimens.
Results
Changes in ER concentration according to type ofsystemic
therapy
The changes in ER concentration in the tumours from the 62
patients, separated into groups according to mode of treat¬
ment, are shown in Table I. Although the changes in individ¬
ual tumours varied considerably, even within one treatment
group (Figure 1), there was no significant change in receptor
concentration in patients treated by surgical or medical
oophorectomy, aromatase inhibitors, chemotherapy or both
cytotoxic and endocrine therapies. Only the three patients
treated with tamoxifen showed a significant (99%) fall in ER
concentration after 3 months.
Statistical analysis
The relationship between the pre- and post-treatment speci¬
men ER concentrations was examined using the paired t test
after logarithmic transformation of the data.
Determination of oestrogen receptor activity
Oestrogen receptor activity was determined by saturation
analysis (Hawkins et al., 1975, 1981) on both the pre-
treatment biopsy and post-treatment tumour from the
mastectomy specimen. Quality control samples, processed
2-4 times per week, consisted of pools of finely divided
uterine tissue and, on occasion lyophilised powders. The
dissociation constant of binding (KA) and receptor site con¬
centration (Pa) were evaluated by Scatchard analysis (1949).
The soluble protein concentration in each tumour extract
was determined by the method of Bradford (1976) using
bovine serum albumin as a standard. Five quality controls of
known value (three albumin, two mixed standard, Sigma
540-10) were also processed; assays in which the quality
controls deviated by more than 10% from the expected
values were repeated. Ultimately the receptor content of each
tumour was expressed as fmol binding sites per mg soluble
protein (P0 protein).
The overall intra-assay precision on a pool of minced
uterine tissue was 15.4% (n — 5). Inter-assay precision on
lyophilised powders (no homogenisation step) was 17.8%
(n = 10) at low levels (27 fmol mg"1 protein) and 11.7% at
higher levels (90 fmol mg"1 protein); on two pools of minced
uterine tissue (including homogenisation) it was 25.5%
(«=144) at low levels (48 fmol mg"' protein) and 17.0%
(n = 48) at a higher level (111 fmolmg"' protein).
Changes in ER concentration according to response to therapy
When the patients were separated into those who achieved a
significant regression to systemic therapy and those who did
not, no significant change in the receptor concentration was
found in either group (Table II). Six of the 62 patients have
been excluded from this table because they were on tamox¬






n = 11 n = 9
Tamoxifen Chemotherapy Endocrine +
n = 3 n = 17 chemotherapy
n = 13
Figure 1 The changes in oestrogen receptor concentration in 63
large, operable primary breast cancers: receptor concentration
was assayed by ligand-binding assay in a pretreatment wedge
biopsy and again, after systemic therapy for 3 or 6 months, in
tumour removed at mastectomy. Each point represents a single
assay: the lines drawn join pre- and post-treatment specimens
from the same patient. Only the change seen in patients on
tamoxifen is significant (paired t test, F<0.05).
Table I Changes in receptor concentration in large primary breast tumours during
systemic therapy
Treatment group
Oestrogen receptor cone. (fmol mg 1 protein)"
Pre-treatment Post-treatment Difference Sig.*
Surgical/medical 49 60 1.2 n.s.
oophorectomy ±3.0
(n= 11)'
Aromatase 163 163 1.1 n.s.
inhibitors ±2.3
(n= 19)
Tamoxifen 186 2 68 P< 0.05
(n = 3) ±3.6
Chemotherapy 4 4 1.0 n.s.
(n= 17) ±3.5
Endocrine & 24 18 1.3 n.s.
chemotherapy1* ±2.1
(n = 13)
"Geometric mean calculated after logarithmic transformation of (receptor
concentration + I); ± one standard deviation. bSignificance calculated from paired t test
on log-transformed data. cn = number of tumours. For the group treated with aromatase
inhibitors, 18 patients were treated, one patient having two tumours. dPatients on
tamoxifen have been excluded.
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Tabic II Changes in receptor concentration and tumour volume in large primary tumours according to response to systemic
therapy
Response Pre-lreatment Post-treatment
group Treatment value" value" Difference Significance
Oestrogen receptor concentration (fmol mg~1 protein)
Regression (n = 33)c
Endocrineb (17) 102 127 1.26 n.s.
±2.96
Chemotherapy (13) 3 4 1.15 n.s.
±2.69
Endob + Chemo (3) 43 34 - 1.26 n.s.
±2.89
No significant regression (n = 23)
Endocrineb (11) 79 70 - 1.14 n.s.
±3.08
Chemotherapy (4) 8 6 - 1.36 n.s.
±7.66
Endob + Chemo (8) 33 24 -1.38 n.s.
±2.63
Clinical tumour volume (cm1)J
Regression all 53.4 9.0 -6.86 P<0.001
±2.93
No significant regression all 34.7 28.4 - 1.25 PC0.005
±1.36
"Geometric means calculated after logarithmic transformation ± one standard deviation. bPatients on tamoxifen have been
excluded (n — 6). cn — number of tumours, one patient having two tumours. dTumour diameter was measured and response
was classified as described previously (Anderson et al., 1989). The results were converted to a tumour volume to give a better
indication of tumour bulk, using the formula 4/3itr3, where r = mean tumour radius.
ks a control, the change in tumour volume for these two
ponse groups was also examined. As expected, the group
patients showing significant regression, taken as a whole,
ibited a highly significant decrease in tumour volume,
hough the remaining patients individually did not show a
rificant reduction in tumour volume, as a group they also
ibited a small decrease.
examination of the relationship between changes in ER
1 change in tumour volume in individual patients (data
shown) equally did not reveal any consistent pattern.
mges in ER concentration in relation to tumour morphology
hough most treatments were, on average, without
lificant effect on ER concentration, in some individual
ients there were large changes in tumour ER. In order to
if these related to tumour heterogeneity and sampling, the
ological sections from 12 paired (pre- and post-treatment)
tour specimens were examined by the pathologist, in the
ence of any knowledge of the ER concentration.
)f six paired tumour specimens showing a 'large' change
eceptor concentration, four showed major differences in
rphology between the pre- and post-treatment specimens,
contrast, none of the six paired specimens from patients
wing little or no change in ER concentration exhibited
striking difference in histopathological appearance.
s study has demonstrated that, on average, tumour ER
centration is little changed by most forms of systemic
apy. Large changes in tumour ER concentration in indi-
tal patients were probably related to tumour
irogeneity (Hawkins et a/., 1977a; Van Netten, 1985; Sen-
jo el al., 1986). Patients on tamoxifen, however, did show
larked fall in receptor concentration during therapy; this
was almost certainly due to interference by tamoxifen or its
metabolites in the ligand-binding assay, as noted by Hull et
al. (1983). In the present study, patients treated by medical or
surgical oophorectomy showed only a slight, but insignificant
rise in tumour ER concentration. In a large number of
patients with fibroids, treated with the LHRH agonist,
zoladex, however, a similar but significant rise in the concent¬
ration of ER in the uterine tissues has been observed (Lums-
den et al., 1989).
Previous studies in patients with breast cancer (Taylor et
al., 1982; Hamm & Allegra, 1988; Toma et al., 1986) and in
experimental animals (Vignon & Rochefort, 1976; Hawkins
et al., 1977b; Cho-Chung et al., 1978) have shown a decrease
in receptor concentration after endocrine manipulation or, as
in the present study, no consistant change (Hull et al., 1983;
Mobbs et al., 1987). The conflicting results,in human breast
cancer may derive from the inclusion of patients on tamox¬
ifen (Taylor et al., 1982), which causes a marked apparent
reduction in ER concentration (this study and Hull et al.,
1983) or from the difficulties in comparing different tumour
deposits (Taylor et al., 1982; Hamm & Allegra, 1988).
In summary, ER concentration in breast tumours changed
little after most common forms of systemic therapy, even in
regressing tumours. Thus, in general, a marked change in ER
concentration does not appear to be a component of the
mechanism by which tumours are initially influenced by
systemic therapy.
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Primary systemic therapy for operable breast cancer
E.D.C. Anderson', A.P.M. Forrest1, R.A. Hawkins1, T.J. Anderson2, R.C.F. Leonard3 &
U. Chetty1
' University Department of Surgery, Royal Infirmary, Lauriston Place, Edinburgh EH3 9 Y W; 2 University Department of
Pathology, Medical School, University of Edinburgh; 3 University Department of Oncology, Western General Hospital,
Crewe Road, Edinburgh, UK.
Summary Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3,
NO, Nl, MO) have received primary systemic therapy. Response was assessed following 12 weeks of systemic
therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastec¬
tomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months).
Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours
with an oestrogen receptor (ER) concentraton of ^ 20 fmol mb-' cytosol protein. Cytotoxic therapy was
reserved for patients with tumours of ER concentration <20 fmol mgcytosol protein (n =27) or when
endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate
at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy
outlined in this paper should now be tested against orthodox management by controlled randomised trial.
It has now been established from statistical analyses of large
controlled randomised trials that the long term survival of
patients with operable breast cancer can be improved by
systemic endocrine or cytotoxic therapy (Early Breast Cancer
Trialists' Collaborative Group 1988). These trials however
have not defined which therapy is most suitable for an
individual patient. Given the morbidity of cytotoxic therapy
(Glass et al., 1981) an unselective policy is not ideal. Further¬
more the value of tumour oestrogen receptor status (ER) in
selecting patients for adjuvant hormonal therapy remains
controversial (Palshof et al., 1985; Rose et al., 1985; Fisher et
al., 1986; Rutquist et al., 1987; Bianco et al., 1988; Scottish
Breast Cancer Trials Committee 1987; Nolvadex Adjuvant
Trial Organisation 1988).
In 1985 we initiated a study in which local surgical treat¬
ment was delayed in patients with large, but still technically
operable breast cancer until the response of the primary
tumour to systemic therapy had been assessed (Forrest et al.,
1986). We now report our experience with primary endocrine
and cytotoxic therapy in 88 such patients.
Patients and methods
Patient population
Patients were considered for entry into the study if they
presented with an invasive breast carcinoma 4 cm or greater
in diameter (T2, T3, NO, Nl, MO). Patients with evidence of
tumour fixation to skin or pectoral muscle, lymphoedema of
the skin, detectable metastases on routine clinical and
radiological investigations (including bone scan) or with a
history of cardiac or mental instability were excluded from
the study. All patients were Karnofsky grade 0.
During the 4 year period between April 1985 and April
1989, 136 patients with tumours measuring 4 cm or greater
presented to the Breast Unit of Longmore Hospital, of whom
88 were included in this study. Sixteen patients failed to fulfil
the selection requirements, in five cases an incisional biopsy
had been performed to confirm the diagnosis and had re¬
moved a large amount of tissue, while in 13 patients the
tumour was either multifocal, partly cystic, bilateral or
difficult to measure reliably. Seven patients were excluded
because they lived more than 50 miles from the hospital.
Correspondence: E.D.C. Anderson.
Received 13 August 1990; and in revised form 15 November 1990.
Only seven patients refused preoperative therapy, preferring
immediate mastectomy.
The mean age of the patient population studied was 53.1
years (range 33-69 years). Thirty-eight patients were
premenopausal (1 year or less since their last menstrual
period) and 50 were postmenopausal. Determination of
menopausal status in patients who had undergone hysterec¬
tomy was based on serum gonadotrophin levels; patients
were defined as postmenopausal if their serum follicle-
stimulating hormone concentration was greater than 30 pi-'.
Initial assessment
An initial presentation, tumour size was assessed both
clinically and mammographically. Clinical diameters were
calculated from the mean of eight caliper-measured diameters
taken at 22.5° axes before fine needle aspiration, tumour
volume was calculated by assuming that the tumour was
spherical (4/3;tr3). Fine-needle aspiration was used to obtain
a cytological diagnosis of malignancy. Staging assessment
was then performed and involved a thorough clinical
examination supplemented by haematological (erythrocyte
sedimentation rate, full blood count), biochemical (urea and
electrolytes, liver function tests, serum calcium, phosphate
and albumin) and radiological (chest X-ray and radioisotope
bone scan) investigation. Any patient with abnormal liver
function tests had a liver ultrasound examination to exclude
the presence of overt metastasis. The philosophy of the study
was explained to all suitable patients both verbally and by
written document and informed consent obtained.
Pretreatment tumour material for histological and bio¬
chemical evaluation, was obtained by incisional wedge biopsy
performed under general anaesthesia. Approximately 0.6 cm3
of tumour was removed. In order to standardise the tech¬
nique this procedure was performed by one person (EDCA)
in the last 50 patients, and to aid post-therapeutic localisa¬
tion of the tumour area, the tumour bed was marked by
ligaclips. In 15 patients, an involved axillary node was
excised in preference to biopsy of the primary tumour. For¬
mal axillary node sampling was not initially performed but
has been routine in the last 29 patients.
The oestrogen receptor concentration of the pretreatment
biopsy was determined by the dextran-coated charcoal
adsorption method (Hawkins et al., 1975, 1981).
Systemic therapy
Of the 88 patients included within this study 41 received only
endocrine therapy, 27 received only cytotoxic therapy while
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20 received both forms of therapy. Systemic therapy was
commenced within 10 days of the wedge biopsy.
Pilot study
The first 36 patients all received primary endocrine therapy
(Anderson el al., 1989). In premenopausal women ovarian
function was ablated initially by surgical bilateral oophorec¬
tomy (n = 5) and subsequently by the lutenising-hormone
releasing-hormone analogue goserelin (Zoladex ICI 118630,
subcutaneous implantation 3.6 mg depot preparation at 28
day intervals following 4 ml lignocaine local anaesthetic,
n — 7). Postmenopausal women received either tamoxifen
(20 mg per day, n = 11) or the aromatase inhibitor amino-
glutethimide (500 mg plus 40 mg hydrocortisone acetate,
n = 10). Three postmenopausal patients received goserelin as
their primary therapy. Cytotoxic therapy was reserved for
those patients whose tumours had failed to respond to
endocrine therapy. The chemotherapeutic regimen used was
four cycles of CHOP, i.e. cyclophosphamide 1 gm"2,
adriamycin 50 mg m"2, vincristine 1.4mgm"2 to a maximum
of 2 g, all by i.v. bolus and oral prednisolone 40 mg per day
for 5 days. The regimen was administered every 21 days. If
cytopenia (WBC < 3,000 ml-3 or platelet count of
< 100,000 ml-3) was presented on day 21, therapy was
delayed until the cytopenia resolved. A dose adjusted course
was then given.
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Figure 1 Response of a postmenopausal patient with an
operable breast cancer of ER concentration 142fmolmg cytosol
protein-1 following intramuscular 4-hydroxyandrostenedione
(250 mg) at 14 day intervals as shown by the arrows. Each closed
point represents tumour volume as calculated from the mean
tumour diameter, while each open point is the volume calculated
from the mean mammographic diameter. The calculated regres¬
sion line had a correlation coefficient of - 0.96 and a slope of
-9 x 10-3 cm3(log) day"'. This indicates statistically significant
regression (P <0.0001, Student's r-test).
Selective policy
Following the demonstration that no patient with an ER
concentration of <20 femtomols mg cytosol protein-1
showed significant regression while receiving endocrine
therapy (Anderson et al., 1989), and indeed two thirds pro¬
gressed (Table III), a more formal selective policy was insti¬
tuted on 1 April 1987. Endocrine therapy thereafter was
reserved only for those patients with ER-moderate/rich
tumours (^20fmolmg cytosol protein-', n = 25). Patients
with ER-poor tumours (ER<20fmolmg cytosol protein-1,
n = 27) or those patients with tumours un- responsive to
endocrine therapy received cytotoxic therapy (n = 7). In this
formalised protocol premenopausal patients received
goserelin (n = 9) and postmenopausal patients received the
selective peripheral aromatase inhibitor, 4-hydroxy¬
androstenedione (250 mg intramuscular injection to alternate
buttocks at 14 days intervals; Ciba-Geigy CGP 32349,
n = 16). The chemotherapeutic regimen was unchanged.
Assessment of response
Patients were reviewed weekly by one of us (EDCA).
Although formal assessment of tumour response was cal¬
culated following completion of 12 weeks systemic therapy,
detection of any interim signs of local progression (n = 16),
such as de novo skin lymphoedema or increasing size of
tumour led to immediate cessation of endocrine therapy. If
progression was detected cytotoxic therapy was instituted
(n = 14) although two patients proceeded directly to surgery.
Statistical evaluation of response was by linear regression
analysis (Apple Mac, Statview) of the changes in tumour
volume between treatment weeks 4 to 12; earlier measure¬
ments were discarded in order to allow the reaction caused
by tumour biopsy to subside (Figure 1). Response was
graded as (i) significant regression (reduction in tumour size
where the probability that the regression line deviated from
the horizontal was greater than 95% (ii) progression
(significant increase in tumour diameter where the probability
that the regression line deviated from the horizontal was
greater than 95% or signs of local advancement (iii) no
change (regression slope intermediate to response and pro¬
gression).
Alterations in tumour size were also assessed radiologically
by a single mammogram, performed at 4 weekly intervals, in
the view known to give the best perspective of the tumour.
Side-effects
Side-effects of therapy were assessed at weekly clinical inter¬
view. The morbidity associated with cytotoxic therapy was
reported using the WHO toxicity grading system (Miller et
al., 1981).
Definitive locoregional surgery
On completion of systemic therapy (3-6 months) mastec¬
tomy with extensive skin removal and axillary node clearance
was performed in 82 patients, of whom 55 had simultaneous
reconstruction by latissimus dorsi myocutaneous flaps. In six
patients with complete clinical response, wide local excision
of the previous tumour site was preferred; this being followed
by radiotherapy in five cases. The excised specimen was
submitted to histological examination.
Patients who had shown a significant response to
preoperative endocrine therapy were continued on endocrine
therapy following definitive locoregional surgery. Premeno¬
pausal patients proceded to oophorectomy, postmenopausal
patients received tamoxifen at a daily dose of 20 mg. Further
cytotoxic therapy was not given to any patient after surgery.
Survival
The follow-up period has been expressed from the time of
initiating systemic therapy to the date of analysis. The
median period of follow-up was 24 months (range 4-55
months). Locoregional relapse has been defined as recurrence
confined to the chest wall, breast or axilla. Supraclavicular
lymph node recurrence has been classified as distant meta¬
stasis, in keeping with the staging classification for disease at
initial presentation (International Union Against Cancer,
1987 TMN classification).
Results
Response to endocrine therapy
Twenty-four of the 61 (39%) patients treated by initial
endocrine therapy had significant regression of their tumours
(Table III). All responding tumours had an ER concentration
of ^20 fmol mg cytosol protein-1. The proportion of patients
achieving regression did not vary greatly in relation to the
PRIMARY SYSTEMIC THERAPY FOR BREAST CANCER 563
type of endocrine therapy received or menopausal status and
for the purpose of this report all patients receiving endocrine
treatment have been considered together.
Of those patients responding to endocrine therapy, the
median time taken to achieve half volume (Tl/2) was 44 days
(range 3-150 days, Figure 2). Only one tumour showed
complete clinical regression within the period of the study;
however all had residual invasive carcinoma detected by
histopathological examination. For various reasons the dura¬
tion of preoperative antioestrogen therapy was prolonged
beyond 12 weeks in eight patients. Seven tumours continued
to regress at the same rate while one tumour regarded as
static underwent a rapid reduction in size at 5 months.
Response to cytotoxic therapy
A significant reduction in tumour volume was observed in 34
of the 47 patients (72%) who received cytotoxic therapy
(Table II). Thirteen patients (27.6%) had complete clinical
regression of their tumour and eight (17%) had no histo¬
logical evidence of invasive carcinoma in their mastectomy or
Table I Relationship between responses to hormonal therapy and
oestrogen receptor concentration of the primary tumour as
determined by the dextram-coated charcoal adsorption method in 61
patients with large operable breast cancer
No. of patients with
significant regression!total
ER <20a ER >20- Total
Premenopausal
Oophorectomy 0/2 2/3 2/5
Goserelin 0/3 7/13 7/16
Postmenopausal
Tamoxifen 0/5 4/6 4/11
Aminoglutethimide 0/4 4/6 4/10
4-hydroxyandrostenedione - 7/16 7/16
Goserelin 0/1 0/2 0/3
Total 0/15 24/46 24/61
















Figure 2 Graph illustrating the difference in the time taken to
achieve half volume (Tl/2) in tumours which responded to endo¬
crine therapy (n = 24) and cytotoxic therapy (n = 34). The
median Tl/2 of tumours responding to endocrine therapy was 44
days (range 3- 150 days). The median Tl/2 of tumours respond¬
ing to cytotoxic therapy was 20 days (range 3-77 days).
Tabic II Response rates in 47 patients with large operable cancers
of the breast treated with four cycles of the chemotherapeutic regime
CHOP (cyclophosphamide lgm~2, adriamycin 50mgm~2,
vincristine l.4mgm"2 to a maximum of 2 g, all by i.v. bolus and
oral prednisolone 40 mg per day for 5 days) before definitive
locoregional surgery. The y2 test has been used to compare the
proportion responding to chemotherapy following failed endocrine
therapy in relation to ER concentration
















afmol mg cytosol protein
P = 0.025.
statistically significant y,2 = 5.05,
Table III Relationship between the pretreatment ER concentration
and response to 12 weeks endocrine therapy in 61 patients with large
operable cancers of the breast. The ER concentration was
determined by the dextran-coated charcoal adsorption method
Total Significant No
ER status no. regression change Progression
ER - poor 15 0 5 10
20*
ER - rich 46 24 16 6
Js 20"
"fmol mg cytosol protein
wide local excision specimens; five patients had no gross
residual disease but invasive carcinoma was visible micro¬
scopically. No patient showed evidence of tumour progres¬
sion during treatment with chemotherapy.
The rate of regression was, on average, more rapid than
that achieved with endocrine therapy (median Tl/2 of 20
days, range 3-77 days, Figure 2). Those patients with steeper
regression slopes were more likely to achieve complete
clinical response within the time scale of the study.
There was no significant relationship between significant
regression to chemotherapy and the pretreatment variables of
age, menopausal status, initial clinical tumour size or
pathological axillary node status (Table IV). Of those who
failed to respond to endocrine therapy, chemotherapy was
more likely to achieve regression in ER-poor tumours (Table
IV).
Survival and preoperative therapy
The overall, distant disease-free and disease-free survival of
all patients within the study is shown in Figure 3. Local
recurrence-free survival is shown in Figure 4. With a median
follow-up of 23 months (range 4-55 months), 18 (20%)
patients have relapsed, seven of whom have died as a result
of their disease. Of these seven patients, three had shown
failed to achieve significant regression in response to systemic
therapy. In five patients relapse was locoregional alone, six
patients had distant metastasis alone while 13 had evidence
of both. At 3 years 86% (76-96%; 95% confidence limits)
remain alive and 67% (55-79%; 95% confidence limits)
remain disease-free, with 81% (70-92%); 95% confidence
limits) having no evidence of local recurrence.
Toxicity
The side-effects experienced with endocrine treatment were
minimal. Hot flushings were noted in seven patients (37%)
receiving goserelin but were only moderately severe in two
patients. Vaginal dryness was a problem in one patient. Of
the 16 patients who received 4-hyroxyandrostenedione
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Table IV Relationship between prctreatment variables and significant tumour
regression following four cycles of preoperative cytotoxic therapy
(cyclophosphamide 1 gm'!, adriamycin 50mgm"2, vincristine 1.4 mgm"2 to a
maximum of 2 g, all by i.v. bolus and oral prednisolone 40 mg per day for 5
days). Patients were designated postmenopausal if more than 1 year had elapsed
since their last menstrua] period. Pretreatmcnt axillary node status as determined
from histological examination fo an axillary node sample was available for 29
patients. The y2 test has been used to compare the relationship between
pretreatment variables and the proportion within each group who achieved
significant regression
No. significant
regression/total no. P value
Tumour diameter
< 5 cm
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Figure 3 Overall, distant disease-free and relapse-free survival
for 88 patients with large operable breast cancer treated by
primary systemic therapy before definitive locoregional surgery.

















Figure 4 Cumulative proportion remaining free from local re¬
lapse in 88 patients with operable breast cancers of greater than
4 cm at diagnosis treated with primary systemic therapy before
definitive locoregional surgery. The median period of follow-up
was 24 months (range 4 55 months).
adverse effects included a tender lump at the injection site
(n = 4), hot flushings (n = 2), erythematous rash on buttocks
(n = 1), and a clinically insignificant, self-limiting abnor¬
mality of liver function tests (n = 2). Four patients who
received aminoglutethimide complained of nausea and
lethargy on initiation of therapy.
The chemotherapeutic regime was moderately toxic. The
principle side-effects were alopecia (100%), nausea and
vomiting (91% WHO grade 2 or greater), stomatitis (68%
WHO grade 2), dyspepsia (20%) mild dysuria (13%) and
neutropenia (26% WHO grade 2 or greater). Premature ter¬
mination of therapy was required in two patients because of
nonspecific toxicity and in one on account of iliofemoral
thrombosis. There were no treatment related deaths and no
increase in morbidity associated with definitive surgery.
Axillary lymph node status
Histological assessment of axillary lymph node status was
performed in 46 patients (51%) before and in 86 patients
(98%) on completion of systemic therapy. Metastatic car¬
cinoma was detected in 33 (72%) and 42 cases (49%) respec¬
tively. Overall 56 patients (64%) had axillary metastases
detectable at some stage in their management.
Comparison of pre- and post-treatment axillary node status
was possible in 43 patients. Of the 33 patients in whom
axillary node metastasis were detected pretreatment, 14 had
no evidence of metastases following systemic therapy. Of
these eight had shown significant regression during systemic
therapy of which five were clinically complete. Axillary node
metastases were found in only one of the ten patients in
whom the pretreatment axillary node sample had failed to
demonstrate metastases. This patient did not respond to
4-hydroxyandrostenedione or proceed to chemotherapy and
so may represent a true progression of axillary node status.
Discussion
This study was undertaken to ascertain whether appropriate
long-term systemic therapy could be selected by direct assess-
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ment of primary tumour response before surgical excision.
Experience of this novel form of management in 88 cases has
shown it to be a feasible approach.
A biopsy of the tumour was performed prior to initiation
of systemic therapy and has allowed direct correlation of
oestrogen receptor concentration to individual tumour re¬
sponse. Of the first 36 patients treated by primary endocrine
therapy, no patient with a tumour of ER concentration less
than 20 fmol mg cytosol protein"1 showed significant regres¬
sion (Anderson et al., 1989). Thereafter a change in protocol
was instituted and primary endocrine therapy was reserved
for those patients with tumours of ER concentration
^20 fmol mg cytosol protein"'. Individual responsiveness to
endocrine therapy, even within ER-moderate/rich tumours
however could only reliably be determined by direct observa¬
tion of the effect of therapy. In this way we have selected out
those patients in whom continuing endocrine systemic
therapy is appropriate. Such patients would appear to have
an excellent prognosis (Anderson et al., 1989). Similarly
direct objective assessment of tumour response to systemic
therapy allows cessation of endocrine therapy where it has
been demonstrated to be of no value with initiation of
chemotherapy if desired.
A variety of endocrine therapies have now been tried and
the proportion of patients achieving regression is similar to
that documented using the same agents in advanced disease
(Hawkins, 1985; Coombes, Stein & Dowsett, 1989; Nicholson
& Water, 1989). Of particular interest is the efficacy of the
gonadotrophin-releasing hormone agonist, goserelin and the
peripheral aromatase inhibitor 4-hydroxandrostenedione in
pre- and post-menopausal women respectively. Gonado¬
trophin-releasing hormone agonists produce an effect similar
to oophorectomy but without operation (Nicholson &
Walker, 1989) and would appear to be suitable for the
primary treatment of premenopausal women. Furthermore
they can be discontinued should therapy prove ineffective.
The requirement for intramuscular injection of 4-
hydroxyandrostenedione is a disadvantage and tamoxifen is
preferred for primary therapy in postmenopausal women.
Within this study cytotoxic therapy with its greater
associated toxicity was reserved for patients in whom endo¬
crine therapy had failed or the likelihood of response to
endocrine therapy was minimal (i.e. patients with ER-poor or
ER-negative tumours). The proportion of such patients with
tumours which were chemosensitive was high and lies within
the observed range of 70-93% described with 'neoadjuvant'
chemotherapy in more locally advanced breast cancers (Jac-
quillat et al., 1988; Hortobagyi et al., 1988; Swain et al.,
1987). Of those individual tumours directly demonstrated as
endocrine-resistant however the proportion of ER-poor/
negative tumours regressing with chemotherapy paralleled
that of primary chemotherapy (~80%) but the efficacy in
ER-rich tumours was much lower (30%). This difference in
response pattern may suggest a common mechanism of
failure to respond to both endocrine and cytotoxic therapies.
The response to endocrine therapy was on average, slower
than that achieved with cytotoxic therapy. Within the period
of the study only one patient achieved complete clinical
regression of their tumour during endocrine therapy and in
no patient was pathological remission complete. In contrast
the response to cytotoxic therapy was occasionally rapid and
in those patients with such a rapid response, complete clinical
and even complete pathological response was observed. None
of the parameters studied were able to define which patients
were more likely to achieve such complete remission.
As this study has progressed refinements have been made
to the protocol. The use of ER data to select systemic
therapy has already been described. Initially axillary node
sampling was not an integral part of the pretreatment assess¬
ment. Analysis of the pathological post-treatment axillary
node staging of the first 43 patients demonstrated a lower
incidence (51%) of positivity than would be expected. Since
clinical axillary node staging is notoriously unreliable it was
felt that pathological staging of the axillary nodes should be
included in the preoperative assessment if survival data was
to be assessed. Of the 45 patients in whom pretreatment
axillary node status was known there was a higher incidence
of lymph node metastases (73%) which is more in keeping
with previous studies for tumours of similar stage (Carter el
al., 1989). Following therapy however only 20 (44%) had
detectable node metastases suggesting that the preliminary
figure of 51% was not due to sample bias. While it is
conceivable that axillary node sampling has simply removed
the few lymph nodes with metastatic disease it is also pos¬
sible that the systemic therapy has been effective in
eradicating axillary metastases.
A possible benefit of primary systemic therapy, which we
have not yet explored, is that it may permit conservative
surgery in patients with large tumours which would otherwise
require mastectomy. The usefulness of initial systemic
therapy with the aim of avoiding mastectomy has been
reported in a series of 57 patients with large but potentially
operable breast cancers (Mansi et al., 1989). With a median
follow-up of 19 months these authors report similar response
rates, loco-regional recurrence, distant relapse and projected
overall survival rates to this study with only 18% (10/57) of
patients subsequently proceeding to mastectomy. Primary
systemic therapy however is not yet orthodox for operable
disease and we did not believe it justified to perform less than
a mastectomy in the majority of patients. In future studies a
more conservative approach would be worthy of trial.
A disadvantage of preoperative systemic therapy is the
potential psychological morbidity induced by leaving the
tumour in situ while initial systemic therapy is undertaken. In
general this did not prove to be a problem even in patients
with nonresponsive disease. This was probably due to the
fact that surgical removal of the tumour, still regarded by
many patients as the critical step in their managment, was
still possible. Formal examination of psychological morbidity
was not however undertaken during this study, but should be
part of any future work.
In addition to the benefit of selecting appropriate systemic
therapy, there is theoretical (Goldie & Coldman, 1979; Skip¬
per 1964), experimental (Fisher et al., 1983) and clinical
(Nissen-Meyer et al., 1986; Ragaz, 1986) evidence, that early
administration of systemic therapy in the treatment schedule
of patients with breast cancer may improve survival. The 3
year cumulative survival rate within this study was 86%, with
81% of patients remaining free of local recurrence. This
compares favourably to 3 year survival rates achieved with
orthodox treatment of large tumours of similar stage which
range from 65-78% (Duncan & Kerr, 1976; Sorace & Lipp-
man, 1988; Carter et al., 1989). Proof requires a controlled
randomised trial in which this selective approach is assessed
against conventional treatment, that is mastectomy followed
by combination chemotherapy in premenopausal women and
tamoxifen in postmenopausal women; such a trial is currently
underway in Edinburgh.
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